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Abstract 
 
Asthma is a chronic inflammatory disease of the airways and is characterised by 
airway hyperresponsiveness (AHR), inflammation and remodelling. House dust mite 
(HDM; Dermatophagoides pteronyssinus) is a complex aeroallergen, commonly 
associated with development of allergic asthma. Animal models have been utilised 
extensively to model the traits of asthma and HDM-induced allergic airways disease 
was established in mice following serial HDM challenge via the respiratory mucosa. 
Mice exposed to HDM developed pulmonary eosinophilia, characterised by Th2 
cytokine production, concomitant with AHR and airway remodelling.  
 
Following the establishment and characterisation of this model of allergic airways 
disease, it was next investigated which features of the HDM allergen were 
responsible for disease pathogenesis. Using genetically modified mice and 
pharmacological approaches, it was found that the TLR-TRIF signalling pathway 
played a crucial role in HDM-induced allergic airways disease. Intrinsic protease 
activity of the HDM extract was also observed to be vital for disease pathogenesis, 
whereby mice exposed to boiled HDM developed a less severe asthma phenotype. 
 
Utilising a pan neutralising antibody directed towards transforming growth factor- 
(TGF-), TGF-β was shown to play a critical role in regulating HDM-induced airway 
inflammation in vivo. Following therapeutic blockade of TGF-, the numbers of 
CD4
+
CD25
+
FoxP3
+
 regulatory T cells and CD4
+
IL-10
+
 cells were decreased resulting 
in exacerbation of AHR and BAL inflammation compared to HDM-treated isotype 
control mice. However, HDM-induced airway remodelling progressed independently 
of TGF-β. 
 
In conclusion, it has been determined that HDM-induced Th2-driven inflammation, 
AHR and airway remodelling in mice is induced by multiple features of the allergen 
and that TGF- regulates HDM-driven airway inflammation. Thus these findings 
provide an insight into the mechanisms by which the aeroallergen HDM promotes 
allergic disease and will aid in the development of potential new therapeutic 
strategies for the treatment of asthma. 
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1.1. Asthma 
 
Approximately 300 million people worldwide suffer from asthma, with an estimated 
8 million sufferers in the UK alone (Holgate, 2008;Holgate and Polosa, 2008). The 
prevalence of allergic sensitisation and severity of asthma has rapidly increased to 
epidemic proportions over the last 50 years and disease control has become 
associated with an escalating economic burden to the NHS (Eder et al., 
2006;Bahadori et al., 2009). 
 
Asthma is a complex heterogeneous condition, believed to arise from interplay 
between environmental and genetic factors. These interactions culminate in an 
inappropriate inflammatory response to normally harmless airborne allergens 
(Nelson, 2001;von Mutius, 2009) (summarised in Figure 1.1). Asthma is a chronic 
immune-mediated inflammatory disorder, which is characterised by attacks of 
wheezing and breathlessness due to bronchoconstriction, airway inflammation, mucus 
secretion, airway hyperresponsiveness to non-specific stimuli and airway wall 
remodelling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. The heterogeneity of asthma.  
Asthma is a complex disease caused by multiple factors. Local airway susceptibility 
factors together with allergen specific immune responses interact both in the 
induction and development of the disease phenotype.  
ORMDL
3 
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Initiation 
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Asthma encompasses several distinct clinical phenotypes that can be divided into 
different disease entities with specific characteristics. The different disease 
phenotypes can be further defined by specific underlying pathophysiological 
mechanisms and, using cluster analysis, five individual clinical phenotypes of asthma 
have been identified (Moore et al., 2010). Following these developments it is believed 
that these new classifications can be used in clinical study and drug development 
design to direct existing and novel therapies to patients in a more specific and tailored 
manner (Fajt and Wenzel, 2009;Hastie et al., 2010).  
 
Clinically, the major focus of treatment and research over the past 25 years has been 
on allergic asthma, the most common form of the disease (Nelson, 2001;Karjalainen 
et al., 2003). Atopy is defined as the genetic predisposition to mount an allergen-
specific immunoglobulin (Ig) type E (IgE) response and atopics have positive skin 
prick tests to common allergens. This IgE-mediated response leads to the 
development of inflammatory responses in the lung, altered pulmonary physiology 
and structural changes termed airway remodelling. In atopic asthmatics, airway 
inflammation is initiated by antigen-specific triggers. House dust mite (HDM) is the 
most common allergen associated with atopy and allergic asthma (Fernández-Caldas, 
2002;Cates et al., 2007;Arshad, 2010), with 50 – 85% of atopic asthmatics HDM 
allergic (Nelson et al., 1996). In addition to this, the airway epithelium is now 
believed to be central to asthma pathogenesis (Holgate, 2008). In conjunction with 
clinical studies, mouse models have been used to investigate the immunopathogenesis 
of asthma and studies of such models have been invaluable in dissecting numerous 
immunological processes underlying the pathophysiology of allergen sensitisation, 
disease propagation and regulation. A murine model of HDM-induced allergic 
airways disease is the focus of this thesis.   
 
1.1.1. Allergic Airway Hyperresponsiveness  
 
Asthma is defined clinically by breathlessness, wheeze and a variable airflow 
obstruction (Bousquet et al., 2000). This is believed to account for the dramatic 
increase in responsiveness to stimulus of the conducting airways known as airway 
hyperresponsiveness (AHR) (Hargreave et al., 1986). AHR is a key characteristic of 
the asthma phenotype and is defined as ‘the ease with which the airways narrow in 
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response to a bronchoconstrictive challenge and manifests as a combination of 
increased sensitivity and reactivity for a given stimulus’ (Juniper et al., 1981). 
Although AHR is a fundamental component of asthma, the specific causes leading to 
altered airway responsiveness in asthmatics are still unclear (Holgate, 2008). AHR is 
believed to be mediated by impaired function and contraction of the underlying 
airway smooth muscle (ASM) as most acute asthmatic symptoms can be improved by 
use of smooth muscle relaxants such as β-agonists (Gil and Lauzon, 2007). Although 
airway inflammation can modify the behaviour of ASM, the extent of airway 
inflammation does not correlate with the degree and severity of AHR (Jiang et al., 
1992;Mitchell et al., 1994;Crimi et al., 1998;Fernandes et al., 2003). This has lead to 
the hypothesis that inflammation induces alterations in the airway wall that make the 
structure more sensitive and responsive to stimuli. These airway changes include 
increases in muscle content, increased mucus secretion and desquamation of airway 
epithelium (Wardlaw et al., 1988;Blosser et al., 1994;Du et al., 1996;Liggett., 1997).  
 
1.1.2. Allergic Airway Inflammation 
 
The inflammatory immune response in the asthmatic airways is diverse and 
heterogeneous and aspects of both the innate and adaptive immune systems have been 
implicated in the development of asthma (Holgate, 2008;Holt and Sly, 2011;Sly and 
Holt, 2011). The allergic inflammatory cascade features mediator release and multi-
cellular leukocyte infiltration to both the lung tissue and airway lumen. These 
inflammatory infiltrates contribute to and mediate many of the immunopathological 
features of asthma (Kraft et al., 1999;Kay, 2005;Holgate, 2008). The allergic 
response is dominated by an adaptive T helper 2 (Th2) response, IgE antibody 
production and eosinophil infiltration of the airways (summarised in Figure 1.2). 
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Figure 1.2. Immune cells and the inflammatory cascade in allergic asthma  
Allergen exposure drives an adaptive Th2 response. This response can be initiated 
either by the allergen acting directly on antigen presenting cells (APCs) residing in 
the airway mucosa or, alternatively, these APCs can be induced via the release of 
epithelial cell-derived cytokines TSLP, IL-33 and IL-25 (IL-17E). Subsequent 
allergen exposures cause inflammatory cell recruitment, activation and mediator 
release. IgE-sensitised mast cells degranulate, releasing mediators such as histamine, 
leukotrienes and cytokines, which promote vascular permeability, smooth-muscle 
contraction and mucus production.  
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1.1.2.1. Initiation of Allergic Airway Inflammation 
 
The pulmonary epithelium is the first point of contact for inhaled environmental 
allergens in the lung and is now hypothesised as a central player in the development 
of Th2-driven inflammation (Holgate, 2008). The relationship and interactions 
between the pulmonary innate immune system and surrounding tissue are essential 
for allergen sensitisation (Suarez et al., 2008). Residing in the airway mucosa are 
dendritic cells (DCs) that are essential APCs for priming, initiation and maintenance 
of Th2-driven inflammation following allergen exposure (Hammad and Lambrecht, 
2008). Both airway epithelial cells and DCs express a number of receptors that enable 
these cells to detect a wide range of inhaled allergens. These receptors include 
pattern-recognition receptors (PRRs) which recognise a broad range of invariant 
structures such as microbial components, known as pathogen-associated molecular 
patterns (PAMPs) (Gordon, 2002;Akira et al., 2006). Many allergens are 
contaminated with PAMPs enabling them to induce DC maturation. DC maturation 
itself involves the up-regulation of co-stimulatory molecules and enables DCs to 
migrate to the draining lymph nodes (LNs) to prime an antigen-specific T cell 
response (de Heer et al., 2005;Condon et al., 2011). However, not all allergens are 
intrinsically immunogenic or activate PRRs. Danger signals or damage-associated 
molecular patterns (DAMPs) in the absence of infection can also influence DC 
activation (Rubartelli and Lotze, 2007;Willart and Lambrecht, 2009).  
 
Epithelial cells can directly modulate DC function through direct cell–cell interaction 
and via the release of mediators (Hammad and Lambrecht, 2008). A group of pro-
allergic innate cytokines are central to the recruitment and activation of DCs and the 
initiation of Th2 responses. Allergens can directly stimulate the production of thymic 
stromal lymphopoietin (TSLP), IL-25 (IL-17E), IL-33 and CCL20/MIP-3α from 
airway epithelial cells. These mediators are able to direct a polarised Th2 response 
and further maintain the salient features of asthma. However, it is important to note 
that although airway epithelial cells are important cellular sources of TSLP, IL-25 
(IL-17E), IL-33 and CCL20/MIP-3α, other cells present in the allergic inflammatory 
cell infiltrate, such as eosinophils, also produce these cytokines. 
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TSLP 
 
TSLP is a 140-amino-acid cytokine of the IL-7 family and is a powerful stimulus of 
Th2 inflammation (Kato et al., 2007;Ziegler and Artis, 2010). TSLP potently 
modulates DCs by binding to the TSLP receptor complex on DCs, which is composed 
of IL-7 receptor and the TSLP receptor (TSLPR) (Liu et al., 2007). TSLP can activate 
DCs and induce maturation, thereby promoting Th2 inflammation, by increasing DC 
expression of OX40L (Soumelis et al., 2002;Ito et al., 2005;Seshasayee et al., 
2007;Liu, 2007). The polarisation of Th2 cells induced by TSLP-matured DCs is 
further enhanced by IL-25 (IL-17E), which is produced by epithelial cells, basophils 
and eosinophils (Wang et al., 2007). 
 
TSLP expression is detected in the airways of asthmatics and TSLP mRNA 
expression correlates with disease severity (Ying et al., 2005). In mice, TSLP mRNA 
expression is higher in the lungs of ovalbumin (OVA)-treated mice and lung-specific 
expression of TSLP induces airway inflammation and AHR (Zhou et al., 2005). Mice 
over-expressing TSLP in the airway epithelium develop features of allergic airways 
disease (Zhou et al., 2005), whereas TSLPR-deficient mice have attenuated OVA-
induced AHR (Al-Shami et al., 2005), likely as a consequence of a reduction in the 
migration of airway DCs, resulting in diminished CD4
+
 T cell priming (Shi et al., 
2008). 
 
IL-25 (IL-17E)  
 
IL-25 (IL-17E) is a member of the IL-17 cytokine family (Fort et al., 2001). IL-25 
(IL-17E) is produced from a variety of cells including epithelial cells (Angkasekwinai 
et al., 2007) and mast cells (Ikeda et al., 2003) in mice in response to allergen 
exposure, as well as from activated eosinophils and basophils (Hurst et al., 
2002;Angkasekwinai et al., 2007). Greater IL-25 (IL-17E) levels are detected in the 
bronchial submucosa of asthmatics compared to non-asthmatics (Letuve et al., 
2006;Wang et al., 2007).  
 
In mouse models of asthma, several reports have shown that IL-25 (IL-17E) amplifies 
Th2 cytokine production and eosinophilia and that IL-25 (IL-17E) acts on both the 
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innate and adaptive immune systems to amplify Th2 responses. Elevated IL-25 (IL-
17E) mRNA expression has been shown in the lungs of allergen challenged mice 
(Angkasekwinai et al., 2007) and blockade of IL-25 (IL-17E) signalling, prior to 
allergen exposure, results in attenuated AHR, Th2 cytokine production and allergen-
specific IgE (Ballantyne et al., 2007). Direct instillation of IL-25 (IL-17E) to the 
airways of mice has been shown to promote AHR and over expression of IL-25 (IL-
17E) by epithelial cells leads to mucus production and airway inflammation 
(Sharkhuu et al., 2006). IL-25 (IL-17E) enhances OVA-induced AHR (Tamachi et 
al., 2006) and IL-17RB
+
 NKT cell numbers (Terashima et al., 2008;Stock et al., 
2009). Furthermore, the administration of recombinant IL-25 (IL-17E) induces the 
production of IL-4, IL-5 and IL-13 from an innate non–B cell, non–T cell c-
Kit
+
FcεRI− cell population (Fallon et al., 2006). 
 
IL-33 
 
IL-33 is a member of the IL-1 cytokine family and is expressed by bronchial 
epithelial cells, fibroblasts, smooth muscle cells, macrophages, DCs, basophils and 
mast cells (Schmitz et al., 2005;Liew et al., 2010). IL-33 has also been shown to be 
released from cells undergoing necrosis to then act as a pro-inflammatory endogenous 
danger signal (Luthi et al., 2009). Thus, in addition to its direct pro-inflammatory 
role, IL-33 could also act as a DAMP or an ‘alarmin’ (Moussion et al., 2008). IL-33 
is the ligand for the receptor ST2 and has been strongly associated with the promotion 
of Th2 responses (Schmitz et al., 2005). Greatest ST2 expression is seen on mast cells 
and Th2 cells (Moritz et al., 1998;Coyle et al., 1999), which has led to the association 
of the ST2/IL-33 axis with asthma. Interaction of IL-33 with ST2 on a range of 
different leukocytes promotes a number of key inflammatory pathways that have the 
potential to initiate and propagate allergic inflammation (Liew et al., 2010). IL-33 
acts in synergy with stem cell factor and the IgE receptor to activate human mast cells 
and basophils (Silver et al., 2010). Incubation of human basophils with IL-33 
increases mRNA expression of IL-4 and IL-13 (Suzukawa et al., 2008). IL-33 also 
enhances the survival of eosinophils and eosinophil degranulation in humans (Cherry 
et al., 2008;Chow et al., 2010;Stolarski et al., 2010). IL-33 expression has been 
shown in airway smooth muscle cells (ASMCs) and airway epithelial cells and higher 
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expression of IL-33 was seen in asthmatics than non-asthmatics (Prefontaine et al., 
2009;Prefontaine et al., 2010).  
 
Studies from mouse models have shown a vital role for IL-33 in the development of 
Th2-driven inflammation. Administration of IL-33 concurrent with antigen 
sensitisation induces the salient features of allergic airways disease (Kondo et al., 
2008;Kurowska-Stolarska et al., 2008;Kurowska-Stolarska et al., 2009) and genetic 
overexpression of IL-33 also leads to eosinophilic inflammation (Zhiguang et al., 
2010). Blockade of ST2 abrogated Th2 cytokine production, eosinophilic 
inflammation and AHR (Coyle et al., 1999) and IL-33 neutralising antibodies 
attenuated OVA-induced eosinophil recruitment, Th2 cytokine production, serum IgE 
and mucus production (Liu et al., 2009).  
 
However, the role of the IL-33 signalling in promoting allergic airway disease is 
complex, as ST2 knockout (KO) mice develop OVA-induced airway inflammation 
and eosinophilia (Hoshino et al., 1999;Townsend et al., 2000) and IL-33 can also 
cause airway inflammation in the absence of T and B cells (Kurowska-Stolarska et 
al., 2008;Kurowska-Stolarska et al., 2009). In the gut of mice IL-33 has been shown 
to cause IL-4 and IL-13 production from either nuocytes (Neill et al., 2010), multi-
potent progenitor type-2 cells (Saenz et al., 2010) or natural helper cells (Moro et al., 
2010). Since the gut is also a mucosal surface, IL-33 induced production of Th2 
cytokines from these innate cells may also occur in the lung, thereby bypassing any 
requirement for T and B cells.  
 
CCL20/MIP-3α 
 
Rapid recruitment of DCs into the bronchial mucosa has been observed in animal 
studies (Vermaelen and Pauwels, 2003) and in human subjects in response to allergen 
challenge (Jahnsen et al., 2001). CCL20/MIP-3α is central to early DC recruitment 
acting via CCR6 (Greaves et al., 1997;Power et al., 1997;Dieu-Nosjean et al., 2000). 
CCL20/MIP-3α is expressed by airway epithelial cells (Starner et al., 2003) and 
CCL20/MIP-3α expression is increased in airways of asthmatics (Pichavant et al., 
2005). Production of CCL20/MIP-3α can be induced from airway epithelial cells by 
multiple stimuli, such as ambient particle matter (Reibman et al., 2003) and the 
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CCL20/MIP-3α-CCR6 axis can also lead to mucus production (Kim et al., 2011). 
CCL20/MIP-3α-CCR6 has been shown to increase Th2-type airway inflammation in 
response to antigen and CCR6-deficient mice are resistant to cockroach-induced 
airway inflammation (Lukacs et al., 2001). 
 
1.1.2.2. Cells and Mediators of Allergic Airway Inflammation 
 
Airway inflammation in asthma is a multi-cellular process involving mainly mast 
cells, eosinophils, basophils, neutrophils and CD4
+ 
T cells. Eosinophilic infiltration is 
a striking feature of allergic airway inflammation, with non-asthmatics usually 
possessing sputum eosinophil counts of less than 1.9% with this elevated in 
approximately 60% of asthmatics (Agbetile and Green., 2011). 
 
Mast cells are effector cells in asthma pathogenesis and are located in both the airway 
epithelium and deeper layers of the mucosa (Yu et al., 2006). In the asthmatic 
airways, the majority of IgE is bound by FcεR1 on mast cells making them highly 
responsive to inhaled antigen (Robinson, 2004). Mast cells can provide an early 
source of pro-inflammatory mediators such as IL-4, which can influence the proximal 
events during allergen-specific effector T cell sensitisation (Bradding et al., 2006), 
and IL-5 which promotes eosinophil recruitment and activation (Lorentz et al., 1999). 
 
Eosinophilia is a feature of allergic airway inflammation (Kay, 2005). Eosinophils are 
found in both the lung tissue and the bronchoalveolar lavage (BAL) fluid of asthmatic 
patients (Lemiere, 2004;Kay, 2005). Recruitment of eosinophils to the airways is 
mediated by eotaxin-1/CCL11, eotaxin-2/CCL24 and eotaxin-3/CCL26 acting via 
CCR3 (Ying et al., 1997;Humbles et al., 2002). Although eosinophilia is the most 
characteristic type of inflammation in asthma, this is neither an exclusive feature nor 
the only type of inflammation observed and eosinophilic asthma is now considered a 
distinct phenotype of asthma associated with thickening of the basement membrane 
and by corticosteroid responsiveness (Fahy, 2009). 
 
Basophils share many of their recruitment mechanisms with eosinophils (Gangur et 
al., 2003) and are implicated in the development of Th2 inflammation (Siracusa et al., 
2011). Basophils express FcεRI and contribute to the local symptoms of inflammation 
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and AHR through degranulation and release of eicosanoids and histamines (Falcone 
et al., 2000). Basophils have also been shown to promote Th2 inflammation via the 
release of cytokines such as IL-4 (Yoshimoto et al., 1999) and by possessing antigen 
presenting function (Sokol et al., 2009;Yoshimoto et al., 2009;Perrigoue et al., 2009). 
 
Elevated numbers of neutrophils, without eosinophilia has been reported in the 
airways of asthmatics (Drews et al., 2009). Elevated neutrophil numbers are 
associated with severe asthma (Jatakanon et al., 1999;Wenzel, 2006), asthma 
exacerbations (Wark and Gibson, 2006) and non-atopic asthma (Baines et al., 2011). 
However, neutrophilic asthma and eosinophilic asthma are not mutually exclusive 
and considerable overlap has been reported between each (Fahy, 2009). 
 
A fundamental feature of allergen sensitisation is the uptake and processing of 
inhaled allergens by DCs and the capacity of DCs to generate IL-12 determines the 
balance between Th1 and Th2 responses, with IL-12 polarising T-cell differentiation 
in favour of a Th1 response (Kuipers and Lambrecht, 2004). Once polarised, Th2 
cells migrate back to the airways under the influence of the chemokines thymus and 
activation regulated chemokine (TARC)/CCL17 and monocyte-derived chemokine 
(MDC)/CCL22, which interact with the receptor CCR4 (Garcia et al., 2005;Kallinich 
et al., 2005). Allergen-specific Th2 cells are central to asthma pathogenesis (Kay., 
1997;Lloyd and Hessel, 2010;Robinson, 2010) and there is vast experimental and 
clinical evidence supporting the critical importance of Th2 cells during allergic 
sensitisation and propagation (Robinson et al., 1992;Del Prete et al., 1993). In 
asthmatics, an increase in effector Th2 cells and their mediators have been reported in 
the bronchial mucosa and BAL fluid and elevated Th2 numbers have also been 
correlated with disease severity (Walker et al., 1991;Corrigan and Kay, 1992). 
 
Th2 cells are potent producers of a range of cytokines, the majority of which are 
expressed on the long arm of chromosome 5, namely IL-4, IL-5 and IL-13 (Kay, 
2006;Robinson, 2010). Together these cytokines promote the salient features of 
asthma such as AHR, airway inflammation and tissue remodelling (Robinson et al., 
1992;Robinson et al., 1993;Larche et al., 2003). IL-4 and IL-13 are involved in the 
class-switching of B cells to IgE synthesis (Finkelman et al., 1990) and promote 
mucus secretion and fibrosis (Kumar et al., 2004;Fattouh and Jordana., 2008). Th2 
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cytokines also activate secondary effector cells in asthma including the recruitment of 
mast cells (IL-4 and IL-13) and basophils (IL-4) (Bradding et al., 2006), while IL-5 
supports growth, differentiation, and activation of eosinophils (Paul and Seder, 
1994;Ying et al., 1997). IL-13 is also strongly linked to the development of AHR 
(Grunig et al., 1998;Wills-Karp, 2004;Kumar et al., 2004).  
 
Traditionally, the asthmatic response was considered to be dominated by Th2 
lymphocytes. However, it is now clear that additional pro-inflammatory and 
regulatory T cell subsets are present in the allergic lung (Afshar et al., 2008), and it is 
now believed that asthma may not be controlled by Th2 cells (Lloyd and Hessel, 
2010). Th1 and Th2 effector cell subsets once represented the paradigm of functional 
naïve CD4
+
 T cell differentiation (Mosmann and Coffman, 1989;Mosmann et al., 
2009). However, the classical Th1-Th2 paradigm of CD4
+
 T cell differentiation has 
been reorganised following the discovery of Th17 cells, which rendered the original 
Th1/Th2 dichotomy too simplistic (Dong, 2008;Murphy and Stockinger, 2010). Th17 
cells, identified by the unique transcription factor RORγt and ability to secrete IL-17, 
have been implicated in neutrophil-dominated asthma (Molet et al., 2001;Hellings et 
al., 2003;Bullens et al., 2006). Furthermore Th effector differentiation was originally 
considered a terminal event (Murphy et al., 1996;Grogan et al., 2001) and this view 
has since been revised following the recent identification of Th9 effector cells. Th9 
cells were induced from differentiated Th2 cells, suggesting that functional plasticity 
may exist within the Th subsets (Dardalhon et al., 2008;Veldhoen et al., 2008). The 
Th source of IL-9 was originally thought to be Th2 cells, however the precise Th 
source of IL-9 requires clarification following the identification of Th9 cells. Two 
recent reviews by Mucida and Cheroutre, and Zygmunt and Veldhoen give the reader 
an up to date overview of CD4
+
 differentiation and plasticity that can occur between 
subsets (Mucida and Cheroutre., 2010;Zygmunt and Veldhoen, 2011). 
 
1.1.2.3. Immune Tolerance and Regulation: Regulatory T Cells, TGF-β and IL-
10 
 
The lung is exposed to the external environment and numerous innocuous antigens on 
a daily basis. Therefore, the lung maintains a state of immune tolerance to these 
harmless stimuli to preserve pulmonary homeostasis and to prevent chronic 
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inflammation. Homeostasis within the lung is an active process that is maintained by 
site-specific mechanisms by lung resident cells (Snelgrove et al., 2011). Immune 
homeostasis in the lung is achieved by the balance of inflammatory and modulatory 
cytokines, as well as the presence of a key subset of regulatory T cells (Tregs) 
(O'Garra et al., 2004;Li et al., 2006b;O'Garra et al., 2008). It is vital that these 
homeostatic mechanisms distinguish harmless airborne antigens, entering via the 
airways, from pathogens. 
 
Tregs are essential for the maintenance of immunological tolerance and immune 
homeostasis in the airways. The induction of tolerance in the airways in animal 
models has been correlated with the induction of Tregs, with repeated exposure of 
mice to low-dose allergen promoting the development of a regulatory CD4
+
 T cell 
population that expressed transforming growth factor-β (TGF-β) and Forkhead box 
protein-3 (FoxP3) (Ostroukhova et al., 2004). A higher dose of inhaled allergen 
stimulated the development of a regulatory T cell population that secreted IL-10 
(Akbari et al., 2002). Further to this, repeated exposure of mice to inhaled antigen 
stimulated pulmonary DCs to produce IL-10, which were then able to induce the 
development of IL-10-producing Tregs (Akbari et al., 2002). Adoptive transfer of IL-
10-producing DCs prevented the development of allergic inflammation after 
subsequent allergen challenge of recipient mice (Akbari et al., 2002).  
 
Tregs also regulate Th1, Th2, and Th17 effector functions and thus play a key role in 
controlling inflammatory responses (O'Garra et al., 2004;O'Garra and Vieira, 2004). 
Tregs form part of the constitutive T cell population in both mouse and humans, 
accounting for 5-10% of peripheral CD4
+
 T cells (Belkaid et al., 2002). Tregs can 
either be naturally occurring (nTreg), derived from the thymus, or induced (iTreg) 
outside of the thymus from naïve CD4
+
 cells during chronic inflammation and during 
homeostasis. Thymically derived regulatory CD4
+ 
T cells that express high levels of 
the IL-2 receptor-α chain, CD25, are maintained by TGF-β (Wan and Flavell, 2007). 
The transcription factor, FoxP3 is important in the generation of 
CD4
+
CD25
+
FoxP3
+
Tregs and is also used as an intracellular identification marker 
(Fontenot et al., 2003;Khattri et al., 2003). iTregs are divided into 3 subsets: (1) 
FoxP3
+
 iTregs, (2) IL-10-secreting CD4
+
CD25
+
FoxP3
-
 Tr1 cells and (3) TGF-β 
expressing CD4
+
FoxP3
-
 Tr3 cells (Ray et al., 2010). 
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Tregs elicit regulatory function by a variety of mechanisms. Interactions between 
Treg stimulatory (IL-2, CTLA-4) and inhibitory (GITR, CD28) receptors with their 
ligands on DCs (CD80/CD86) have a suppressive function on antigen presentation 
(Read et al., 2006). Furthermore, direct cell-cell inhibition can be achieved via 
membrane-bound TGF-β (Wilczynski et al., 2008). Tregs can also induce anergy in 
effector cells through secretion of immunosuppressive cytokines such as IL-10 and 
TGF-β in a process known as "bystander suppression" (Wilczynski et al., 2008). 
TGF-β is also required for FoxP3 expression and for the differentiation of naive CD4 
cells to CD4
+
CD25
+
FoxP3
+
 nTregs (Chen et al., 2003). Alveolar epithelial cells 
promote the development of FoxP3
+
 cells via a TGF-β-dependant mechanism in mice 
(Gereke et al., 2009) and mice carrying a dominant-negative mutation in the TGF-β 
receptor on CD4
+
 T cells show profound inflammation in the lungs, as well as the 
liver and the pancreatic islets, with impaired development of Tregs (Li et al., 2006a). 
Together these observations showed a vital role for TGF-β and Tregs in maintaining 
T cell and lung homeostasis. 
 
An important role for CD4
+
CD25
+
FoxP3
+
Tregs in immune regulation of asthma has 
been reported (Ling et al., 2004). CD4
+
CD25
+
FoxP3
+
Tregs from non-allergic donors 
but not allergic donors suppressed proliferation and Th2 cytokine secretion by 
CD4
+
CD25
-
T cells (Ling et al., 2004). A direct link between 
CD4
+
CD25
+
FoxP3
+
Tregs and suppression of allergen-induced AHR (Strickland et 
al., 2006;Joetham et al., 2007) and inflammation has now been demonstrated in vivo 
(Leech et al., 2007). Together with these observations, depletion of CD4
+
CD25
+
Tregs 
in mice elevates susceptibility to AHR (Lewkowich et al., 2005). Transfer of antigen 
specific Tregs suppressed features of established allergic airway inflammation 
(Kearley et al., 2005) and prevented the development of airway remodelling (Kearley 
et al., 2008). This effect was found to be dependent on IL-10 since increased levels of 
IL-10 were observed after cell transfer and regulation was reversed by blocking the 
IL-10 receptor. However, the CD4
+
CD25
+
 Tregs were found not to be the source of 
the IL-10 since the transfer of these cells from IL-10 deficient mice yielded the same 
result (Kearley et al., 2005). 
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TGF-β is a key regulatory cytokine and a central role for TGF-β in maintaining 
immune homeostasis and peripheral tolerance was illustrated when TGF-β KO mice 
were observed to die soon after birth from multi-organ inflammation (Shull et al., 
1992). In addition to promoting FoxP3 expression (Chen et al., 2003), TGF-β also 
regulates lymphocyte homeostasis, inhibits Th2 and Th1 cell responses, inhibits IgE 
production and promotes IgA production (Li et al., 2006a). Several in vivo studies 
have illustrated a vital role for endogenous TGF-β in suppressing the development of 
allergic airways disease. Allergen sensitisation and challenge in mice with reduced 
TGF-β expression resulted in exacerbated airway disease compared to wild-type (wt) 
animals (Scherf et al., 2005). Intratracheal (i.t.) delivery of TGF-β suppresses 
allergen-induced inflammation (Joetham et al., 2007) and CD4
+
 T cells engineered to 
secrete latent TGF-β suppress allergen-specific airway inflammation and AHR 
(Hansen et al., 2000). Blockade of TGF-β signalling specifically in T cells also results 
in enhanced AHR, airway inflammation, and increased Th2 cytokine production 
(Nakao et al., 2000). Collectively, these data show that TGF-β regulates immune 
responses in the lung and that alterations in the degree of expression of either the 
cytokine, its receptor, or molecules within its signalling pathway have profound 
consequences for the maintenance of pulmonary homeostasis. 
 
Although TGF-β has been implicated in CD4+CD25+FoxP3+ control of allergic 
airways disease (Ostroukhova et al., 2004;Joetham et al., 2007), the majority of 
studies have described a central role for IL-10, with or without TGF-β in the control 
of allergic airway inflammation. IL-10 is a key homeostatic and immunosuppressive 
cytokine (Moore et al., 1993). IL-10 is secreted by many cells including several T cell 
subsets (Tregs, Th2, Th1) (O'Garra et al., 2004), macrophages and DCs (Moore et al., 
1993) and has been shown to inhibit T cell responses through down-regulation of 
costimulatory molecules on APCs (de Waal Malefyt et al., 1991). IL-10 is thought to 
contribute to homeostasis in the airways (Borish et al., 1996) and has been shown to 
modulate many effector functions that are associated with allergic asthma including 
Th2 activation, IgE production (Nouri-Aria et al., 2004) and eosinophil and mast cell 
function (Takanaski et al., 1994;Arock et al., 1996;Royer et al., 2001).  In human 
asthmatics, it was found that the numbers of allergen-specific cells producing IL-10 
were significantly lower than healthy controls, suggesting that a defect in IL-10 
production may contribute to the asthmatic phenotype (Akdis et al., 2004). 
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Diminishing IL-10 can break tolerance to allergens suggesting a role in regulation of 
responses to allergens (Borish et al., 1996). 
 
1.1.3. Allergic Airway Remodelling 
 
In addition to AHR and airway inflammation, asthma is also associated with 
pathological alterations of the bronchial airway structures. Airway remodelling in 
asthmatic subjects represents a complex multi-cellular process that leads to structural 
changes involving the composition, content, and organisation of many of the cellular 
and molecular constituents of the bronchial wall (Boulet et al., 2000;Holgate et al., 
2001;Girodet et al., 2011). These structural changes are believed to contribute 
significantly to the pathophysiology of asthma (James and Carroll, 2000;Durrani et 
al., 2011) and these modifications are partly reversible
 
in mild asthma, but are mostly 
irreversible in chronic severe
 
asthma (Vignola et al., 2003).  
 
Airway remodelling encompasses a wide range of structural changes in the airways 
including epithelial detachment, compromised epithelial function, sub-epithelial 
fibrosis and increased fibroblast proliferation (Jeffery et al., 1989;Knight et al., 
1994;Trautmann et al., 2002). Changes to the underlying mesenchyme occur 
including dysregulated extracellular matrix (ECM) protein deposition (Boulet et al., 
1997), sub-epithelial fibrosis (Roche et al., 1989;Kaminska et al., 2009) and increased 
peri-bronchiolar ASM mass (Lambert et al., 1993). Goblet cell hyperplasia and 
angiogenesis are also features of airway remodelling (Ordoñez et al., 2001;Vermeer 
et al., 2003;Vignola et al., 2003). Current asthma therapies such as inhaled 
corticosteroids are the most effective anti-inflammatory therapy for asthma, however, 
there is minimal impact on airway remodelling (Chakir et al., 2003;Ward and 
Walters, 2005) and this has led to problems for disease management (Kariyawasam et 
al., 2007;Kelly et al., 2010). For a current overview on the development of airway 
remodelling in asthma and the effects of current asthma therapies treatment on these 
processes, these have been recently reviewed (Al-Muhsen et al., 2011;Durrani et al., 
2011). 
 
The mechanisms that regulate airway remodelling and the precise sequence of events 
that take place in the course of the remodelling process are not fully understood. 
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Opinion is divided as to whether inflammation drives airway remodelling or whether 
an intrinsic alteration in the bronchial wall induces chronic inflammation (Holgate, 
2008). Airway remodelling was traditionally thought to be initiated as a repair 
process in response to airway injuries resulting from sustained airway inflammation. 
Exposure to allergens was hypothesised to be responsible for impaired regulation of 
ECM proteins, via dysregulation of regeneration and repair mechanisms following 
airway inflammation. Airway structural cells, such as ASM cells, epithelial cells and 
fibroblasts were believed to participate in enhancing inflammation and remodelling 
through the release of cytokines, chemokines and proteins of the ECM (Hakonarson 
et al., 1999;Johnson, 2001;Panettieri, 2002;Bhandari et al., 2006).  
 
However, emerging theories have challenged the concept that airway inflammation 
drives the development of airway remodelling. Reactivation of the epithelial 
mesenchymal trophic unit (EMTU) is a key feature of induction of airway 
remodelling and has led to the hypothesis that inflammation and remodelling occur in 
parallel rather than as sequential events. Communication between the epithelium and 
the underlying fibroblast layer is thought to be similar to the processes that drive 
branching morphogenesis in the foetus, where the epithelium and the mesenchyme 
function as a trophic unit. Indeed it has been proposed that the EMTU becomes 
reactivated during chronic asthma to drive pathological airway remodelling (Holgate 
et al., 2000;Davies et al., 2003). It is, therefore, conceivable that airway remodelling 
might precede airway inflammation associated with asthma and this has been 
investigated in studies of childhood asthma. Reticular basement membrane (RBM) 
thickening, an early feature of airway remodelling, has been shown in bronchial 
biopsies from children with moderate asthma (Cokugras et al., 2001) and this was of 
similar degree to that seen in adult asthma (Warner et al., 1998;Payne et al., 2003). 
There is also evidence for early bronchial smooth muscle hypertrophy in biopsies 
from schoolchildren (Hogg et al., 1970;Bai., 1990). Eosinophilic inflammation and 
RBM thickening, that are characteristics of asthma in older children and adults, are 
not present in infants with reversible airflow obstruction and there is no correlation 
with atopy (Saglani et al., 2005). Indeed, unlike inflammatory markers, ASM 
remodelling is correlated with asthma severity (Benayoun et al., 2003). Taken 
together, these findings suggest that structural changes develop very early in the 
course of the disease and that remodelling may precede the development of chronic 
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inflammation, and, therefore, could be a crucial component for the development of 
asthma (Saglani et al., 2005;Saglani et al., 2007). 
 
TGF-β and Airway Remodelling 
 
TGF-β has long been associated with airway remodelling in asthma. Numerous 
clinical studies have shown increased TGF-β expression as detected in lung biopsies 
by immunohistochemistry and RNA expression (Ohno et al., 1996;Magnan et al., 
1997;Minshall et al., 1997;Vignola et al., 1997) and by absolute protein levels in the 
BAL of asthmatics (Redington et al., 1997). The active signalling
 
of TGF-β, as 
determined by the nuclear immunostaining of
 
phosphorylated Smad 2 (pSmad 2), and 
the increased nuclear
 
expression of Smad 4 has also been reported in
 
the bronchial 
mucosa of asthmatics (Torrego et al., 2007). The airway epithelium is the major site
 
of TGF-β1 expression in non-asthmatics (Magnan et al., 1994) however, the main 
source of TGF-β in an allergic airway remains controversial. Some researchers have 
shown the airway epithelium to be the major source of TGF-β in both asthmatics 
(Sagara et al., 2002;Phipps et al., 2004) and in animal models of allergic airways 
disease (Rosendahl et al., 2001;Kelly et al., 2005;Alcorn et al., 2007), whereas others 
have proposed that eosinophils are the main source of TGF-β in asthmatic airways 
(Minshall et al., 1997;Vignola et al., 1997;Flood-Page et al., 2003).  
 
TGF-β has been linked directly to the underlying processes in airway remodelling, 
specifically epithelial changes, sub-epithelial fibrosis, ASM remodelling and goblet 
cell hyperplasia. In asthmatics, TGF-β–induced apoptosis results in the detachment of 
epithelial cells (Undevia et al., 2004) and TGF-β has also been shown to induce 
epithelial-mesenchymal transition (EMT) in primary
 
airway epithelial cells from 
asthmatics (Hackett et al., 2009). TGF-β signalling promotes ECM synthesis from 
fibroblasts and ASM (Morishima et al., 2001;Gu et al., 2007). Fibroblasts and 
myofibroblasts are the primary
 
source of ECM deposition in sub-epithelial fibrosis 
(Matsumoto et al., 2005) and TGF-β promotes the differentiation of fibroblasts to 
myofibroblasts, as well as promoting myofibroblast proliferation (Michalik et al., 
2009). In addition, TGF-β induces the expression of matrix metalloproteinases 
(MMPs) and
 
tissue inhibitors of metalloproteinases (TIMPs), both of which
 
regulate 
ECM deposition (Mattos et al., 2002).
 
TGF-β can also contribute to fibrosis indirectly 
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by triggering the production of IL-6, which is linked with increased collagen
 
synthesis and AHR (Gomes et al., 2005).
 
TGF-β can directly promote ASM 
hypertrophy, which can influence airway responsiveness (Chen and Khalil., 
2006;Goldsmith et al., 2006). TGF-β has also been shown to increase the proliferation 
of ASM cells and TGF-β also enhances the migration of ASM cells, which 
contributes to tissue remodelling (Chen and Khalil., 2006). TGF-β has also been 
shown to promote goblet cell hyperplasia, by inducing the transcription and 
translation
 
of mucin in bronchial epithelial cells (Chu et al., 2004).  
 
In addition to asthmatic patient findings, TGF-β expression is increased in murine 
models
 
of allergic airway disease, induced by fungal extracts (Blease et al., 2002) and 
OVA respectively (Kumar et al., 2004;McMillan and Lloyd, 2004;Kelly et al., 2005). 
Blockade of TGF-β using a TGF-β neutralising Ab reduced OVA-induced airway 
remodelling (McMillan et al., 2005;Alcorn et al., 2007). TGF-β signalling through 
Smad 2/3 also mediated fibroblast α-smooth muscle actin expression, which is a 
marker of myofibroblast differentiation, and Smad 3 KO mice demonstrated reduced 
OVA-induced airway remodelling (Kobayashi et al., 2006;Le et al., 2007). Following 
the induction of allergic airway disease, decreases in airway fibrosis were associated 
with a reduction in myofibroblasts without associated changes in inflammation (Le et 
al., 2007). Furthermore, overexpression of TGF-β in the lung induced severe fibrosis 
with ECM deposition (Sime et al., 1997;Kolb et al., 2002). 
 
1.2. The Airway Epithelium: Central to Asthma Pathogenesis 
1.2.1. Structure of the Airway Epithelium 
 
The airway epithelium is the first point of contact of inhaled pathogens with the lung 
and forms a complex physicochemical
 
barrier complemented by the mucociliary 
escalator to provide
 
an important first line of defence against inhaled pathogens 
(Vareille et al., 2011). The airway
 
epithelium is pseudostratified in the large airways, 
becoming
 
columnar and cuboidal in the small airways, and the major cell types
 
are 
ciliated columnar, undifferentiated, secretory and basal
 
cells (Crystal et al., 2008). 
Ciliated columnar epithelial cells are the predominant cell type within the airways, 
accounting for over 50% of all epithelial cells, and the primary role of these cells is 
the directional transport of mucus from the lung to the throat (Crystal et al., 2008). 
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Mucus overlying the airway epithelium provides protection
 
by creating a semi-
permeable barrier that enables
 
the exchange of nutrients, water, and gases while being 
impermeable
 
to most pathogens (Voynow and Rubin, 2009). The epithelial basement 
membrane acts as an anchor for the epithelium and facilitates adhesion and migration 
of epithelial cells, as well as being essential for regulating the phenotype of epithelial 
cells and establishing and maintaining polarity. The basement membrane also acts as 
a barrier between the surface epithelium and the underlying mesenchymal 
compartments (Terranova et al., 1980;Boudreau et al., 1996).  
 
Epithelial cells are connected by cell-cell junctions located at the apex of columnar 
cells (Mullin et al., 2005). These junctions are composed of tight junctions (TJs), 
adherens junctions (AJs), gap
 
junctions and desmosomes that maintain structural 
integrity (Roche et al., 1993;Knight, 2002). Inter-epithelial junctions form an 
impermeable
 
and effective mechanical barrier and permit maintenance of an
 
ionic 
gradient for directional secretion of many substances (Davies and Garrod., 1997), as 
outlined in Figure 1.3. TJs are the most important
 
for maintaining epithelial integrity 
and consist of a series
 
of interacting proteins and receptors which ensure 
impermeability
 
of the barrier and also enable communication between adjacent
 
cells 
and regulate intercellular transport (Roche et al., 1993). TJs are composed of the 
proteins claudins, occludin, tricellulins, junctional adhesion molecules, cytoplasmic 
linker proteins zonula occludens (ZO)-1, ZO-2, and ZO-3, and associated signalling 
molecules and cell cycle regulators that control proliferation and differentiation 
(Steed et al., 2010).
 
Under normal circumstances the epithelium forms a highly 
regulated and almost impermeable barrier through the formation of TJs (Godfrey, 
1997). Located below
 
TJs, AJs provide important adhesive contacts between 
neighbouring
 
epithelial cells. E-cadherin, a component of AJs, is an important 
regulator of airway epithelial innate immune function (Nawijn et al., 2011). Gap 
junctions are cell-to-cell channels
 
that allow diffusion of small metabolites, second 
messengers and ions between neighbouring cells (Mese et al., 2007). Desmosomes 
are intercellular junctions that provide strong
 
adhesion between cells and form 
adhesive bonds in a network
 
which gives mechanical strength to tissues (Green and 
Simpson, 2007). Thus, through the physical presence and the network
 
formed at the 
surface of the airway mucosa, epithelial cells
 
represent an efficient and crucial first-
line of defence against aeroallergens. 
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Figure 1.3. An overview of inter-epithelial junctions. 
Key components of epithelial tight junctions, adherens junctions, gap junctions and 
desmosomes are shown. Together these structures maintain an almost impermeable 
barrier and prevent transepithelial delivery of allergens and other inhaled substances 
into the basal regions. 
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1.2.2. Airway Epithelium and Asthma 
 
Previously, the epithelium was considered to be only a physical barrier between the 
external environment and the inner tissues of the lung. However, the epithelium is 
now regarded as playing a pivotal in asthma pathogenesis (Holgate, 2008). Building 
further on this concept, a new paradigm for persistent asthma has emerged by which a 
damaged epithelium repairs incompletely and leads to a chronic wound scenario with 
the secretion of a range of growth factors capable of driving structural changes linked 
to airway remodelling (Holgate et al., 2009;Crosby and Waters, 2010). 
 
Epithelial Damage and Airway Remodelling 
 
Epithelial desquamation is a pathological feature of asthma (Shebani et al., 
2005;Shahana et al., 2006). In asthma, the epithelium is more fragile, compared to 
non-asthmatics, with easy loss of the columnar cells due to disruption of both TJs and 
desmosomal attachments (Montefort et al., 1992;Shebani et al., 2005;Shahana et al., 
2006;Barbato et al., 2006). Bronchial biopsy studies from asthmatics demonstrate 
physical damage to the columnar cell layer, epithelial metaplasia and damage, 
thickening of the sub-epithelial basal lamina and increased numbers of 
myofibroblasts (Fedorov et al., 2005;Saglani et al., 2005;Barbato et al., 2006). 
Evidence from asthmatics suggests that a dysfunctional
 
epithelium displaying an 
abnormal structure and immunological
 
profile can result in a compromised airway 
epithelial
 
barrier (Diamond et al., 2000;Fokkens and Scheeren, 2000;Knight and 
Holgate, 2003), with the barrier function of the airway epithelium being shown to be 
impaired in asthmatics (Knight, 2002;Swindle et al., 2009) and increased epithelial 
permeability has also been shown in vivo (Ilowite et al., 1989). Epithelial TJs in 
asthmatics have been shown to be severely disrupted and this is correlated with 
increased epithelial permeability (Wan et al., 2000). It has been reported that 
expression of ZO-1 and E-cadherin is lower in asthmatics compared to non-
asthmatics, suggesting a broad defect in adhesion mechanisms (de Boer et al., 
2008;Xiao et al., 2011). Impaired wound healing and failure to form adequate TJs 
suggest that the epithelium is primarily defective in asthma (Holgate, 2007;de Boer et 
al., 2008). 
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The expression of markers of cell stress are also a further indication of epithelial 
injury in asthmatics (Bertorelli et al., 1998;Comhair et al., 2001;Ercan et al., 
2006;Mak et al., 2007;Cohen et al., 2007) and in murine models of allergic airways 
disease (Truong-Tran et al., 2002). These markers of cell stress include enhanced 
surface expression of epidermal growth factor receptors (EGFRs) (Polosa et al., 
2002;Hamilton et al., 2003;Hamilton et al., 2005) and toll-like receptors (TLRs) 
(Ritter et al., 2005). Markers of cell stress have also been observed in moderate and 
severe childhood asthma (Fedorov et al., 2005), suggesting that epithelial injury and 
aberrant repair is involved at the disease initiation. Evidence of epithelial damage 
with upregulation of EGFRs and features of impaired proliferation, such as reduced 
expression of proliferative markers (Puddicombe et al., 2003) suggest that the 
epithelium is chronically injured and unable to repair properly (Bucchieri et al., 
2002;Kicic et al., 2006). 
 
Asthma Susceptibility Genes and the Airway Epithelium  
 
Genetic studies have revealed molecules and pathways that may underlie the origins 
of asthma (Meurer et al., 2006;Holloway et al., 2010). A number of recently 
identified asthma susceptibility genes are preferentially expressed in either the 
epithelium or underlying mesenchyme and smooth muscle. This is in addition to 
asthma susceptibility genes located in the immune or inflammatory pathways 
(Cookson, 2004;Vendelin et al., 2005). Asthma susceptibility genes expressed in the 
epithelium and/or the underlying ASM include POSTN, SERPINB2, CLCA1, 
COL29A1, DPP10, GPRA, HLA-G, IRAKM and PHF11 (Woodruff et al., 
2007;Vercelli, 2008). Indeed, many of the molecules that are involved in disordered 
epithelial–mesenchymal signalling in asthma are also utilised in fetal branching 
morphogenesis of the lung, suggesting that asthma at least in some of its 
manifestations has morphogenetic origins (Holgate et al., 2006;Eder et al., 2006). 
These findings strengthen the idea that asthma occurs as a result of aberrant gene 
expression within the epithelium and that structural cells are key drivers of the 
allergic response.  
 
Sentinel Role of the Airway Epithelium 
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Epithelial cells lining the respiratory tract constitute the primary cellular barrier and 
orchestrate immune responses to inhaled allergens. Airway epithelial cells possess 
microbial detection mechanisms, and these cells express a specifically localised set of 
PRRs (Hammad and Lambrecht, 2008). The PRRs present on the airway epithelium 
include TLRs, the nucleotide-binding oligomerisation domain protein (NOD)-like 
receptors (NLRs), and the RNA retinoic-acid-inducible gene-I (RIG)-like receptors 
(RLRs), as well as protease-activated receptors (PARS) 1 – 4 that allow recognition 
of protease active allergens. TLRs are a family of PRRs that are type I membrane 
glycoproteins, consisting of extracellular leucine rich repeats (LRRs) and a 
cytoplasmic Toll/interleukin-1 receptor (TIR) domain, required for PAMP 
recognition and downstream signalling, respectively (Kawai and Akira, 2010). For a 
current update on TLRs, NLRs and RLRs and the association with allergic diseases, 
these have recently been reviewed (Heine, 2011). PARs are a family of cell surface, 
proteolytically activated G-protein coupled receptors (GPCRs) that have a unique 
mechanism of activation that distinguishes them from other GPCRs (Macfarlane et 
al., 2001). When PARs are activated by proteolytic cleavage of a specific site within 
the receptor N-terminus, a tethered ligand (TL) is produced that binds to and activates 
the receptor (Coughlin, 2005;Steinhoff et al., 2005;Adams et al., 2011).  
 
The ligation of TLRs and PARs expressed by epithelial cells leads to a cascade of 
events that culminates in the production of chemokines that attract neutrophils, 
monocytes and DCs to the airways, and to the production of cytokines that can induce 
DC maturation including TSLP, IL-25 (IL-17E) and IL-33 (Stumbles et al., 2001;Kiss 
et al., 2007;Ebeling et al., 2007). The expression of TLRs and PARs enables airway 
epithelial cells to respond to antigens and allergens, thereby initiating the first step in 
the host–pathogen interaction. The epithelial barrier influences the development of 
antigen-specific immunity, suggesting that the type of immune response elicited by 
the host highly depends on the nature of the response defined by the local tissue 
microenvironment. Innate immune recognition by barrier cells determines the 
functional properties of tissue-residing DCs, thereby instructing the outcome of 
antigen-specific immunity (Hammad and Lambrecht, 2008). 
 
Epithelial Communication with DCs 
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Airway DCs form a dense network in the lung where they are ideally placed to 
sample inhaled antigens (Holt et al., 1990;Huh et al., 2003). Mucosal DCs are 
situated in the basolateral space and are only separated from the inhaled air by the 
epithelial TJ barrier (GeurtsvanKessel and Lambrecht, 2008). In the airways, DCs can 
extend dendrites between epithelial cells directly into the airway lumen, thus 
performing a periscope function enabling continuous immune surveillance of the 
airway lumen (Jahnsen et al., 2006). In mice intraepithelial airway CD103
+
 DCs 
express the TJ proteins claudin-1, claudin-7 and ZO-2, which form TJs with airway 
epithelial cells, thereby allowing DCs to sample the content of the airway lumen 
without disturbing the function and integrity of the epithelial barrier (Sung et al., 
2006). Airway epithelial cells regulate both innate and adaptive immunity
 
through 
production of functional molecules and physical interactions
 
with cells of the immune 
system. Activation of epithelial cells
 
results in immediate host defence responses that 
include production
 
of pro-inflammatory cytokines
 
which recruit and activate other 
mucosal innate immune cells
 
and initiate mechanisms of adaptive immunity 
(Hiemstra, 2001).
 
The epithelium can produce a diverse array of lipid mediators, 
growth factors, and bronchoconstricting peptides, as well as chemokines and 
cytokines (Stumbles et al., 2001;Reibman et al., 2003;Pichavant et al., 2005). As part 
of the innate immune function in response to allergens and TLR ligands, epithelial 
cells produce cytokines that attract and activate DCs including TSLP, IL-25 (IL-17E), 
IL-33 and CCL20/MIP-3α, as outlined in 1.1.2.1.  
 
1.3. House Dust Mite  
 
House dust mites (HDM) are arthropods belonging to the subphylum Chelicerata, 
class Arachnida, order Acari, and suborder Astigmata (Arlian and Platts-Mills., 
2001). Dermatophagoides was first identified as the source of allergen associated 
with house dust in 1967 (Voorhorst et al., 1967) and thirteen species have since been 
found in house dust. The most common of these species are Dermatophagoides 
pteronyssinus and Dermatophagoides farinae that are found in temperate climates 
(Arlian and Platts-Mills., 2001). Dermatophagoides pteronyssinus is generally found 
in Europe, and Dermatophagoides farina is generally found in North America 
(Thomas., 2010;Thomas et al., 2010).  
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Mite bodies and mite faeces are the sources of many allergens (Tovey et al., 
1981;Arlian et al., 1987). The allergens associated with mite faecal matter are 
enzymes that originate from the digestive tracts of the mites. However, some 
allergens may be components of mite saliva that is left in the environment on food 
substrates where mites feed. Secretions from the supracoxal glands that are involved 
in the active uptake of water likely contain proteins, as well as sodium and potassium 
chloride (Wharton and Furumizo, 1977). After death, soluble protein in body fluids 
may be released as the mite body disintegrates. 
 
Allergens derived from HDM are perennial and are one of the most frequently 
associated with allergic asthma, in temperate climates (Fernández-Caldas., 
2002;Thomas et al., 2010). House dust can contain a huge number of proteins and 
structures, many of which have been shown to induce IgE production and many 
asthmatics have raised levels of HDM-specific IgE (Maunsell et al., 1968;McAllen et 
al., 1970). The allergens associated with HDM have been identified by analysing 
aqueous extracts of whole mites, nymphs, faecal pellets and eggs (Thomas et al., 
2010). 
 
1.3.1. HDM Allergenicity 
 
Mite allergens are divided into specific groups on the basis of their biochemical 
composition, sequence homology, and molecular weight, as summarised in Table 1.1. 
Absolute IgE-binding measurements have been used to establish the hierarchy of the 
isolated Dermatophagoides pteronyssinus allergens (Hales et al., 2006). Laboratory 
investigations have used preparations of HDM extract in order to elicit allergic 
responses in vitro and in vivo. The majority of the allergenicity has been attributed to 
group 1 (Der p 1 or Der f 1) and group 2 (Der p 2 or Der f 2) allergens (Robinson et 
al., 1997). The cellular and molecular mechanisms driving the allergic phenotype and 
sensitisation in mouse models of HDM allergic asthma have recently begun to be 
elucidated.  
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Allergen Biological Action/Homology Molecular Weight (kDa) Frequency of Reactivity Reference 
Der p 1 Cysteine protease 24 >90% (Chruszcz et al., 2009) 
Der p 2 MD-2 homologue 15 >90% (Gafvelin et al., 2001) 
Der p 3 Serine protease 31 57 – 90% (Cheong et al., 2003) 
Der p 4 Alpha amylase 60 25 – 46% (Hales et al., 2007) 
Der p 5 Alpha helical protein 14 45 – 60% (Mueller et al., 2010b) 
Der p 6 Serine protease 25 40 – 60% (Chapman et al., 2007) 
Der p 7 Lipid binding protein 26, 30 and 31 50% (Mueller et al., 2010a) 
Der p 8 Glutathione S-transferase 27 40% (O'Neill et al., 1994) 
Der p 9 Serine protease 29 80% (King C et al., 1996) 
Der p 10 Tropomysin 36 60% (Yi et al., 2002) 
Der p 11 Paramyosin 103 41-67% http://www.allergen.org/viewallergen.php?aid=291 
Der p 12 Chitinase   (Thomas et al., 2010) 
Der p 13 Lipocalin   (Batard et al., 2006) 
Der p 14 Apolipophorin 177 70% (Thomas et al., 2005) 
Der p 15 Chitinase 59-61 70% 
(O'Neil et al., 2006) 
Der p 18 Chitinase 49.2 63% 
(O'Neil et al., 2006) 
Der p 20 Arginine kinase   (Hales et al., 2007) 
Der p 21 Alpha-helical protein (Similar to Der p 5) 15 26% (Weghofer et al., 2008) 
Der p 23 Peritrophin-A 14 Unknown http://www.allergen.org/viewallergen.php?aid=296 
 
Table 1.1. Characterisation of HDM allergens. 
Information was derived from the respective scientific publication or the following allergen websites; www.allergen.org – the official site for the systematic 
allergen nomenclature approved by the World health organisation and International Union of Immunological Societies. www.allergome.org – contains 
information on allergenic molecules causing allergic diseases. http://pfam.sanger.ac.uk. - protein classification database 
www.meduniwien.ac.at/allergens/allfam – database for classifying allergens into protein families. 
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HDM Proteases 
 
Group 1 allergens (Der p 1 and Der f 1) are cysteine proteases and those allergens of 
groups 3, 6 and 9 are serine proteases (Der p 3, 6, 9 and Der f 3, 6, 9) (Chapman et 
al., 2007). The protease activity of these allergens accounts for 79% of the proteolytic 
activity of house dust (Stewart et al., 1994). The protease activity of groups 1, 3, 6 
and 9 allows HDM to evoke a wide range of biological effects which may be critical 
to development of allergen sensitisation. Der p 1 is one of the common allergens 
associated with HDM and it has been the most widely and frequently studied. 
However, in addition to Der p 1, the other protease active allergens within HDM and 
their links to allergy have been investigated.  
 
Der p 1 can directly program Th2 responses by interacting with cells of the immune 
system. The proteolytic activity of Der p 1 has been shown to promote the activation, 
function and behaviour of DCs and the enzymatic activity of this allergen is pivotal in 
directing DCs to induce Th2 responses, while concomitantly dampening Th1 
responses. Der p 1 increased the expression of CD86 on DCs from HDM allergic 
patients, which was associated with elevated T cell proliferation and production of the 
pro-inflammatory cytokines TNF-α and IL-1β (Hammad et al., 2001). Der p 1 has 
also been shown to cleave and decrease the expression of DC-specific intercellular 
adhesion molecule-3-grabbing non-integrin (DC-SIGN) and DC-SIGN-receptor (DC-
SIGN-R) on DCs, which resulted in reduced Th1 cytokine production 
(Furmonaviciene et al., 2007;Huang et al., 2011). DCs matured with Der p 1 also 
produced significantly less IL-12, due to the cleavage of CD40 by the proteolytic 
activity of Der p 1, which rendered DCs less responsive to stimulation through the 
CD40L-CD40 pathway (Ghaemmaghami et al., 2002). Concomitantly, DCs matured 
in the presence of Der p 1 produced less IFN-γ and more IL-4 by CD4+ T cells, 
compared to DCs that were matured in the presence of proteolytically inactive Der p 
1 (Hammad et al., 2001;Ghaemmaghami et al., 2002). Der p 1-pulsed DCs from 
allergic patients also showed increased production of the Th2-associated chemokines 
TARC/CCL17 and MDC/CCL22, without altering the release of the Th1 associated 
chemokine IFN-γ-induced protein-10 (IP-10)/CXCL10 (Hammad et al., 2003). The 
pro-inflammatory effects of Der p 1 are not restricted to DCs, as basophils upon 
exposure to Der p 1 can produce IL-4, IL-5 and IL-13 (Phillips et al., 2003). Der p 1 
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has been shown to further promote Th2 responses by cleaving CD25 on T cells, 
which results in diminished IFN-γ production (Shakib et al., 1998;Schulz et al., 
1998;Harris et al., 2004). A direct link between HDM and IgE production has also 
been demonstrated, whereby Der p 1 cleaves the low affinity IgE receptor (FcεRII) 
CD23 on B cells. Since CD23 regulates IgE uptake, by interfering with the negative 
feedback loop regulating IgE, Der p 1 stimulates IgE production as a consequence 
(Hewitt et al., 1995;Schulz et al., 1995). In addition to having a direct effect on B 
cells and IgE production, human T cells exposed to Der p 1 augment IgE synthesis by 
B cells (Ghaemmaghami et al., 2001).   
 
Natural protective mechanisms present in the airway are also targeted by Der p 1, 
whereby Der p 1 degrades lung surfactant proteins (SP)-A and SP-D that are critical 
components of the host defence. SP-A and SP-D are calcium-dependent 
carbohydrate-binding proteins predominantly synthesised and secreted in the lung by 
alveolar type II cells and Clara cells (Hickman-Davis and Matalon, 1999;Hansen and 
Holmskov., 2002). In addition to playing a crucial role in innate immune defence by 
modulating leukocyte function, SP-A and SP-D have also been implicated in the 
allergic response. SP-A and SP-D interact with Der p 1 by competing with their 
binding to cell-sequestered IgE resulting in inhibition of mast cell degranulation. 
Thus, the degradation and consequent inactivation of SP-A and SP-D by Der p 1 may 
also contribute to elevated IgE levels and to the potent allergenicity of HDM (Deb et 
al., 2007). α1-anti-trypsin protects the lower respiratory tract against damage by 
proteases and Der p 1 catalytically inactivates α1-anti-trypsin, thereby reducing the 
defensive capabilities of the airway (Kalsheker et al., 1996). α1-anti-trypsin 
deficiency is associated with the onset of childhood asthma and cleaved α1-anti-
trypsin has been shown to be recruit neutrophils in vivo (Banda et al., 1988;Lindmark 
et al., 1990). Thus inactivation of the major natural inhibitor of neutrophil enzymes 
by Der p 1 may exacerbate tissue damage and contribute to inflammation. 
 
The most widely investigated impact of Der p 1, 3, 6 and 9, has been on airway 
epithelial cells, with protease active allergens from HDM increasing epithelial 
permeability (Herbert et al., 1990;Herbert et al., 1995) and promoting pro-
inflammatory cytokine release (Kauffman et al., 2006). Der p 1, 3, 6 and 9 have been 
shown to degrade epithelial TJs and increase epithelial permeability. The protease 
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active allergens disrupted intercellular TJs, via proteolysis of occludin and ZO-1, 
desmosomes and adherens junctions, thereby altering the structure and organisation 
of the airway epithelium (Herbert et al., 1995;Wan et al., 1999;Wan et al., 2001). 
Importantly, these findings suggest that the disruption of epithelial TJs may be the 
initial step in the development of asthma to a variety of allergens. By increasing 
epithelial permeability, conditions would be optimum for the transepithelial delivery 
of allergens allowing for greater access to APCs residing in the airway mucosa. 
However, the impaired barrier function observed in asthmatics (Bhure et al., 2009) is 
not replicated following a single dose of HDM extract when administered to mice in 
vivo (Turi et al., 2011) and, therefore, may be a function of chronic as opposed to 
acute exposure. Airway epithelial cells upon exposure to Der p 1, 3, 6 and 9 release a 
vast array of pro-inflammatory cytokines and chemokines, including MCP-1/CCL2, 
IL-6, IL-8, GM-CSF, eotaxin-1/CCL11 (Tomee et al., 1998;King et al., 1998;Sun et 
al., 2001;Asokananthan et al., 2002a;Asokananthan et al., 2002b;Gough et al., 
2003;Pichavant et al., 2005;Adam et al., 2006;Kauffman et al., 2006) and TSLP 
(Kouzaki et al., 2009), that attract neutrophils, eosinophils, monocytes and DCs to the 
airways, and induce DC maturation.  
 
The release of pro-inflammatory mediators from the airway epithelium has been 
shown to require PAR2 (Asokananthan et al., 2002a;Kauffman et al., 2006;Adam et 
al., 2006). In addition to airway epithelial cells (Asokananthan et al., 2002a), PAR2 is 
also expressed by fibroblasts (Akers et al., 2000), macrophages (Colognato et al., 
2003), mast cells (D'Andrea et al., 2000) and DCs (Ramelli et al., 2010). The 
expression of PAR2 by DCs and airway epithelial cells is of particular significance as 
this allows the recognition of protease active allergens. Asthmatics have increased 
expression of PAR2 on respiratory epithelial cells compared to non-asthmatics 
(Knight et al., 2001) and proteases can activate PAR2 in the airways to generate 
leukocyte infiltration and to amplify the response to allergens (Cocks and Moffatt, 
2001;Lan et al., 2002;Reed and Kita, 2004). Activation of PARs on eosinophils and 
mast cells cause these cells to degranulate and release pro-inflammatory mediators 
(Schmidlin et al., 2002;Stenton et al., 2002). Fibroblasts mature and proliferate and 
produce collagen in response to activation of PARs on the cell surface (Akers et al., 
2000). Proteases can induce bronchial smooth muscle contraction and proliferation 
(Hauck et al., 1999;Miglino et al., 2011) and are capable of activating basophils in the 
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absence of antigen-specific IgE (Siracusa et al., 2010). An important function of 
PARs in the respiratory system involves the regulation of airway tone by causing 
either the contraction or relaxation of smooth muscle cells (Lan et al., 2002). PAR2 
involvement has also been demonstrated in remodelling of the lung, through the 
secretion of pro-inflammatory and pro-fibrotic mediators (Mercer et al., 2007), the 
production of ECM components and through stimulating cell mitogenesis (Moffatt et 
al., 2004). HDM proteases stimulate EMT in airway epithelial cells, leading to airway 
remodelling (Heijink et al., 2010a;Heijink et al., 2010b). The redistribution of E-
cadherin in human bronchial epithelial cells by mite protease allergens has been 
shown to be mediated through EGFR-dependent activation of PAR2 (Heijink et al., 
2010a). 
  
In several other studies, there have been mechanisms proposed by which other HDM 
proteases can further polarise the immune response to an allergic, Th2-driven 
phenotype. These include the findings that, Der p 3 cleaves the C3 and C5 
components of complement pathway to produce anaphylatoxins (Maruo et al., 1997). 
Products of C3 and C5 cleavage are C3a and C5a respectively, which can cause 
smooth muscle contraction, histamine release from mast cells, and inflammatory cell 
recruitment (Wills-Karp, 2005).  
 
HDM and TLR Signalling 
 
TLRs are strategically located on structural cells, such as epithelial cells, and immune 
cells, including DCs, macrophages and T cells, to detect PAMPs (Akira et al., 2006). 
LPS is the primary ligand for TLR4 and, although not a HDM-specific component, 
LPS is routinely detected in HDM extracts (Douwes et al., 2000). The role of LPS 
and asthma has been widely investigated and a complex role has been highlighted 
whereby LPS
 
exposure has been shown to both protect against and promote the 
development of asthma. An up-to-date review on LPS and association with asthma 
has recently been carried out (Doreswamy and Peden, 2011). Mechanistically, the 
role of LPS in either promoting or being protective against asthma is believed to be as 
a consequence of differing exposure levels. This has been addressed in vivo, with 
Eisenbarth and colleagues showing that mice primed with low-dose LPS before OVA 
exposure developed Th2 responses via TLR4 signalling and activation of DCs. 
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However, high-dose LPS was shown to induce a Th1, IL-12-driven response and in 
the absence of LPS there was no inflammatory response (Eisenbarth et al., 2002).  
 
With respect to HDM, two studies have suggested that LPS present in the inhaled 
HDM extract is pivotal in the generation of HDM-induced allergic airway 
inflammation. Mice deficient in either TLR4 or a key TLR adaptor protein myeloid 
differentiation primary response gene 88 (MyD88) have attenuated HDM-induced 
AHR, eosinophilia and Th2 responses (Phipps et al., 2009). An essential role for 
TLR4 signalling on airway epithelial cells, but not DCs, has also been shown to be 
required for the development of HDM-specific Th2 responses (Hammad et al., 2009). 
TLR activation on epithelial cells also results in transactivation of the EGFR (Koff et 
al., 2008), which can cause inflammatory cell migration and production of pro-
allergic cytokines. EGFR signalling in the airway epithelium plays an important role 
in mediating HDM-induced AHR and ASM remodelling (Le Cras et al., 2011). 
 
In addition to LPS, HDM allergens have been shown to signal via TLRs or have been 
strongly linked with TLR signalling. The group 2 allergens, Der p 2 and Der f 2, have 
the highest rates of skin test positivity in atopic patients (Heymann et al., 1989). 
Sequence homology has shown that group 2 allergens share structural similarities 
with the MD-2, which is the LPS-binding component of the TLR4 signalling complex 
(Inohara and Nunez, 2002;Derewenda et al., 2002;Ohto et al., 2007;Kim et al., 2007). 
Der p 2 has been shown to facilitate TLR4 signalling, in both in a low dose LPS 
setting and in MD-2 deficient mice, thereby suggesting that Der p 2 has auto-adjuvant 
properties contributing to allergenicity (Trompette et al., 2009). The ability of Der p 2 
to reconstitute LPS-driven TLR4 signalling in the absence of MD-2 is of critical 
importance in the lung, since airway epithelial cells express TLR4 but not MD-2 (Jia 
et al., 2004). Administration of Der p 2 has been shown to induce the characteristics 
of allergic airways directly in vivo, including eosinophilia, inflammatory cell 
recruitment, goblet cell hyperplasia and IgE production (Trompette et al., 2009;Ye et 
al., 2011). Der p 2 has also been shown to promote pro-inflammatory cytokine 
release via NF-κB and MAPK pathways in primary cultured ASMCs (Chiou and Lin, 
2009) and epithelial cells (Osterlund et al., 2009). 
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Der p 5, 7 and 14 elicit strong IgE and T cell responses in patients with HDM allergy 
(Chew et al., 1999;Epton et al., 2001;Thomas and Hales., 2007). Airway epithelial 
cells exposed to Der p 5 secrete the pro-inflammatory cytokines IL-6 and IL-8 
(Kauffman et al., 2006). Der p 5 has also been shown to create large hydrophobic 
cavities (Kuo et al., 2003), which could have functional significance as these cavities 
could represent ligand binding sites that allow the transport of lipid based PAMPs, 
similar to Der p 2. Since many allergens are known to bind hydrophobic cavities, Der 
p 5 is believed to stimulate the innate immune system and have adjuvant-like effects 
on IgE-mediated inflammatory responses (Mueller et al., 2010b). Although no studies 
to date have evaluated the direct stimulation of innate immune cells by group 7 
allergens, Der p 7 is of a similar structure to LBP, which interacts with TLRs after 
binding LPS and Der p 7 binds the bacterially derived lipid product, lipopeptide 
polymyxin B (Mueller et al., 2010a). Der p 14 is a member of the apolipophorin-like 
group 14 allergens which are also lipid binding proteins and is a major constituent of 
the lipid bodies that can act as Th2 adjuvants (Brewer et al., 1998). Allergens from 
HDM of groups 13 and 21 can, according to sequence homology, also be considered 
lipid-binding proteins (Thomas et al., 2010). 
 
HDM and Carbohydrate Structures 
 
Carbohydrate moieties contained in common allergens function as strong Th2 
inducers through activation of a variety of C-type lectin receptors (CLRs) on DCs. 
Glucans are a diverse class of naturally occurring glucose polymers and are 
commonly found in the cell walls of fungi, pollens and bacteria (Hay et al., 1992) and 
β-glucans are also present within HDM extracts (Douwes et al., 2000). HDM has 
been shown to induce the release of the chemokine CCL20/MIP-3α from human 
airway epithelial cells, which resulted in the recruitment of immature DCs via CCR6. 
This was shown to occur through β-glucan and spleen tyrosine kinase (Syk)-
dependent signalling pathways and independently of TLR activation and protease 
activity (Nathan et al., 2009). Importantly, neither ragweed nor cockroach allergens 
were able to elicit CCL20/MIP-3α production, suggesting that this allergenic property 
may be unique to HDM (Nathan et al., 2009). Although the exact lectin receptor 
mediating these effects was not identified, the results suggested that β-glucan 
moieties contained in HDM were central to immature DC recruitment to the airways. 
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Dectin-2 is a receptor for glycans in allergen extracts from HDM and has been shown 
to mediate cysteinyl leukotriene generation from DCs, thus providing a link between 
Dectin-2 and the initiation of Th2 inflammation elicited by HDM (Barrett et al., 
2009;Barrett et al., 2011).  
 
Glycosylation of natural Der p 1 and Der p 2 promoted the uptake of these allergens 
by DCs following binding to the mannose receptor (MR), which plays a key role in 
Th2 polarisation (Royer et al., 2010). Ligation of the MR also polarises human DCs 
towards a Th2 promoting phenotype and, consistent with a role for lectins in 
promoting Th2 immune responses, blockade of the MR significantly reduced Der p 1 
uptake by DCs (Deslee et al., 2002). Binding of the naturally glycosylated Der p 2 to 
DC-SIGN on DCs elicited the release of TNF-α, whereas unglycosylated Der p 2 
cannot activate this receptor (Hsu et al., 2010). 
 
Chitin and Chitinases 
 
The exoskeleton of HDM contains chitin, a widespread environmental biopolymer of 
N-acetyl-β-D-glucosamine and provides structural rigidity to mites (Elias et al., 
2005;Lee et al., 2011). Chitin is considered a size-dependent PAMP that stimulates 
TLR2, Dectin-1 and the MR (Koller et al., 2011) and chitin differentially stimulates 
the production of pro- and anti-inflammatory cytokines (Lee et al., 2011). Chitin acts 
as a recognition element for tissue infiltration by innate cells and induces the 
accumulation of IL-4-expressing eosinophils and basophils in mice (Reese et al., 
2007). Thus the chitin presence within the dust mite itself may provide another 
pathway by which HDM can elicit activation of the immune system.  
 
Der p 15 and Der p 18 are chitinase allergens and show a high frequency of binding 
to IgE in allergic patients and are therefore potentially important in the development 
of allergy to HDM (McCall et al., 2001;O'Neil et al., 2006). Der p 15 and 18 thus are 
a different class of epitope within HDM and chitinases catalyse the hydrolysis of N-
acetyl-D-glucosamine 1,4-β-linkages in chitin polymers. Chitinases are essential for 
the arthropod life cycle and important for arthropod gastrointestinal epithelia (O'Neil 
et al., 2006). 
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Immune Sensing and Danger Signals 
 
An additional avenue by which HDM could promote airway inflammation is through 
the release of DAMPS, such as uric acid and ATP that are normally located 
intracellularly but are released into the extracellular regions upon physical or 
metabolic stress (Matzinger, 2002). HDM exposure has also been shown to release 
uric acid into the BAL of asthmatics and uric acid promotes DC activation directly 
through a Syk/PI3K δ signalling pathway (Kool et al., 2011).  
 
ATP is released in the airways of allergen-challenged patients and contributes to 
disease pathogenesis via signalling at purinergic receptors, expressed at the epithelial 
surface (Idzko et al., 2007). Der p 1-mediated stimulation of eosinophils and DCs 
derived from HDM allergic subjects resulted in increased P2Y2 receptor expression 
that is not observed in non-atopic patients, and is accompanied by eosinophil and DC 
chemotaxis to ATP (Muller et al., 2010).  
 
1.3.2. HDM and the Immune Response 
 
HDM is the most common allergen associated with atopic asthma (Nelson et al., 
1996;Lodge et al., 2011). However, there is still an incomplete understanding of the 
allergenic components of HDM and the precise mechanisms by which HDM 
facilitates the development of allergic airways disease in vivo at the site of the airway 
epithelium. A more complete understanding of both HDM allergenicity and the 
contribution of airway structural cells and aspects of the innate immune system 
directing such robust Th2 inflammatory responses will likely lead to the development 
of new therapeutic strategies, particularly targeting airway remodelling. A summary 
of the known interactions of HDM with the airway epithelium is shown in Figure 1.4. 
 
Thus the establishment and characterisation of a murine model of HDM-induced 
allergic airways disease will be the initial basis of this thesis. Using this model, the 
contribution of TLR signalling and the role of intrinsic protease in the development of 
allergic airways disease will be investigated. This murine model of HDM-induced 
allergic airways disease will also be utilised to determine the role of TGF-β in disease 
pathogenesis.  
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Figure 1.4. A summary of the interactions of HDM with the airway epithelium. 
HDM is a complex aeroallergen that contains multiple antigenic epitopes that are capable of triggering pro-inflammatory responses at the site of the airway 
epithelium. These facets include proteases, signalling via PAR2-dependent and –independent mechanisms, and ligands that signal via TLRs. Together HDM 
triggers the release of TSLP, IL-25 (IL-17E), IL-33 and CCL20/MIP-3α that are central to DC recruitment and Th2 polarisation.  
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1.4. Hypothesis and Aims 
 
1.4.1. Hypothesis 
 
HDM exposure to immunologically naïve mice will lead to the development of AHR, 
airway inflammation and airway remodelling, characterised by the pulmonary 
expression of Th2 cytokines. Since HDM is a multi-faceted allergen, no single feature 
of HDM will be responsible for the development of disease pathogenesis and several 
aspects of the allergen are responsible for breaching the airway epithelium and 
promoting allergic airways disease. 
 
1.4.2. Aims 
 
The aims of this thesis are to: 
 
Aim 1: 
 
Characterise a murine model of allergic airways disease, whereby continuous 
exposure of immunologically naïve mice to HDM will lead to the development of the 
salient features of human asthma in vivo.  
 
Aim 2: 
 
Utilise this model to determine the contribution of TLR signalling and protease 
activity to the development of HDM-induced allergic airways disease pathogenesis in 
vivo.  
 
Aim 3: 
 
Determine the role of TGF-β in the development of HDM-induced allergic airways 
disease. 
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2.1. Animals 
Female BALB/c, C3H-HeN, C3H-HeJ and C57BL/6 mice were purchased from 
Harlan Olac Ltd (Bicester, UK) and were used at age 6-8 weeks in all experiments.  
MyD88 knockout (KO) animals were originally generated and kindly provided by 
Cancer Research UK. MyD88 KO mice were on a C57BL/6 background, backcrossed 
at least 20 generations and genotyped. Animals were housed at Imperial College 
animal facility with food and water ad libitum. All animal studies were ethically 
reviewed and carried out in accordance with Animals (Scientific Procedures) Act 
1986 and the GSK Policy on the Care, Welfare and Treatment of Laboratory 
Animals. 
 
2.2. Murine models of allergen induced airway inflammation 
House dust mite extract (HDM; Dermatophagoides pteronyssinus; Greer 
Laboratories, Lenoir, NC) was used as the allergen to induce allergic airways disease 
in mice as described below. The Der p 1 content was 31.4 μg per mg of whole protein 
and the LPS content was 20 U per mg of whole protein.  
 
2.2.1. House dust mite challenge  
2.2.1.1. Allergen exposure   
Mice were repeatedly challenged by intranasal (i.n.) instillation of either 15 µl or 25 
µl of a 1 mg/ml solution of whole HDM allergen extract in PBS under inhalational of 
isoflurane anaesthesia. This volume of allergen equates to either 15 µg or 25 µg of 
protein, respectively.  
 
2.2.1.2. HDM exposure   
Female mice were exposed to purified HDM extract (Greer Laboratories, Lenoir, NC) 
i.n. for 5 consecutive days per week for up to 5 weeks, based on the model by 
Johnson and colleagues (Johnson et al., 2004). Control animals received either 15 µl 
or 25 µl PBS i.n. Disease parameters were assessed either 2h, 4h, 8h or 24h post final 
challenge.  
 
2.3. Manipulation of mouse models  
2.3.1. HDM challenge – Chapter 3 
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Female BALB/c mice were administered either 25 µl PBS or 25 µg (in 25 µl) HDM 
i.n. 5 times a week for 3 weeks and culled either 2h, 4h, 8h or 24h post final 
challenge.  
 
2.3.2. HDM challenge in TLR4 signalling deficient mice – Chapter 4 
Female wt C3H-HeN or TLR4 signalling deficient C3H-HeJ mice were given either 
25 µl PBS or 25 µg (in 25 µl) HDM i.n. 5 times a week for 3 weeks and culled 24h 
post final challenge.  
 
2.3.3. Prophylactic treatment with a TLR4 Antagonist – Chapter 4 
Female BALB/c mice administered either 25 µl PBS or 25 µg (in 25 µl) HDM i.n. 3 
times a week for 3 weeks. Prior to each PBS or HDM challenge, mice received either 
vehicle (water) or a TLR4 antagonist (Invivogen, San Diego, CA) 1 µg via the 
intratracheal (i.t.) route. The vehicle or TLR4 antagonist were administered in a 
volume of 20 µl. Mice were culled 24h post final challenge. 
 
2.3.4. HDM challenge in MyD88 knockout mice – Chapter 4 
Female wt C57BL/6 or MyD88 KO mice were administered either 25 µl PBS or 25 
µg (in 25 µl) HDM i.n. 3 times a week for either 1 week, 3 weeks or 5 weeks. Mice 
were culled 24h post final challenge. 
 
2.3.5. Prophylactic treatment with a SAPS Inhibitor – Chapter 4 
Female BALB/c mice given either 25 µl PBS or 25 µg (in 25 µl) HDM i.n. 3 times a 
week for 3 weeks. Prior to each PBS or HDM challenge, mice received either vehicle 
(PBS) or SAPS inhibitor (gift from Anthony Berry, Vaccine Technology Ltd, UK) 1 
mg/Kg i.n. The vehicle or SAPS inhibitor were administered in a volume of 50 µl. 
Mice were culled 24h post final challenge. 
 
2.3.6. Boiled HDM challenge – Chapter 5 
Female BALB/c mice were given either 25 µl PBS, 25 µg (in 25 µl) HDM or 25 µg 
(in 25 µl) boiled HDM (bHDM) i.n. 5 times a week for 5 weeks and culled 24h post 
final challenge. HDM was boiled for 10 minutes at 100
o
C prior to challenge 
(Lombardero et al., 1990;King et al., 1998).  
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2.3.7. Epithelial Permeability – Chapter 5 
Female BALB/c mice were administered either 25 µl PBS, 25 µg (in 25 µl) HDM or 
25 µg (in 25 µl) bHDM i.n. 5 times a week for one week. 24h after the final PBS, 
HDM or bHDM challenge, each mouse was given 20 μl of 50 mg/ml FITC-Dextran 
(4 kDa; Sigma, UK) i.n. and culled 1h later. The amount of FITC-Dextran present in 
the lung homogenate was determined by Fluostar Galaxy software (MTX Lab 
Systems, Virginia, USA). Lung homogenate samples were run against a standard 
curve of FITC-dextran that was generated after being read at an excitation wavelength 
of 490 nm and an emission wavelength of 525 nm. 
 
2.3.8. Labelled HDM – Chapter 5 
Female BALB/c mice were administered either 25 µl PBS, 25 µg (in 25 µl) HDM or 
25 µg (in 25 µl) bHDM i.n. 3 times a week for 1 week. All mice were then given 25 
µg (in 25 µl) of Alexa Fluor-488-labelled HDM and were culled 24h post final 
challenge. HDM was labelled with Alexa Fluor 488 Protein Labeling Kit (Invitrogen, 
UK). A group of PBS-treated mice did not receive the Alexa-488 labelled HDM. 
 
2.3.9. Therapeutic Blockade of TGF-β – Chapter 6 
Female BALB/c mice were administered either 15 µl PBS or 15 µg (in 15 µl) HDM 
3 times a week for 5 weeks. A therapeutic regimen of anti-TGF-β antibody (Ab), 
which neutralised all mouse isoforms of TGF-β (Clone 1D11, Genzyme Corporation, 
MA, USA), was instigated at the beginning of week 3 and mice were given 100 µl of 
either 0.5 mg/Kg or 5 mg/Kg intraperitoneal (i.p.) 30 minutes before each allergen 
challenge. Mice received an isotype (IgG1) control Ab instead of anti-TGF-β Ab and 
served as the controls. Mice were culled either at 4h, for cell analysis, or at 24h, for 
lung function analysis, post final challenge.  
 
2.3.10. Prophylactic Blockade of TGF-β – Chapter 6 
Female BALB/c mice were administered either 15 µl PBS or 15 µg (in 15 µl) HDM 3 
times a week for 3 weeks. A prophylactic regimen of anti-TGF-β antibody (Ab), 
which neutralised all mouse isoforms of TGF-β (Clone 1D11, Genzyme Corporation, 
MA, USA), was instigated at the beginning of week 1 and mice were given 100 µl of 
either 0.5 mg/Kg or 5 mg/Kg i.p. 30 minutes before each allergen challenge. Mice 
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received an isotype (IgG1) control Ab instead of anti-TGF-β Ab and served as the 
controls. Mice were culled 24h post final challenge.  
 
2.4. Non-invasive measurements of lung function 
2.4.1. Whole body plethysmography 
AHR was measured by whole body plethysmography, and presented as enhanced 
pause (Penh), which is a mathematically derived value as described by Hamelmann 
and colleagues (Hamelmann et al., 1997). Following allergen challenge, Penh was 
measured in response to increasing doses of aerosolised methacholine (MCh; Sigma, 
UK). 
 
2.5. Invasive measurements of lung function 
2.5.1. Resistance Compliance 
Direct measurements of dynamic lung resistance (RI) and pulmonary compliance 
(Cdyn) were measured in anaesthetised and trachestomised mice. Anaesthesia was 
induced with an i.p. injection of 10 mg/ml Pentobarbitone (50 mg/Kg) (Pfizer, UK) 
and intramuscular (i.m.) injection of 100 mg/ml Ketamine (200 mg/Kg) (Fortdodge 
Animal Health Ltd, Southampton, UK). Mice were ventilated using a small animal 
ventilator (Harvard Apparatus, Kent, UK) and measurements were taken in response 
to inhalational doses of the cholinergic agonist methacholine (MCh - Sigma, UK) at 
increasing concentrations (3 mg/ml – 100 mg/ml) (Martin et al., 1988) in an EMMS 
system (Electro-Medical Measurement Systems, Bordon, Hants, UK). The trachea 
was exposed and cannulated then mice were ventilated at 160 breaths/minute with a 
stroke volume of 150 μl, comparable with normal breathing. Baseline measurements 
were obtained for 2 minutes followed by a PBS dose. Each subsequent MCh dose 
lasted 10 seconds, and the response to each dose was measured for 5 minutes with 
measurements taken every 25 breaths. Lung RI and Cdyn values were averaged for 
each 5 minute period following MCh challenge and expressed as cmH2O/mls/s and 
ml/cmH2O respectively. Resistance Compliance was used to measure lung function in 
Figures 3.1, 4.1 and 6.11. 
 
2.5.2. Flexivent 
Measurements of dynamic resistance and compliance were performed
 
using a 
Flexivent system (Scireq, Montreal, Canada). After induction
 
of anaesthesia with an 
58 
 
i.p. injection of 10 mg/ml Pentobarbitone (50 mg/Kg) (Pfizer, UK) and i.m. injection 
of 100 mg/ml Ketamine (200 mg/Kg) (Fortdodge Animal Health Ltd, Southampton, 
UK), mice were tracheostomised and connected
 
to the flexivent ventilator via a blunt-
ended 19-gauge needle.
 
Mice were ventilated using the following settings; tidal 
volume
 
of 7 ml/kg body weight, 150 breaths/minute; positive end-expiratory
 
pressure 
approximately 2 cm H2O. Mice were initially ventilated
 
for 5 minutes. 
Standardisation of the lung volume history was
 
done by performing two deep 
inflations. Subsequently, measurements
 
of airway function were made. Measurements 
of resistance and
 
compliance were determined from a user defined protocol using
 
the 
snapshot-150 perturbation, which is a single frequency sinusoidal
 
wave at a frequency 
equivalent to ventilation rate (i.e., 2.5
 
Hz). Resultant data was fitted using multiple 
linear regression
 
to the single compartment model in the form: pressure = resistance
 x 
flow + elastance x volume + fitting constant. Fitting the data to this model provides 
readings of resistance and compliance.
 
Changes in resistance and compliance were 
measured in response
 
to increasing concentrations of nebulised MCh
 
from either 3 
mg/ml – 100 mg/ml or 10 mg/ml - 300 mg/ml, delivered into the inspiratory line of 
the flexivent ventilator. Airway resistance was expressed as cmH2O.s/ml and 
compliance was expressed as mL/cmH2O. Flexivent was used to measure lung 
function in Figures 4.8, 4.14, 4.21, 5.5 and 6.2. 
 
2.6. Blood Removal 
2.6.1. Exanguination and serum isolation 
Mice were bled under terminal anaesthesia by cardiac puncture, recovering 
approximately 0.5 - 1 ml per mouse. After overnight clotting, samples were 
centrifuged at 13000 rpm (10000 g) for 15 minutes at 4
o
C, serum removed and stored 
at -80
o
C for use in ELISA.  
 
2.6.2. Serum isolation from the tail 
Mice were also bled from the tail, recovering 50 μl per mouse. After overnight 
clotting, samples were centrifuged at 13000 rpm (10000 g) for 15 minutes at 4
o
C, 
serum removed and stored at -80
o
C for use in ELISA. 
 
2.7. Cell recovery  
59 
 
Following isolation of leukocytes from each tissue below, cells were resuspended in 
complete media (RPMI containing 10% FCS, 2 mM L-Glutamine, 100 U/ml 
Penicillin/Streptomycin, was used throughout all leukocyte preparations) and cell 
counts were performed in a haemocytometer using white blood cell counting fluid 
(Turks Solution; trace gentian violet in 1% v/v acetic acid in H2O) (2.1. Appendix of 
buffers). 
 
2.7.1. Bronchoalveolar lavage of airway lumen   
Bronchoalveolar lavage (BAL) was performed by flushing out the lungs three times 
with 0.4 ml of PBS via a tracheal canulae as described previously (Kearley et al., 
2005). The fluid collected was centrifuged for 5 minutes (1200 rpm (120 g), 5 
minutes, 4
o
C) and recovered cells re-suspended in 0.5 ml complete media. The 
supernatant was aliquoted and stored at -80
o
C for use in downstream applications. 
 
2.7.2. Lung parenchyma   
Either the right hand lob or inferior left lobe of lung tissue was removed, weighed and 
mechanically chopped prior to being incubated at 37
o
C for 1 hour in digest reagent; 
150 μg/ml Collagenase (Roche Diagnostics, Lewes, UK), 25 μg/ml DNase (Type 1, 
Roche Diagnostics, Lewes, UK) in 4 ml of media. Cells were recovered by 
mechanical disruption and filtration through a 70 μm nylon sieve (Falcon, Marathon 
Lab Supplies, London, UK), washed twice by centrifugation (1900 rpm (150 g), 10 
minutes, 4
o
C) and re-suspended in 1ml complete media.  
 
2.7.3. Lung draining lymph nodes   
Lung draining lymph nodes (LNs) were removed, weighed, cells extracted by 
mechanical disruption and filtered through a 70μm nylon sieve before washing twice 
by centrifugation (1900 rpm (150 g), 10 mins, 4
o
C). The resulting pellet was re-
suspended in 1 ml complete media.  
 
2.8. Differential leukocyte counts 
BAL and lung leukocytes (5x10
4
 cells) were applied to glass slides by 
cytocentrifugation for 4 minutes at 400 rpm (60 g) (Cytsopin 4, ThermoShandon, 
UK). Slides were allowed to air dry and were fixed in 100% methanol for 5 minutes. 
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2.8.1. Wright-Giemsa staining of cytocentrifuge preparations   
Following cytocentrifuge application to glass slides, BAL and lung tissue leukocytes 
were stained with Wright-Giemsa stain (Sigma, UK) for 5 minutes followed by a 
rinse with water. Percentages of macrophages, lymphocytes/monocytes, eosinophils 
and neutrophils were determined under light microscopy (40x magnification) by 
counting cells in 8 randomly selected fields and dividing this number by the total 
number of cells counted. To obtain absolute numbers, this percentage was multiplied 
by the total number of cells recovered in the BAL fluid and lung digest suspension. 
All counts were blinded to group designation.  
 
2.9. Lung tissue pathology and immunohistochemistry 
After removal from the animal, one lobe of lung (either the right hand lobe or inferior 
left hand lobe) was inflated with PBS. Lungs were fixed in 10% normal buffered 
formalin for 24h. Specimens were paraffin embedded and transverse sectioned (4 μm) 
onto glass slides. Embedding, sectioning and staining with Haematoxylin & Eosin, 
Periodic Acid Schiff and sirius red were performed in house by the Leukocyte 
Biology Histology Service. All histological and immunohistochemical assessments 
were done blinded to group designation. 
 
2.9.1 Cellular infiltration – Haematoxylin & Eosin 
The degree of cellular infiltration was determined on Haematoxylin & Eosin (H&E) 
stained lung sections using an arbitrary scoring system as previously described (Lloyd 
et al., 2001). Cellular infiltration in the lung was scored as; 0=no infiltrate, 1= one 
small pocket of infiltrate, 2= small infiltrate around more than one airway or vessel, 
3= large infiltrate (>3 cells deep) around >one airway or vessel, 4= most airways and 
vessels have large infiltrates and 5= most airways and vessels have infiltrates and 
cells are present in the alveolar bed. 
 
2.9.2. Mucus production – Periodic Acid-Schiff 
Mucus containing cells were counted on Periodic Acid-Schiff (PAS)-stained sections 
using an arbitrary scoring system as previously described (Grunig et al., 1998). 
Goblet cells in the airway epithelium were quantified according to the following 
scoring system; 0=<0.5%, 1=5-25%, 2=25-50%, 3=50-75% and 4=>75% of positive 
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purple cells. The total scores for each section were divided by the number of airways 
examined and expressed as mucus index in arbitrary units. 
 
2.9.3. Collagen deposition – Sirius Red 
Sirius red is an anionic dye with sulfonic acid side chain groups
 
that react with the 
basic amino acid side chain groups of collagen,
 
allowing detection and quantification 
of types I through V collagen
 
(Lee et al., 2001). Collagen deposition was assessed on 
sirius red stained sections. Peri-bronchiolar collagen deposition was quantified on 
sirius red stained sections viewed under polarised light using Leica QWin Image 
analysis software package (Leica Microsystems, Milton Keynes, UK). Digital 
photographs of four intact bronchioles per lung section were taken at 40X 
magnification. Image analysis was performed using Leica DM2500 microscope with 
21 40x HC xPL 4.0 x 0.85 corr lens, at 25ºC and Leica DFC300F digital Camera and 
Leica suite software. These data is expressed as the mean intensity of peri-bronchial 
collagen deposition (Saglani et al., 2009). 
 
2.9.4. Staining of Mast Cell Tryptase 7 by Immunohistochemistry 
Tissue sections were deparaffinised with xylene and rehydrated through 100%, 90% 
and 75% changes of ethanol to H2O. For antigen retrieval, slides were placed in 10 
mM sodium citrate and heated at a high temperature, three times for 3 minutes. Slides 
were washed (PBS x 2, 5 minutes) and endogenous peroxidise was removed using 
hydrogen peroxide in methanol for 30 minutes. Following this, slides were washed 
(PBS x 2, 5 minutes) prior to addition of an avidin/biotin binding kit (Vector 
Laboratories, Peterborough, UK). Slides were then washed (PBS x 2, 5 minutes) and 
blocked using 10% donkey serum in PBS (Sigma, UK). Serum block was removed 
and slides were incubated with either 50 μl/slide of 0.2 μg/ml of anti-mouse tryptase 
beta-1/MCPT7 primary antibody (R&D Systems, UK) or 0.2 μg/ml rabbit Ig isotype 
control (Sigma, UK) in PBS containing 10% donkey serum (Sigma, UK) overnight. 
Slides were then washed twice for 5 minutes with PBS and 0.05% Tween-20. After 
washing, slides were incubated with the secondary biotinylated goat anti-rabbit 
antibody (Jackson Labs, distributed by Stratech Scientific Limited, Suffolk, UK) for 
45 minutes at room temperature (RT). After washing, this was followed by addition 
of streptavidin made according to the manufacturer’s instructions (Vectastain ABC 
method, Vector Laboratories, Peterborough, UK) for 45 minutes, RT before 
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visualisation with a DAB peroxidise substrate prepared according to the 
manufacturer’s instructions (Vectorlabs, Peterborough, UK). Tissues were 
counterstained with Gill’s haematoxylin (Polysciences Inc, Germany) and dehydrated 
through 75%, 90% ethanol to H2O then 100% ethanol before mounting. 
 
2.9.5. Staining of ZO-1 by Immunofluorescence   
Tissue sections were deparaffinised with xylene and rehydrated through 100%, 90% 
and 75% changes of ethanol to H2O. For antigen retrieval, slides were incubated with 
2 mg/ml protease K (Sigma, UK) at 37
o
C for 10 minutes. Endogenous biotin and 
avidin binding sites were blocked using a commercially available kit and used 
according to the manufacturer’s instructions (Vector Laboratories, Peterborough, 
UK). Slides were then washed (PBS x 2, 5 minutes) and blocked using 10% donkey 
serum (Sigma, UK). Serum block was removed and slides were incubated with 5 
μg/ml rabbit anti-mouse ZO-1 polyclonal primary antibody (Invitrogen, UK) or 5 
μg/ml rabbit Ig isotype control (Sigma, UK) in PBS containing 1% mouse serum 
(Sigma, UK) was added overnight at 4°C. Slides were washed twice (5 minutes each) 
with PBS containing 0.1% Tween. After washing, slides were incubated with the 
secondary biotinylated goat anti-rabbit antibody (Jackson Labs, distributed by 
Stratech Scientific Limited, Suffolk, UK) for 45 minutes at room temperature (RT). 
This was followed by addition of AlexaFluor-488 Streptavidin Complex (Sigma, UK) 
for 30 minutes. The slides were washed twice in PBS and 0.1% Tween, immersed in 
water and mounted with Prolong Gold anti-fade that contains DAPI and acts as a 
nuclear counterstain (Invitrogen, UK). Slides were then viewed by confocal 
microscopy (Leica SP2 upright, Leica Microsystems, UK). 
 
2.9.6. Staining for cell nuclei by Immunofluorescence 
Tissue sections, from mice treated in 2.3.8., were deparaffinised with xylene and 
rehydrated through 100%, 90% and 75% changes of ethanol to H2O. The sections 
were then mounted with Prolong Gold anti-fade that contains the nuclei stain DAPI 
(Invitrogen, UK). 
 
2.10. Total lung collagen analysis 
2.10.1. Lung tissue homogenisation   
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Snap frozen lung tissue samples were homogenised at 50 mg tissue/ml in HBSS 
(Invitrogen, Paisley, UK) containing a protease inhibitor cocktail (Roche Diagnostics, 
Lewes, UK). Samples were them centrifuged (1600 rpm (135 g), 20 minutes) and 
supernatant collected and stored at -80
o
C.  
 
2.10.2. Total lung collagen analysis   
Total lung collagen was measured using the Sircol
TM
 Collagen Assay in accordance 
with the manufacturer’s instructions (Biocolor Ltd, Belfast, UK). Samples of 
homogenised lung were acidified with 20 μl 0.5M acetic acid and Sircol dye reagent 
added. Samples were then left to shake for 30 minutes at room temperature. Samples 
were centrifuged (1400 rpm; 130 g) and the pellet resuspended in Sircol Alkali 
reagent. Quantification of dye reagent bound to collagen was performed using a 
spectrophotometer and read at a wavelength of 540nm (Tecan, Reading, UK).  
 
2.11 Staining of leukocytes and flow cytometric analysis  
2.11.1. Antibodies   
Directly labelled anti-mouse antibodies to the cell surface proteins CD4, CD8, 
cKIT/CD117 and the intracellular cytokine IL-10 and their respective isotype controls 
were purchased from BD Pharmingen (BD Pharmingen, Oxford, UK). Anti-mouse 
T1/ST2 was purchased from Morwell Diagnostics (Zurich, CH). Anti-mouse CD11c, 
CD11b, Gr-1, MHCII and FcεR1 were purchased from EBioscience (EBioscience, 
UK). Anti-mouse 120G8 was purchased from Dendritics (Dendritics, Lyon, France). 
CD4
+
CD25
+
FoxP3
+
 Treg staining kit was purchased from EBioscience (EBioscience, 
UK).  Antibodies are detailed in Table 2.1 and buffers in Appendix 2.1.  
 
2.11.2. Extracellular staining of cell surface antigens  
3 x 10
5
 cells from either BAL, lung tissue or lung draining LNs (prepared as 
described in Section 2.7.1 - 3), were stained in staining buffer (PBS containing 1% 
foetal calf serum and 0.01% sodium azide). To reduce non-specific binding, cells 
were incubated with rabbit serum (Sigma, UK) for 15 minutes at 4
o
C. Cells were then 
stained with cell surface antibodies or relevant isotype controls for 20 minutes at 4
o
C, 
followed by twice washing with staining buffer and fixation in CellFix
TM
 (BD 
Pharmingen, Oxford, UK). Flow cytometric analysis was performed using a 
FACSCalibur
TM
 (Becton Dickenson, Oxford, UK) and subsequently analysed using 
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FlowJo software (Treestar, Ashland, Oregon). A minimum of 50,000 events were 
collected and dead cells were excluded on the basis of forward and side scatter.    
 
2.11.3. Intracellular cytokine staining  
For intracellular cytokine staining, cells were first stimulated by incubation with 
PMA (4 μg/ml) and ionomycin (4 μM) (Merck, New Jersey, USA) in the presence of 
Brefeldin A (10 μg/ml) (Sigma, UK) for 4 hours 37oC in a humidified incubator (5% 
CO2) before extracellular staining as described in Section 2.11.2. After fixation, cells 
were washed in permeablisation buffer (staining buffer containing 0.05% saponin 
(Sigma, UK). Afterwards, cells were incubated in permeablisation buffer for 5 
minutes then washed and stained with antibodies against cytokines or relevant isotype 
controls diluted in permeablisation buffer (listed in Table 2.1). Flow cytometric 
analysis was performed using a FACSCalibur
TM
 (Becton Dickenson, Oxford, UK) 
and subsequently analysed using FlowJo software (Treestar, Ashland, Oregon). A 
minimum of 50,000 events were collected and dead cells were excluded on the basis 
of forward and side scatter.    
 
2.11.4. Flow Cytometric staining of CD4
+
CD25
+
FoxP3
+
Tregs 
Tregs were detected using the CD4
+
CD25
+
FoxP3
+
 staining kit available from 
EBioscience (EBioscience, UK) according to the manufacturer’s instructions. Flow 
cytometric analysis was performed using a FACSCalibur
TM
 (Becton Dickenson, 
Oxford, UK) and subsequently analysed using FlowJo software (Treestar, Ashland, 
Oregon). A minimum of 50,000 events were collected and dead cells were excluded 
on the basis of forward and side scatter.    
 
2.12. Analysis of mediators by Enzyme Linked Immunosorbent Assay 
Cytokine and chemokine levels were measured in BAL samples and homogenised 
lung tissue (prepared as described in Section 2.7.1. and 2.10.1. respectively) using 
paired antibodies against murine IL-13, TSLP, IL-25 (IL-17E), IL-33, MIP-
3α/CCL20, MCP-1/CCL2, RANTES/CCL5, eotaxin-2/CCL24, TARC/CCL17, 
MDC/CCL22 and KC/mCXCL1 (R&D Systems, Abingdon, UK). Eotaxin-1/CCL11 
was quantified by paired antibodies from 2 batches of Abs from R&D Systems. TGF-
β, IL-4 and IL-5were quantified by paired antibodies (BD Biosciences, Oxford, UK). 
IL-1β, KC/mCXCL1, IL-4, IL-5, IFN-γ, IL-10 and IL-12 were quantified using a 
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mouse Th1/Th2 multiplex kit and IL-17 using a mouse singleplex kit (Meso Scale 
Discovery, Maryland, USA). Mast cell protease-1 (mMCP-1) was quantified in serum 
with paired antibodies from Moredun (Moredun Scientific, Scotland, UK). IL-25 (IL-
17E) and IL-1β were also quantified using Ready Set Go kits (EBioscience, UK). 
Total IgE, IgG1, IgG2a, IgA and IgM were measured in the serum (isolated as 
described in Section 2.6) using paired antibodies (BD Biosciences, Oxford, UK). For 
antigen specific serum IgE, IgG1, IgG2a and IgA, plates were coated with HDM (50 
μg/ml).  Buffers used are outlined in Appendix 2.1.  
 
2.12.1. ELISA Protocol   
All mediators were assessed using a standardised sandwich ELISA. Flat bottomed 
high binding 96 well plates (Costar, Corning, NY, USA) were coated overnight with 
100 μl/well of anti-mouse antibodies diluted to appropriate concentration in coating 
buffer. Wells were blocked using appropriate blocking buffer (Appendix 2.1.) 
followed by washing and samples or standards (recombinant protein diluted in assay 
buffer to the appropriate range) were added in duplicate and incubated for either 2 
hours RT or overnight at 4
o
C. After incubation, cells were washed (x4) and the 
secondary biotinylated anti-mouse antibodies added for either 2 hours or overnight at 
4
o
C. Following washes (x4) samples were then incubated with streptavidin-HRP 
(diluted in assay buffer) for 30 minutes. Plates were washed and K-blue substrate 
(Neogen, Lexington, KY, USA) or DuoSet Substrate Reagent Pack (R&D Systems, 
Abingdon, UK) was added to each well. The colourimetric reaction was stopped by 
the addition of 0.19M H2SO4 and optical density readings at 450 nm were measured 
using a spectrophotometer (Tecan, Reading, UK) within 30 minutes. Standard curves 
were plotted using either linear or non-linear regression depending on the fit of the 
data and unknowns were calculated from the standard curve. 
 
2.13. Protease Activity of HDM 
To assess the protease activity of HDM, 50 μl of HDM extract or control proteases 
were assayed in triplicate to a 96 well plate. The proteases were either incubated with 
10 μl PBS or 10 μl of 1 mM DL-Dithiothreitol (DTT; Sigma, UK) for 5 minutes to 
activate cysteine proteases. 20 μl of either AEBSF (Sigma, UK) (20mM), E-64 
(Sigma, UK) (100 µM) or both AEBSF (20 mM) and E-64 (100 µM) combined for 15 
minutes at room temperature. AEBSF specifically inhibits serine proteases such as 
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trypsin and E-64 specifically inhibits cysteine proteases such as papain. Volumes 
were then made up to 150 μl in PBS and incubated for a further 15 minutes. 50 μl of 
N-Benzoyl-Phe-Val-Arg-p-nitroanilide hydrochloride (NBP-VANA; Sigma, UK), 
which is a substrate for trypsin, thrombin and reptilase, was added at a concentration 
of 1 mM to each well. Absorbances were read immediately at 405 nm and then at 20 
minute intervals over 2 hours and stored at 37
o
C in the dark between readings. 
Breakdown of NBP-VANA correlated with increased absorbance readouts. Trypsin 
(Sigma, UK) and papain (Sigma, UK), activated with DTT (Sigma, UK), acted as 
positive controls for serine and cysteine proteases respectively. 
 
2.14. RNA extraction from the lung 
The smallest lung lobe (post-caval) was perfused and flash frozen at -80
oC. 500 μl of 
Trizol (Invitrogen, UK) was added and, following homogenisation, 200 μl chloroform 
was added (Sigma, UK). This mixture was manually mixed for 15 seconds, followed 
by 2 minutes at room temperature and then centrifuged for 15 minutes at 20000rpm 
(12000 g) at 4
o
C. The top aqueous layer was then removed and transferred to a new 
epindorff where an equal volume of ethanol was added. This solution was then used 
for RNA extraction according to the manufacturer’s instructions (Qiagen RNAeasy, 
West Sussex, UK). 
 
2.15. PCR Array 
A Toll-like receptor (TLR) signalling pathway PCR array was carried out using RNA 
extracted from mouse lung tissue and carried out according to the manufacturer’s 
instructions (SABiosciences, Maryland, USA). Briefly, 1 µg of RNA was used for RT 
and the cDNA was added to the PCR master mix. Thermal cycling was performed 
using Roche LightCycler 480 (Roche, USA) and the changes in gene expression were 
analysed using the manufacturer’s analysis spreadsheet (SABiosciences, Maryland, 
USA). 
 
2.16. Data Analysis  
Data are expressed as either median or mean ± SEM as stated. Data was not assumed 
to be normally distributed and statistical significance between groups was tested 
using a non-parametric Mann-Whitney U Test as stated. A p value of <0.05 was 
accepted as significant. All other statistical and regression analysis was performed by 
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using GraphPad Prism software (Version 4.00, San Diego, CA). For the gene array a 
Student’s t-test was performed as according to the manufacturers guidelines. A p 
value of <0.05 was accepted as significant. 
 
2.1. List of Buffers 
 
Complete media 
RPMI 
10% FCS 
2 mM L-glutamine 
100 U/ml Penicillin/streptomycin 
 
FACS staining buffer 
PBS 
1% FCS 
0.1% NaN3 
 
FACS permeablisation buffer 
PBS 
1% FCS 
0.1% NaN3 
0.5% saponin 
 
Blocking buffer (BD ELISAs, total Ig ELISAs and RnD kits) 
PBS 
1% BSA 
 
Blocking buffer (HDM-specific Ig) 
PBS 
3% BSA 
 
ELISA wash buffer 
5.5l H2O 
44g NaCl 
55ml 1m NaPO4 
1g Thimerasol 
11ml Tween20 
 
ELISA coat wash 
5.5l H2O 
55ml 1M KPO4 
1g Thimerasol 
2.75ml Tween20 
 
White Cell Counting Fluid 
Gentian violet in 1% v/v acetic acid in H2O 
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Table 2.2. FACS Antibodies 
 
Antibody Clone Isotype Fluorescent label Company 
Anti-T1/ST2 DJ8 Rat IgG1 FITC Morwell 
Diagnostics 
Anti-
cKit/CD117 
2B8 Rat IgG2b PE BD 
Pharmingen 
Anti-CD8 Ly-2 Rat IgG2a PE BD 
Pharmingen 
Anti-CD11c N418 Armenian 
Hamster IgG 
PerCP Cy5.5 EBioscience 
Anti-FcεR1 Mar-1 Armenian 
Hamster IgG 
APC EBioscience 
Anti-Gr-1 RB6-8C5 Rat IgG2b Pacific Blue/Alexa-
450 
EBioscience 
Anti-CD11b M1/70  Rat IgG2b PE-Cy7 EBioscience 
Anti-MHCII NIMR-4 Rat IgG2b PE EBioscience 
Anti-CD4 L3T4 Rat IgG2a APC BD 
Pharmingen 
Anti-IL-10 JES5-16E3 Rat IgG2b PE BD 
Pharmingen 
Anti-120G8 120G8.04 Rat IgG2a APC Dendritics 
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Table 2.3. ELISA kits and paired antibodies  
 
Mediator Company Product/Ab Ids Figure Used 
Eotaxin-1/CCL11 RnD Systems Coat: AF-420-NA 
Standard: DAF-420 
Detect: BAF-420 
3.5; 4.3 
Eotaxin-1/CCL11 RnD Systems DY420 4.10; 4.17; 4.23; 5.8; 
Eotaxin-2/CCL24 RnD Systems DY528 All 
TARC/CCL17 RnD Systems DY529 All 
KC/mCXCL1 RnD Systems DY453 4.10; 4.17; 4.23; 
RANTES/CCL5 RnD Systems DY478 All 
MCP-1/CCL2 RnD Systems DY479 All 
MDC/CCL22 RnD Systems DY439 All 
TSLP RnD Systems DY555 All 
IL-25 (IL-17E) RnD Systems DY1399e 3.7; 4.5; 4.11; 4.24; 5.10 
IL-33 RnD Systems DY3626 All 
CCL20/MIP-3α RnD Systems DY760 All 
IL-13 RnD Systems M1300CB All 
IL-1β, IL-12, 
KC/mCXCL1, 
IL-4, IL-5, IL-10 
and IFN-γ 
Mesoscale 
Discovery 
SI6000 
(Multiplex) 
IL-1β: 3.7; 4.4 
IL-12: 4.4 
KC/mCXCL1: 3.5; 4.3; 
5.8 
IL-4 and IL-5: 3.6; 4.4; 
5.9; 6.8 
IL-10: 3.7 
IFN-γ: 4.4   
IL-17 Mesoscale 
Discovery 
SI2400 
(Singleplex) 
All 
mMCP-1 Moredun 
Scientific 
MS-RM3 All 
IL-4 BD 
Bioscience 
Capture: 554433 
Standard: 550067 
Detection: 554390 
4.11; 4.24; 6.12; 6.13 
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IL-5 BD 
Bioscience 
Capture: 554393 
Standard: 554581 
Detection: 554397 
4.24; 6.12; 6.13 
TGF-β BD 
Bisocience 
Capture: 555052 
Standard: 354039 
Detection: 555053 
All 
Total IgM BD 
Bisocience 
Capture: 553435 
Standard: 550963 
Detection:553436 
All 
Total IgE BD 
Bisocience 
Capture: 553413 
Standard: 03231D 
Detection: 553419 
All 
Total IgG1 BD 
Bisocience 
Capture: 553445 
Standard: 555746 
Detection: 553441 
All 
Total IgG2a BD 
Bisocience 
Capture: 553446 
Standard: 553454 
Detection: 553928 
All 
Total IgA BD 
Bisocience 
Capture: 556969 
Standard: 553476 
Detection: 556978 
All 
HDM-specific 
IgE 
BD 
Bisocience 
Coat: See 2.12 
Detection: 553419 
All 
HDM-specific 
IgG1 
BD 
Bisocience 
Coat: See 2.12 
Detection: 553441 
All 
HDM-specific 
IgG2a 
BD 
Bisocience 
Coat: See 2.12 
Detection: 553928 
All 
HDM-specific 
IgA 
BD 
Bisocience 
Coat: See 2.12 
Detection: 556978 
All 
IL-1β EBioscience 88-7913 4.11; 4.18; 4.24 
IL-25 (IL-17E) EBioscience 88-7002 4.18 
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Chapter 3 – Establishment of a murine model of 
HDM-induced allergic airways disease 
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3.1. Introduction 
 
Animal models have been used to outline functional roles for cytokines and cells in 
the characteristic pathological features of asthma. The vast majority of these studies 
have used a model of ovalbumin (OVA) sensitisation and challenge whereby mice are 
immunised peripherally with OVA in the presence of the adjuvant alum before local 
airway challenge with OVA. The OVA model of allergic lung inflammation can 
replicate many of the main features of allergic asthma including increased allergen-
specific IgE production, mucus production, Th2-driven eosinophilic inflammation, 
AHR and airway remodelling (McMillan and Lloyd, 2004). Studies utilising the OVA 
model of sensitisation and challenge have provided important insights into the nature 
of the allergic airway inflammation, including the importance of the Th2 pathway in 
disease pathogenesis. However, there are several drawbacks of the OVA sensitisation 
and challenge model. It is necessary to immunise mice peripherally with OVA, since 
mice become tolerant to inhaled or aerosol challenge with OVA in the absence of 
systemic sensitisation (Tsitoura et al., 1999;Herrick et al., 2000;Swirski et al., 
2002a;Swirski et al., 2002b;Clausen et al., 2003). Since this model relies on use of the 
adjuvant alum there may be bias towards promoting a Th2-mediated inflammatory 
response (Brewer et al., 1999;Sun et al., 2003;Piggott et al., 2005;Gavin et al., 
2006;Eisenbarth et al., 2008;Kool et al., 2008a;Kool et al., 2008b). Although OVA is 
the main protein found in egg white and associated with human gut allergy (Sampson, 
2004), OVA is not associated with any form of human asthma (Huntington and Stein, 
2001). The sensitisation process in the OVA model does not replicate the scenario in 
the human disease and the process may distort the immunological development of 
disease since the initial contact with the immune system occurs in the peritoneum 
rather than in the lung. Thus, different populations of DCs and other types of APCs 
will be encountered and stimulated.  
 
It has recently been reported that continued intranasal (i.n.) delivery of an 
immunologically complex allergen, house dust mite (HDM; Dermatophagoides 
pteronyssinus) extract, results in a chronic inflammatory responses and structural 
remodelling in the lungs of immunologically naïve, unsensitised mice (Johnson et al., 
2004;Southam et al., 2007). This model represents a step forward in that it does not 
require a peripheral sensitisation step, uses an environmentally and clinically relevant 
73 
 
allergen, and replicates the relevant features of human asthma. HDM models have 
now been used to determine the role of key mediators in the allergic response, such as 
GM-CSF (Cates et al., 2004;Johnson et al., 2007). However, the temporal 
relationships between critical inflammatory mediators and inflammatory cells with 
the development of AHR have not yet been determined after inhaled HDM. Previous 
studies have documented the production of Th2 cytokines by splenocytes 
restimulated with HDM in vitro (Johnson et al., 2004). However, these levels may not 
accurately reflect the amount of mediators of interest in the lung following allergen 
challenge in vivo.  
 
3.2. Hypothesis and Aims 
3.2.1. Hypothesis 
 
HDM exposure will result in Th2 cytokine and pro-inflammatory chemokine 
production in the lung tissue and BAL, concomitant with airway eosinophilia and 
AHR. 
 
3.2.2. Aims 
 
The aims of Chapter 3 are to: 
 Determine the temporal and spatial relationship of leukocytes and 
inflammatory mediators in the lung and BAL associated with the allergic 
response and the development of AHR in mice after exposure to inhaled 
HDM 
 Quantify Th2 cytokines and pro-inflammatory mediators in the lung and BAL 
following exposure to HDM. 
 
3.3. Experimental Design: Induction of HDM-induced allergic airways disease 
 
Airway inflammation and AHR were induced in female BALB/c mice in response to 
HDM challenge as discussed in the general methods. Mice were administered either 
25 µl PBS or 25 µg (in 25 µl) HDM i.n. 5 times a week for 3 weeks and culled 2h, 4h, 
8h and 24h post final challenge. At each time point PBS-treated mice were culled and 
these were pooled for clarity. 
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3.4. Results: Time course analysis of HDM exposure 
3.4.1. HDM exposure results in AHR 
 
HDM-treated mice developed AHR compared to PBS controls. HDM exposure 
significantly increased airway resistance at 24h post final exposure (Figure 3.1A and 
B), whereas lung compliance was decreased as early as 2h post challenge and was 
maintained throughout the 24h period, compared to PBS controls (Figure 3.1C and 
D).  
 
3.4.2. HDM exposure results in the early recruitment of inflammatory leukocytes 
to the lung and airway lumen 
 
Elevated numbers of total cells were observed in HDM-treated mice compared to 
PBS controls in the lung from 2h post final challenge and this was maintained 
throughout the 24h time period (Figure 3.2A). Differential cell counts determined that 
the majority of these cells were eosinophils (Figure 3.2B). The numbers of 
neutrophils, lymphocytes and monocytes recovered from the lung were also 
significantly higher in HDM-treated mice compared to PBS controls at all time points 
post final challenge (Figure 3.2C and D). Cell recruitment to the airway lumen, as 
determined in BAL, was maintained over the 24h period following allergen 
inhalation. Significant increases in total cells, eosinophils, neutrophils and 
lymphocytes and monocytes were observed at each time point in response to HDM 
(Figure 3.2E - H). In order to investigate the degree of cellular inflammation, sections 
of lung isolated from PBS and HDM-treated mice were examined. HDM exposure 
induced widespread peri-bronchial and peri-vascular inflammation (Figure 3.3A and 
B). 
 
FACS analysis showed there was a population of CD8
+
 T cells recruited to the lung 
and BAL following HDM challenge (Figure 3.4A and B). However, the majority of T 
cells in the lung and BAL were of the CD4
+
 phenotype (Figure 3.4C and D). Within 
the CD4
+
 population, there were cells that also stained positive for the surrogate Th2 
surface marker T1ST2. Increased Th2 cell numbers (CD4
+
 T1ST2
+
 cells) were 
observed in the lung and BAL over the 24h period investigated (Figure 3.4E and F).  
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Airway Resistance    Airway Compliance 
 
 
Figure 3.1. AHR in HDM-treated mice.  
(A) Airway resistance (RI) of PBS and HDM-treated mice at 2, 4, 8 and 24h post 
final challenge. (B) Airway resistance is expressed as mean RI ± SEM for the 
30mg/ml dose of methacholine. (C) Dynamic airway compliance (Cdyn) of PBS and 
HDM-treated mice at 2, 4, 8 and 24h post final challenge. (D) Airway compliance is 
expressed as mean Cdyn ± SEM for the 30mg/ml dose of methacholine. (n=12 mice 
treated with PBS, n=5-6 mice treated with HDM at each time point). *, P<0.05 
(Mann-Whitney U test) compared with PBS. Data are mean ± SEM. One experiment. 
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Figure 3.2. Inflammatory cell profile of HDM-treated mice.  
Total cells, eosinophils, neutrophils and lymphocytes and monocytes recovered from 
the lung (A - D) and BAL (E - H) 2, 4, 8 and 24h after the final i.n. challenge (n=12 
mice treated with PBS, n=5-6 mice treated with HDM at each time point). Total cell 
counts were determined using a haemocytometer with white blood cell counting fluid 
and eosinophils, neutrophils and lymphocytes/monocytes were quantified from 
Wright-Giemsa stained cytospins, as described in the Materials and Methods. *, 
P<0.05 (Mann-Whitney U test) compared with PBS. Bars depict median of the 
groups. One experiment. 
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A. PBS         B. HDM 
 
 
 
Figure 3.3. HDM-induced airway inflammation.  
Representative photomicrographs of H&E stained lung sections from (A) PBS and 
(B) HDM-treated mice 4h post final challenge (original 20X magnification). Scale 
bar = 50 µm. 
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Figure 3.4. Inflammatory T Cell Profile.  
CD8
+
, CD4
+
 and CD4
+
T1ST2
+
 T Cells recovered from the lung (A, C and E) and 
BAL (B, D and F) 2, 4, 8 and 24h after the final i.n. challenge (n=12 mice treated 
with PBS, n=5-6 mice treated with HDM at each time point). All cells were 
quantified by flow cytometry. *, P<0.05; (Mann-Whitney U test) compared with 
PBS. One experiment. 
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3.4.3. Chemokine levels correlate with cell recruitment and are maintained after 
allergen challenge 
 
Concentrations of chemokines important in the development of allergen-induced 
airway inflammation were determined in the lung and BAL. These included the DC 
chemokine MCP-1/CCL2, the eosinophil chemokines eotaxin-1/CCL11 and eotaxin-
2/CCL24 and the neutrophil chemoattractant KC/mCXCL1. TARC/CCL17, 
MDC/CCL22 and RANTES/CCL5, which are associated with Th2 cell migration and 
activation, were also quantified. Eotaxin-1/CCL11, TARC/CCL17 and KC/mCXCL1 
were significantly elevated in the lung and BAL of HDM-treated mice, compared to 
PBS controls, at all time points post final challenge (Figure 3.5A – F).  MCP-1/CCL2 
and eotaxin-2/CCL24 were elevated in the lungs of HDM-treated mice 2h and 4h post 
final challenge and levels declined to baseline by 24h post final challenge (Figure 
3.5G - H). MDC/CCL22 and RANTES/CCL5 was observed to be increased at all 
time points post final challenge in response to HDM (Figure 3.5I and J). 
 
3.4.4. Th2 cytokines are produced in the lung following inhaled HDM challenge 
 
The levels of Th2 and Th1 cytokines were quantified in the lung and BAL in response 
to HDM. HDM-treated mice developed increased levels of the Th2 associated 
cytokines IL-4, IL-5 and IL-13 in the lung and BAL, compared to PBS-treated mice, 
at all time points post final challenge, with the highest production at 4h (Figure 3.6A - 
F). Cytokine levels in the BAL declined to near baseline by 24h post challenge. The 
Th1 associated cytokine IFN-γ was detectable at very low levels only in the lungs of 
HDM-treated mice, also with a maximum release 4h post challenge (Figure 3.6G and 
H). 
 
HDM-treated mice also showed increased levels in the lung homogenate of the pro-
allergic mediators TSLP, IL-25 (IL-17E) and IL-33 when compared to PBS-treated 
mice (Figure 3.7A - C). IL-1β levels were higher in the lungs of HDM-treated mice 
compared to PBS controls (Figure 3.7D). TGF-β and the regulatory cytokine IL-10 
were also observed to be elevated in the lungs of HDM-treated mice (Figure 3.7E and 
F).  
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3.4.5. Serum immunoglobulin levels following HDM challenge 
 
IgE has important functions in the development of allergic disorders and asthma. 
Following HDM challenge, total and HDM-specific IgE in the serum were 
significantly elevated from levels in PBS controls at all time points post final 
challenge (Figure 3.8A and B). Serum IgG1 and IgG2a, which are indicators of Th2 
and Th1 immune responses in mice respectively, were also found to be elevated in 
HDM-treated mice. IgG1 levels were observed to be greater in HDM-treated mice 
than PBS exposed controls at 4h, 8h and 24h post final challenge, whereas IgG2a was 
elevated in the serum of HDM-treated mice throughout the 24h time period (Figure 
3.8C and D).  
 
3.4.6. Goblet cell hyperplasia occurred following HDM challenge 
 
Hypersecretion of mucus from goblet cells is a feature of asthma. An increase in PAS 
positive cells was observed in the bronchial epithelium in HDM-treated mice 
compared to PBS controls (Figure 3.9A). Representative lung sections from PBS and 
HDM-treated mice stained with PAS are shown (Figure 3.9B - C).  
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Figure 3.5. Chemokine profile of HDM-treated mice.  
Eotaxin-1/CCL11, TARC/CCL17 and KC/mCXCL1 levels measured in the lung (A, C and 
E) and BAL (B, D and F) 2, 4, 8 and 24h after the final i.n. challenge. (G) MCP-1/CCL2, (H) 
eotaxin-2/CCL24, (I) MDC/CCL22 and (J) RANTES/CCL5 levels measured in the lung 2, 4, 
8 and 24h after the final i.n. challenge. Eotaxin-1/CCL11, TARC/CCL17, MCP-1/CCL2, 
eotaxin-2/CCL24, MDC/CCL22 and RANTES/CCL5 levels were determined by ELISA and 
KC/mCXCL1 levels by MSD (n=12 mice treated with PBS, n=5-6 mice treated with HDM at 
each time point). *, P<0.05; (Mann-Whitney U test) compared with PBS. Bars depict the 
median of the groups. One experiment. 
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Figure 3.6. Inflammatory cytokine profile of HDM-treated mice. 
IL-4, IL-5, IL-13 and IFN-γ measured in the lung (A, C, E and G) and BAL (B, D, F 
and H) 2, 4, 8 and 24h after the final i.n. challenge. IL-4, IL-5 and IFN- γ levels were 
determined by MSD and IL-13 levels by ELISA (n=12 mice treated with PBS, n=5-6 
mice treated with HDM at each time point). *, P<0.05; (Mann-Whitney U test) 
compared with PBS. Bars depict the median of the groups. N.D., not detected. One 
experiment. 
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Figure 3.7. Inflammatory cytokine profile in the lung of HDM-treated mice.  
(A) TSLP, (B) IL-25 (IL-17E), (C) IL-33, (D) IL-1β, (E) TGF-β and (F) IL-10 
measured in the lung 2, 4, 8 and 24h after the final i.n. challenge. TSLP, IL-25 (IL-
17E), IL-33 and TGF-β levels were determined by ELISA and IL-10 and IL-1β levels 
by MSD (n=12 mice treated with PBS, n=5-6 mice treated with HDM at each time 
point). *, P<0.05; (Mann-Whitney U test) compared with PBS. Bars depict the 
median of the groups. One experiment. 
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Figure 3.8. Serum immunoglobulin profile of HDM-treated mice.  
(A) Total IgE, (B) HDM-specific IgE, (C) total IgG1 and (D) total IgG2a levels 
measured in the serum 2, 4, 8 and 24h after the final i.n. challenge. All levels were 
determined by ELISA. (n=12 mice treated with PBS, n=5-6 mice treated with HDM 
at each time point). *, P<0.05; (Mann-Whitney U test) compared with PBS. Bars 
depict the median of the groups. One experiment. 
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A. Mucus Score   
        
 
 
 
 
 
 
 
 
 
B. PBS     C. HDM 
 
 
Figure 3.9. Goblet cell hyperplasia in HDM-treated mice.  
(A) Semi-quantitative scoring of PAS stained lung sections. (n=12 mice treated with 
PBS, n=5-6 mice treated with HDM at each time point).*, P<0.05; (Mann-Whitney U 
test) compared with PBS. Bars depict the median of the groups. Representative 
photomicrographs of PAS stained lung sections from (B) PBS and (C) HDM-treated 
mice 4h post final challenge (original 20X magnification). Scale bar = 50 µm. One 
experiment. 
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3.5. Discussion 
 
The pathophysiological features of asthma, namely AHR, airway inflammation and 
airway remodelling, have been modelled in mice in order to determine the molecules 
responsible for disease pathogenesis. The pulmonary response to inhaled HDM in 
mice was shown to follow a distinct time course from the development of AHR, with 
Th2 cytokines in particular being produced early after inhaled challenge. The peak 
time to measure changes in lung function did not correspond with the highest 
production of Th2 cytokines which has important consequences for the study of the 
molecular mechanisms of tissue pathophysiology in this model of inhaled HDM 
challenge. 
 
Previous to this work, HDM has been shown to sensitise immunologically naïve mice 
via the respiratory mucosa and that prolonged exposure to HDM can mimic certain 
aspects of chronic asthma, namely airway inflammation, AHR and airway 
remodelling (Johnson et al., 2004). Inflammatory cytokine generation was 
demonstrated by these authors after in vitro restimulation of splenocytes isolated from 
mice exposed to HDM (Johnson et al., 2004). Although these observations are 
important to define antigen-specific memory responses, local lung cytokine 
production was not reported and the cytokine levels determined from restimulated 
splenocytes may not accurately reflect the cytokine levels in the lung and BAL 
following allergen challenge in vivo. Indeed, allergen challenge in both asthmatic 
patients and OVA sensitised mice is characterised by AHR and increased production 
of IL-4, IL-5 and IL-13 in the BAL (Robinson et al., 1992;Pilette et al., 
2004;McMillan and Lloyd, 2004;Koya et al., 2007). Therefore, the aim of the 
experiment was to determine whether key cells, inflammatory mediators and Th2 
cytokines associated with the allergic response were produced locally in the lung and 
BAL after exposure to HDM concomitant with AHR.  
 
Three weeks of exposure to HDM has been shown to be the earliest time point at 
which AHR is observed (Gregory et al., 2009). Thus to determine the Th2 cytokine 
profile and inflammatory mediator response to HDM locally in the lung and BAL 
together with AHR,  mice were exposed to 3 weeks of inhaled HDM and were then 
sacrificed 2, 4, 8 and 24h following the final allergen challenge. It is important to 
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note at this time point that airway remodelling, although initiated, is not fully 
established (Johnson et al., 2004;Southam et al., 2007). 
 
The results show that following continuous exposure to HDM, greatest levels of 
cytokines are quantified early post-final challenge in the lung and BAL and then 
decrease over the 24h period monitored. In contrast, levels of chemokines are 
maintained and persist throughout. The decline in cytokine levels at 24h, although not 
to baseline, contrasts with the increase in lung resistance which only reached 
significance at 24h post challenge. This implies that the optimum time point for 
cytokine analysis occurs at a time when significant changes in lung resistance are not 
fully established in the model. It is interesting to note that the peak of cellular influx 
and Th2 cytokine production in response to HDM occurs before the onset of AHR 
and thus demonstrates a temporal relationship between the onset of pathological and 
physiological changes seen in this murine model of allergic airways disease. Three 
weeks of HDM exposure led to the production of allergen-specific IgE production, 
therefore, indicating a true allergic response. 
 
Described here is a murine model of HDM-induced allergic airways disease that was 
developed to reproduce the characteristics of in human allergic asthma. Several key 
features of human asthma (AHR and Th2-driven eosinophilic airway inflammation) 
are replicated following the exposure of immunologically naïve mice to HDM. 
Concomitant with HDM-induced AHR, Th2-associated cytokines, chemokines, 
inflammatory cells and pro-allergic innate cytokines (TSLP, IL-33 and IL-25 (IL-
17E)) linked to the development of asthma were profiled in the lung tissue and BAL. 
A time-course relationship between these mediators and cells with the functional 
consequence of AHR was determined and the optimum time points to investigate 
various aspects of the inflammatory response following 3 weeks of HDM challenge 
were deduced. 
 
All mediators found to be elevated in the lung and BAL of HDM-treated mice, have 
been linked to the pathogenesis of asthma, such as IL-13 and AHR (Wills-Karp et al., 
1998;Wills-Karp, 2004). Indeed, several of these mediators have been targeted 
therapeutically in clinical trials, including IgE (Poole et al., 2005;Holgate et al., 
2005), eosinophils (Nair et al., 2009;Haldar et al., 2009) and Th2 cytokines (Leckie et 
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al., 2000;Flood-Page et al., 2007;Corren et al., 2010;Corren et al., 2011). The data 
from the current study have important implications for the analysis of a murine model 
that is more closely related to allergen exposure and sensitisation that occurs in 
humans and can build on knowledge from OVA sensitisation and challenge models. 
These findings are of fundamental importance because mouse models are used to 
explore the molecular and biochemical pathways leading to immunopathophysiology. 
In particular, when used for delineation of mechanisms of action of potential novel 
therapies. 
 
The relationship between chronic inflammation, airway remodelling,
 
and airway 
dysfunction is complex because these are interacting
 
processes each with distinct 
kinetics. Thus, an experimental
 
model mimicking the phenotype of chronic asthma is 
valuable as
 
it will allow further investigations into the mechanisms by which allergic 
airways disease is initiated and maintained. However, it is interesting to note that 
HDM-driven inflammation is not solely a Th2-associated response, since IFN-γ and 
the regulatory cytokines IL-10 and TGF-β were also quantified in the lung tissue. 
 
HDM is a complex aeroallergen and the inflammatory profile in response to HDM is 
composed of a variety of cells, such as eosinophils and neutrophils, and characterised 
by a diverse cytokine profile. Whole HDM extract was used in these experiments to 
mimic human pulmonary exposure and it is unlikely that one single feature of the 
allergen is responsible for the immune response. The observed disease pathology 
leads to several important questions regarding the properties of the HDM allergen and 
what roles these features play in the development of the immune response.  
 
Using the model of HDM exposure as described in Chapter 3 to elicit the 
characteristics of allergic asthma in mice, the focus and aims of Chapters 4 and 5 are 
investigating the contribution of TLR signalling and protease activity to the immune 
response to HDM. In addition to this, determining the role of TGF-β in HDM-induced 
allergic airways disease was also undertaken in Chapter 6.  
    
 
 
89 
 
 
 
 
 
 
 
 
 
Chapter 4 – Contribution of Toll-like receptor 
signalling to HDM-induced allergic airways disease 
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4.1. Introduction 
 
Activation of pattern recognition receptors (PRRs) on epithelial cells and DCs 
provide the signalling information for appropriate programming of the adaptive 
immune response to inhaled antigens. Toll-like receptors (TLRs) are the most widely 
studied family of PRRs in allergic inflammation and TLRs recognise antigens that 
express TLR ligands (Kawai and Akira, 2010). Mice express TLRs 1-9 and 11-13 
(Akira et al., 2006). TLR1, 2, 4, 5 and 6 are primarily expressed on the cell surface 
and recognise pathogen-associated molecular patterns (PAMPs) derived from 
bacteria, fungi and protozoa, whereas TLR3, 7, 8 and 9 are exclusively expressed 
within endocytic compartments and primarily recognise nucleic acid PAMPs derived 
from viruses and bacteria (Kawai and Akira, 2010). The cytoplasmic portion of TLRs 
shows similarity to that of the IL-1 receptor family and is known as the Toll/IL-1 
receptor (TIR) domain (Takeda and Akira, 2005). However, despite this similarity, 
the extracellular regions of IL-1 receptors possess an Ig-like domain, whereas TLRs 
bear leucine-rich repeats (LRRs) (Akira et al., 2006).  
 
The activation of TLR signalling pathways originates from the cytoplasmic TIR 
domains and TLR signalling is primarily mediated via the recruitment of different 
TIR domain-containing adaptor molecules such as myeloid differentiation primary 
response gene 88 (MyD88), TRIF (TICAM-1), TIRAP (Mal), and TRAM to the TIR 
domains (Kawai and Akira, 2010). All TLRs, except for TLR3 and TLR4, signal 
exclusively via MyD88 and, in addition to MyD88, TLR1, TLR2, TLR4 and TLR6 
recruit TIRAP to initiate MyD88-dependent signalling (Akira et al., 2006). MyD88 
associates with the TIR domain of TLRs and, upon stimulation, MyD88 recruits IL-1 
receptor-associated kinase (IRAK) to TLRs (Kawai and Akira, 2010). IRAK is 
activated by phosphorylation and then associates with TRAF6, leading to the 
activation of JNK and NF-κB signalling pathways (Kawai and Akira, 2010). MyD88 
signal transduction results in the production of pro-inflammatory cytokines such as 
TNF-α and IL-12 (Kawai and Akira, 2010).  
 
A MyD88-independent signalling pathway exists for TLR3 and TLR4 and the 
MyD88-independent pathway is mediated by TRIF (Kawai and Akira, 2010). The 
TLR3-TRIF pathway is initiated through the recruitment of TRAF6 to the distinct 
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domain of TRIF (Kawai and Akira, 2010). The TLR3 ligand dsRNA has been shown 
to induce NF-κB activation and IFN-β production in cells deficient in MyD88 
(Alexopoulou et al., 2001) and, in mice deficient in TRIF signalling, TLR3-mediated 
expression of IFN-β and IFN-inducible genes is impaired (Yamamoto et al., 2003). 
TLR4 is unique in that this TLR signals via both MyD88-dependent and TRIF-
dependent pathways (Kawai and Akira, 2010). TLR4 first recruits TIRAP, which 
facilitates the recruitment of MyD88 to initiate the first phase of NF-κB and MAPK 
activation. For TRIF-dependent signalling, TLR4 is trafficked to the endosome via 
dynamin-dependent endocytosis and forms a complex with TRAM and TRIF (Kawai 
and Akira, 2010). LPS-TLR4 signalling has been shown to activate the transcription 
factor IRF-3 that induces IFN-β and IFN-β subsequently activates STAT1, which 
then promotes the IFN-inducible gene expression (Kawai and Akira, 2010). In TRIF 
knockout (KO) mice TLR4-mediated expression of IFN-inducible genes is defective 
(Hoebe et al., 2003). A summary of the TLR signalling pathways and ligands is 
shown in Figure 4.1 (adapted from Takeda and Akira, 2005). 
 
Lipopolysaccharide (LPS) is component of Gram negative bacteria found in HDM 
extracts (Douwes et al., 2000). LPS signals through TLR4, with LPS-binding protein 
(LBP), CD14 and MD-2 facilitating this pathway (Akira et al., 2006) and low level 
inhaled LPS signalling through TLR4 is necessary to induce Th2 responses to OVA 
(Eisenbarth et al., 2002). The major HDM allergen Der p 2 shares structural 
homology with MD-2 (Derewenda et al., 2002;Gruber et al., 2004) and Trompette 
and colleagues have demonstrated that Der p 2 facilitates TLR4 signalling through 
direct interactions with the TLR4 complex by reconstituting LPS-driven TLR4 
signalling in the absence of MD-2 (Trompette et al., 2009). The authors also 
illustrated in vivo that Der p 2 drives experimental allergic asthma in a TLR4-
dependent manner and that this TLR4 signalling pathway was retained in mice 
genetically deficient in MD-2 (Trompette et al., 2009). This is of particular 
importance as human airway epithelial cells express TLR4, but minimal amounts of 
MD-2 under homeostatic conditions (Jia et al., 2004).  
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Figure 4.1. TLR signalling pathways.  
TLR signalling pathways originate from the cytoplasmic TIR domain. A TIR domain-
containing adaptor, MyD88, associates with the cytoplasmic TIR domain of TLRs, 
and recruits IRAK to the receptor upon ligand binding. IRAK then activates TRAF6, 
leading to the activation of the IκB kinase (IKK) complex. The IKK complex 
phosphorylates IκB, resulting in nuclear translocation of NF-κB which induces 
expression of inflammatory cytokines. A second TIR-domain containing adaptor, 
TIRAP, is involved in the MyD88-dependent signalling pathway via TLR2 and 
TLR4. In TLR3- and TLR4-mediated signalling pathways, activation of IRF-3 and 
induction of IFN-β are observed in a MyD88-independent manner. The TIR domain-
containing adaptor TRIF is essential for the MyD88-independent pathway. A fourth 
TIR domain-containing adaptor, TRAM, is specific to the TLR4-mediated MyD88-
independent/TRIF-dependent pathway. The main TLR ligands are also shown. 
ssRNA, single-stranded RNA; dsRNA, double-stranded RNA (adapted from Takeda 
and Akira, 2005). 
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Upon commencement of the current project, the contribution of TLR signalling to the 
immune response to HDM in vivo remained to be elucidated. However, concurrent 
with the work discussed in this thesis, utilising intermittent HDM exposure protocols, 
Hammad and colleagues showed that stromal cell TLR4 signalling was sufficient to 
drive Th2 immune responses to HDM (Hammad et al., 2009) and Phipps and 
colleagues showed that attenuated HDM-driven Th2 responses occurred in MyD88 
KO and TLR4 KO mice (Phipps et al., 2009). The importance of these two reports 
with the observations from this Chapter will be discussed further in section 4.5.  
 
In this Chapter the contribution of TLR signalling to the immune response to HDM-
induced allergic airways disease was investigated using both genetically modified 
mice and pharmacological approaches. Firstly, mice lacking systemic TLR4 
signalling were exposed to HDM in order to determine how a deficiency in this 
pathway influenced disease pathogenesis. C3H-HeJ mice possess a mutation in the 
LPS response locus of TLR4 that results in these mice being hyporesponsive to LPS 
(Poltorak et al., 1998) and cells derived from C3H-HeJ mice are resistant to LPS 
stimulation in vitro (Hoshino et al., 1999). Macrophages fail to develop an activation 
phenotype or die when exposed to high concentrations of LPS, B cells do not respond 
to the mitogenic, adjuvant or immunogenic properties of LPS and fibroblasts fail to 
undergo metabolic activation upon LPS exposure (Hoshino et al., 1999). A 
pharmacological approach was then undertaken to prevent pulmonary TLR4 
signalling, whereby a TLR4 antagonist (an underacylated form of Rhodobacter 
sphaeroides LPS) blocked TLR4 signalling via direct competition for the same 
binding site as LPS on MD-2 and by inhibiting LPS-MD-2 function at TLR4 (Saitoh 
et al., 2004;Coats et al., 2005;Teghanemt et al., 2005;Visintin et al., 2005). 
Consequently, this antagonist abolishes both LPS and Der p 2 TLR4 signalling.  
 
In order to proceed forward from TLR4 and to investigate the contribution of multiple 
TLRs to the immune response, two further approaches were utilised. MyD88 KO 
mice were exposed to HDM as this adaptor protein is vital in signalling of all TLR 
family members, apart from TLR3 and the TRIF-TRAM signalling pathway of TLR4 
(Yamamoto et al., 2002;Yamamoto et al., 2003;Akira et al., 2006). An additional 
pharmacological approach was carried out, targeting multiple TLRs, using a naturally 
occurring species of phosphotidyl serine (PS), 1-stearoyl-2-arachidonoyl-sn-glycero-
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3-[phospho-L-serine] (SAPS) (Parker et al., 2008). SAPS has been shown to block 
TLR1-4, 7 and 8 signalling by disruption of membrane microdomains and preventing 
the association of TLR2 and TLR4 with their respective membrane signalling 
partners (Parker et al., 2008).  
 
Following these in vivo experiments, the impact of HDM on the gene expression of 
TLRs, and associated TLR signalling family members, in the lung was determined by 
PCR array. This was done in order to investigate what effect HDM had on TLR 
expression and whether these observations were influenced by either the strain of 
mouse, the absence of MyD88 or the SAPS inhibitor. Thus through the experiments 
carried out in this Chapter the contribution of TLR signalling, and associated MyD88-
dependent and MyD88-independent TRIF signalling, to the immune response to 
HDM following continuous respiratory exposure was investigated. 
 
 
4.2. Hypothesis and Aims 
 
4.2.1. Hypothesis 
 
TLR signalling is vital for the in vivo immune response to HDM and disruption of 
TLR pathways will result in reduced Th2-driven airway inflammation, AHR and 
airway remodelling. 
 
4.2.2. Aims 
 
Thus, the aims of Chapter 4 are to dissect: 
 
 The specific role of TLR4 in the immune response to HDM 
 
 The contribution of MyD88 to the development of HDM-induced disease 
pathogenesis 
 
 How a broad TLR antagonist will influence the development of the immune 
response to HDM. 
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4.3. Experimental Plan 
 
4.3.1. Protocol A: HDM administration to TLR4-deficient mice 
 
Female wildtype (wt) C3H-HeN or TLR4-deficient C3H-HeJ mice were administered 
either 25 µl PBS or 25 µg (in 25 µl) HDM i.n. 5 times a week for 3 weeks and culled 
24h post final challenge. 
 
4.3.2. Protocol B: Prophylactic treatment with a TLR4 antagonist 
 
Female BALB/c mice were given either 25 µl PBS or 25 µg (in 25 µl) HDM i.n. 3 
times a week for 3 weeks. Prior to each PBS or HDM challenge, mice received either 
vehicle (water) or a TLR4 antagonist 1 µg i.t. The vehicle or TLR4 antagonist were 
administered in a volume of 20 µl. Mice were culled 24h post final challenge. 
 
4.3.3. Protocols C: Administration of HDM to MyD88 KO mice 
 
Female wildtype (wt) C57BL/6 or MyD88 knockout (KO) mice were given either 25 
µl PBS or 25 µg (in 25 µl) HDM i.n. 3 times a week for either 1 week, 3 weeks or 5 
weeks. After the respective treatment, mice were culled 24h post final challenge. 
 
4.3.4. Protocol D: Prophylactic treatment with SAPS inhibitor antagonist 
 
Female BALB/c mice were administered either 25 µl PBS or 25 µg (in 25 µl) HDM 
i.n. 3 times a week for 3 weeks. Prior to each PBS or HDM challenge, mice received 
either vehicle (PBS) or SAPS inhibitor 1 mg/Kg i.n. The vehicle or SAPS inhibitor 
were administered in a volume of 50 µl. Mice were culled 24h post final challenge. 
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4.4. Results 
 
4.4.1. Protocol A: HDM challenge in TLR4-signalling deficient mice 
 
4.4.1.1. HDM exposure causes AHR in TLR4-signalling deficient mice 
 
To determine the contribution of functional TLR4 signalling to HDM-induced 
allergic airways disease, wildtype (wt) C3H-HeN and naturally occurring TLR4-
signalling deficient C3H-HeJ (TLR4 -ve) mice were exposed to either PBS or HDM 
for 3 weeks.  
 
HDM exposure resulted in increased airway resistance in both wt and TLR4 -ve mice 
24h post-final challenge (Figure 4.2A and B). However, only HDM-treated TLR4 –ve 
mice showed decreased airway compliance compared to the respective PBS control 
group (Figure 4.2C and D).  
 
4.4.1.2. HDM promotes inflammatory cell recruitment to the lungs of TLR4 –ve 
mice 
 
HDM inhalation resulted in elevated numbers of total cells in the lung and BAL of wt 
and TLR4 -ve mice (Figure 4.3A and B). As expected eosinophils composed a 
significant component of these populations and the numbers of eosinophils recovered 
from the lung and BAL in response to HDM were not reduced by the absence of 
functional TLR4 signalling (Figure 4.3C and D). Indeed the number of total cells and 
eosinophils recovered from the BAL were greater in HDM-treated TLR4 –ve mice 
than HDM wt mice (Figure 4.3B and D). HDM-treated wt mice were observed to 
have increased numbers of neutrophils in the lungs compared to PBS controls, 
however in contrast, neutrophilia was not observed in the lungs of HDM-treated 
TLR4 -ve mice (Figure 4.3E). This observation was restricted to the lung, as HDM-
induced neutrophilia persisted in the BAL of HDM exposed TLR4 –ve mice (Figure 
4.3F). Greater numbers of Th2 cells were recovered from the lung and BAL of HDM-
treated mice compared to PBS controls and there was no impact of systemic TLR4 
signalling deficiency on the number of these cells (Figure 4.3G - H).  
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Airway Resistance    Airway Compliance 
 
 
 
 
Figure 4.2. AHR in TLR4 –ve HDM-treated mice.  
(A) Airway resistance (RI) of PBS and HDM-treated mice at 24h post final challenge. 
(B) Airway resistance expressed as mean RI ± SEM for the 30mg/ml dose of 
methacholine. (C) Airway compliance (Cdyn) of PBS and HDM-treated mice at 24h 
post final challenge. (D) Airway compliance expressed as mean Cdyn ± SEM for the 
30mg/ml dose of methacholine. (n=4 PBS and n=5-6 HDM). *, P<0.05 (Mann-
Whitney U test) HDM compared with PBS for the corresponding strain. Data are 
mean ± SEM. N.S., not significant. One experiment. 
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Figure 4.3. Eosinophilia in HDM-treated TLR4 -ve mice.  
Total cells, eosinophils, neutrophils and CD4
+
T1ST2
+
 cells recovered from the lung 
(A, C, E and G) and BAL (B, D, F and H) 24h after the final challenge (n=4 PBS and 
n=5-6 HDM). Total cell counts were determined using a haemocytometer with white 
blood cell counting fluid, eosinophils and neutrophils were quantified from Wright-
Giemsa stained cytospins and CD4
+
T1ST2
+
 cells were quantified by flow cytometry, 
as described in the Materials and Methods. *, P<0.05; (Mann-Whitney U test) HDM 
compared with PBS from corresponding strain. #, P<0.05 (Mann-Whitney U test) 
TLR4 -ve HDM compared with wt HDM. Bars depict median of the groups. One 
experiment. 
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4.4.1.3. Inflammatory chemokine and cytokine production in HDM-treated 
TLR4 -ve mice  
 
The chemokines associated with the eosinophil, neutrophil and Th2 cell recruitment 
in response to HDM were assessed in both wt and TLR4 -ve mice. Eotaxin-1/CCL11 
and eotaxin-2/CCL24 levels were elevated in the lungs of both wt and TLR4 -ve mice 
in response to HDM, with no significant differences observed between each HDM-
treated group (Figure 4.4A and B). HDM challenged wt mice demonstrated increased 
levels of KC/mCXCL1 in the lung compared to PBS controls. However, in TLR4 –ve 
mice there was reduced production of KC/mCXCL1 in response to HDM compared 
to wt controls (Figure 4.4C), concomitant with reduced neutrophilia in the lung 
(Figure 4.3E). HDM-induced production of TARC/CCL17 and RANTES/CCL5 was 
not seen in the TLR4 –ve mice, due to the high baseline levels in the PBS TLR4 –ve 
group (Figure 4.4D and E). MCP-1/CCL2 production was unaltered by the absence of 
TLR4 signalling (Figure 4.4F). 
 
HDM-induced production of IL-4, IL-5 and IL-1β were not affected by the lack of 
TLR4 signalling (Figure 4.5A - C). Similarly, TLR4 signalling deficiency did not 
influence HDM-induced production of the Th1 associated cytokines IFN-γ or IL-12 
(Figure 4.5D and E).  
 
IL-33 levels were greater in the lung tissue of HDM TLR4 –ve mice than the wt 
(Figure 4.6A). TLR4 signalling deficiency did not alter IL-25 (IL-17E), TSLP and 
CCL20/MIP-3α responses to HDM. The baseline levels of IL-25 (IL-17E), TSLP and 
CCL20/MIP-3α in the lung tissue of TLR4 –ve mice were higher than those of the 
respective wt group (Figure 4.6B - D). 
 
  
 
 
 
 
 
 
100 
 
 
 
 
Figure 4.4. Altered chemokine profile of TLR4 -ve mice.  
(A) Eotaxin-1/CCL11, (B) Eotaxin-2/CCL24, (C) KC/mCXCL1, (D) TARC/CCL17, 
(E) RANTES/CCL5 and (F) MCP-1/CCL2 levels measured in the lung 24h after the 
final challenge. Eotaxin-1/CCL11, eotaxin-2/CCL24, TARC/CCL17, 
RANTES/CCL5 and MCP-1/CCL2 levels were determined by ELISA and 
KC/mCXCL1 by MSD. (n=4 PBS and n=5-6 HDM). *, P<0.05; (Mann-Whitney U 
test) HDM compared with PBS from corresponding strain. #, P<0.05 (Mann-Whitney 
U test) TLR4 -ve HDM compared with wt HDM. Bars depict the median of the 
group. One experiment. 
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Figure 4.5. Pro-inflammatory cytokine production in HDM-treated mice. 
(A) IL-4, (B) IL-5, (C) IL-1β, (D) IFN-γ and (E) IL-12 were measured in the lung 24h 
after the final challenge. All mediator levels were determined by MSD. (n=4 PBS and 
n=5-6 HDM). *, P<0.05; (Mann-Whitney U test) HDM compared with PBS from 
corresponding strain. N.S. Not significant. Bars depict the median of the group. One 
experiment.  
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Figure 4.6. Innate cytokine production in HDM-treated mice. 
(A) IL-33, (B) IL-25 (IL-17E), (C) TSLP and (D) CCL20/MIP-3α were measured in 
the lung 24h after the final i.n. challenge. All mediator levels were determined by 
ELISA. (n=4 PBS and n=5-6 HDM). *, P<0.05; (Mann-Whitney U test) HDM 
compared with PBS from corresponding strain. #, P<0.05 (Mann-Whitney U test) 
either TLR4 –ve PBS compared with wt PBS or TLR4 -ve HDM compared with wt 
HDM. Bars depict the median of the group. One experiment. 
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4.4.1.4. Pro-inflammatory serum immunoglobulin production in TLR4 -ve mice 
 
As expected, HDM inhalation induced the production of IgE, IgG1 and IgG2a in the 
serum of wt mice. The total IgE response to HDM was elevated in TLR4 –ve mice 
compared to HDM exposed wt controls (Figure 4.7A), whereas HDM-specific IgE 
and total IgG1 and IgG2a production was not altered between strains (Figure 4.7B - 
D).  
 
4.4.1.5. Goblet cell hyperplasia is not altered by the absence of TLR4 
 
PAS staining of lung sections showed that HDM challenge elicited mucus production 
in the airways, to similar levels, in both wt and TLR4 -ve mice (Figure 4.8A). 
Representative pictures of PAS stained lung sections from PBS and HDM-treated wt 
and TLR4 -ve mice are shown (Figure 4.8B – E). 
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Figure 4.7. Allergic immunoglobulin production in HDM-treated TLR4 -ve 
mice.  
(A) Total IgE, (B) HDM-specific IgE, (C) total IgG1 and (D) total IgG2a levels 
measured in the serum 24h after the final i.n. challenge. All levels were determined 
by ELISA (n=4 PBS and n=5-6 HDM). *, P<0.05; (Mann-Whitney U test) HDM 
compared with PBS from corresponding strain. #, P<0.05 (Mann-Whitney U test) 
TLR4 -ve HDM compared with wt HDM. Bars depict the median of the group. N.S., 
not significant. One experiment. 
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A. Mucus Score 
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Figure 4.8. Goblet cell hyperplasia in TLR4 -ve mice.  
(A) Semi-quantitative scoring of PAS stained lung sections. (n=4 PBS and n=5-6 
HDM). *, P<0.05; (Mann-Whitney U test) HDM compared with PBS. Bars depict the 
median of the groups. Lung histological sections prepared with Periodic-acid Schiff 
stain from (B) wt PBS, (C) TLR4 -ve PBS, (D) wt HDM and (E) TLR4 -ve HDM-
treated mice (original 20X magnification). Scale bar = 50 µm. One experiment. 
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4.4.2. Protocol B: Effect of a TLR4 antagonist on HDM-induced allergic airway 
inflammation 
 
4.4.2.1. AHR in HDM-treated mice 
 
In order to investigate the specific contribution of TLR4 signalling in the lung to the 
immune response to inhaled HDM, the effects of prophylactic administration of a 
TLR4 antagonist on HDM-induced allergic airways disease were assessed. HDM 
exposure resulted in AHR, as measured by increased airway resistance and decreased 
airway compliance 24h post-challenge. Administration of a TLR4 antagonist did not 
affect HDM-induced AHR (Figure 4.9A – D).  
 
4.4.2.2. Reduced inflammatory cell recruitment following TLR4 antagonism 
 
HDM exposure resulted in greater numbers of total cells, eosinophils, neutrophils and 
Th2 cells recovered from the lung and BAL (Figure 4.10A - H). Following 
pharmacological antagonism of TLR4, there was a reduction in the numbers of total 
cells in the lung and BAL, eosinophils in the lung, neutrophils in the lung and BAL 
and Th2 cells in the BAL (Figure 4.10A, B, C, E, G and H).  
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 Airway Resistance    Airway Compliance 
 
 
 
Figure 4.9. TLR4 antagonist does not prevent HDM-induced AHR.  
(A) Airway resistance of PBS and HDM-treated mice at 24h post final challenge 
treated with either vehicle or TLR4 antagonist. (B) Airway resistance is expressed as 
mean resistance ± SEM for the 30mg/ml dose of methacholine. (C) Airway 
compliance of PBS and HDM-treated mice at 24h post final challenge treated with 
either vehicle or TLR4 antagonist. (D) Airway compliance is expressed as mean ± 
SEM for the 30mg/ml dose of methacholine. (n=4 PBS and n=6 HDM). *, P<0.05 
(Mann-Whitney U test) HDM compared with PBS from corresponding treatment 
group. Data are mean ± SEM. One experiment. 
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Figure 4.10. Inflammatory cell profile of HDM-treated mice. 
Total cells, eosinophils, neutrophils and CD4
+
T1ST2
+ 
cells recovered from the lung 
(A - D) and BAL (E - H) 24h after the final challenge (n=4 PBS and n=5-6 HDM). 
Total cell counts were determined using a haemocytometer with white blood cell 
counting fluid, eosinophils and neutrophils were quantified from Wright-Giemsa 
stained cytospins and CD4
+
T1ST2
+
 cells were quantified by flow cytometry, as 
described in the Materials and Methods. *, P<0.05; (Mann-Whitney U test) HDM 
compared with PBS from corresponding treatment. #, P<0.05 (Mann-Whitney U test) 
TLR4 antagonist HDM compared with vehicle HDM. Bars depict median of the 
groups. One experiment. 
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4.4.2.3. No alteration of chemokine production with a TLR4 antagonist 
 
Eotaxin-1/CCL11, KC/mCXCL1, MDC/CCL22, MCP-1/CCL2, TARC/CCL17 and 
RANTES/CCL5 which are recruitment mediators of eosinophils, neutrophils and Th2 
cells, were quantified in the lung tissue. HDM exposure resulted in increased levels of 
each of these chemokines as compared to PBS controls. The administration of a 
TLR4 antagonist did not alter HDM-induced production of these mediators (Figure 
4.11A – F). 
 
4.4.2.4. Abrogated IL-25 (IL-17E) production following TLR4 antagonism 
 
HDM-induced production of IL-4 and IL-1β was not altered by the administration of 
a TLR4 antagonist (Figure 4.12A and B). IL-25 (IL-17E), TSLP, CCL20/MIP-3α and 
IL-33 were quantified in the lungs following the respective treatments. HDM-treated 
mice showed elevated levels of IL-25 (IL-17E) in the lung tissue as compared to PBS 
controls and this was completely abrogated following the administration of the TLR4 
antagonist (Figure 4.12C). Increased levels of TSLP, CCL20/MIP-3α and IL-33 were 
observed in the lung tissue of HDM-treated mice as compared to PBS controls and 
these levels were not altered by the TLR4 antagonist (Figure 4.12D - F).  
 
4.4.2.5. IgE production in HDM-treated mice 
 
Elevated levels of total and HDM-specific IgE were observed in the serum of HDM-
treated mice. The TLR4 antagonist did not alter the levels of HDM-induced 
production of IgE (Figure 4.13A and B). 
 
4.4.2.6. Goblet cell hyperplasia in HDM-treated mice 
 
Goblet cell hyperplasia was observed in HDM-treated mice. Despite the 
administration of a TLR4 antagonist, no effect was seen on the mucus production 
(Figure 4.14A). Representative PAS stained lung sections are shown (Figure 4.14B – 
E). 
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Figure 4.11. TLR4 antagonist does not prevent inflammatory chemokine 
production.  
(A) Eotaxin-1/CCL11, (B) KC/mCXCL1, (C) MDC/CCL22, (D) MCP-1/CCL2, (E) 
TARC/CCL17 and (F) RANTES/CCL5 levels measured in the lung 24h after the 
final challenge. All mediator levels were determined by ELISA. (n=4 PBS and n=6 
HDM). *, P<0.05; (Mann-Whitney U test) HDM compared with PBS from 
corresponding treatment. Bars depict the median of the group. N.S., not significant. 
One experiment. 
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Figure 4.12. TLR4 antagonist blocks HDM-induced IL-25 (IL-17E) production. 
(A) IL-4, (B) IL-1β (C) IL-25 (IL-17E), (D) TSLP, (E) CCL20/MIP-3α and (F) IL-33 
measured in the lung 24h after the final challenge. All mediator levels were 
determined by ELISA. (n=4 PBS and n=6 HDM). *, P<0.05; (Mann-Whitney U test) 
HDM compared with PBS from corresponding treatment. #, P<0.05 (Mann-Whitney 
U test) TLR4 antagonist HDM compared with vehicle HDM. Bars depict the median 
of the group. N.S., not significant. One experiment. 
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Figure 4.13. Allergic immunoglobulin production in TLR4 antagonist-treated 
mice.  
(A) Total IgE and (B) HDM-specific IgE levels measured in the serum 24h after the 
final challenge. All levels were determined by ELISA (n=4 PBS and n=6 HDM). *, 
P<0.05; (Mann-Whitney U test) HDM compared with PBS from corresponding 
treatment. Bars depict the median of the groups. One experiment. 
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Figure 4.14. TLR4 antagonist does not prevent HDM-induced goblet cell 
hyperplasia.  
(A) Semi-quantitative scoring of PAS stained lung sections. (n=4 PBS and n=6 
HDM). *, P<0.05; (Mann-Whitney U test) HDM compared with PBS. Bars depict the 
median of the group. Lung histological sections prepared with Periodic-acid Schiff 
stain from (B) vehicle PBS, (C) vehicle HDM, (D) TLR4 antagonist PBS and (E) 
TLR4 antagonist HDM-treated mice (original 20X magnification). Scale bar = 50 
µm. One experiment. 
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4.4.3. Protocol C: Impact of MyD88 deficiency on HDM-induced allergic airways 
disease 
 
Thus far it has been established that neither the absence of systemic TLR4 signalling 
nor the pharmacological antagonism of TLR4 prevented the development of several 
key features of HDM-induced allergic airways disease, including AHR and HDM-
specific IgE production. To investigate the contribution of multiple TLRs to the 
immune response, MyD88 knockout (KO) mice were exposed to HDM, for either 1, 3 
or 5 weeks, in order to determine the role of this adaptor protein in the development 
of Th2 pathology. MyD88 signalling contributes to all TLR signalling pathways 
except for TLR3 and the TLR4 TRIF-TRAM-dependent signalling cascade (Kawai 
and Akira, 2006).  
 
4.4.3.1. AHR in HDM-treated MyD88 KO mice 
 
To investigate the contribution of MyD88 to HDM-induced AHR, wt C57BL/6 and 
MyD88 KO mice were dosed for 3 or 5 weeks. No increased airway resistance was 
observed in HDM-treated wt mice, whereas MyD88 KO mice showed increased 
airway resistance at week 3 (Figure 4.15A – D). HDM-treated MyD88 KO mice also 
showed decreased airway compliance compared to the respective PBS-treated My88 
KO mice at weeks 3 and 5 (Figure 4.15E – H).  
 
4.4.3.2. Inflammatory cell recruitment in MyD88 KO mice 
 
Following 1 week of HDM exposure, there was no elevation in the number of total 
cells, eosinophils or neutrophils in the lung tissue in either wt or MyD88 KO mice 
(Figure 4.16A - C). After HDM exposure for either 3 or 5 weeks, the number of total 
cells and inflammatory cell numbers in the lung were not reduced by the absence of 
MyD88 (Figure 4.16A – D), with lung eosinophilia greater in the MyD88 KO mice 
than wt mice at week 3 (Figure 4.16B). HDM exposure resulted in elevated numbers 
of total cells and inflammatory cell recruitment to the BAL from as early as 1 week 
and this was not reduced in the absence of MyD88 (Figure 4.17A - D). 
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Figure 4.15. AHR in HDM-treated MyD88 KO mice.  
(A) Airway resistance of PBS and HDM-treated mice 24h post final challenge following 3 
weeks of exposure. (B) Airway resistance is expressed as mean resistance ± SEM for the 
100mg/ml dose of methacholine. (C) Airway resistance of PBS and HDM-treated mice 24h 
post final challenge following 5 weeks of exposure. (D) Airway resistance is expressed as 
mean resistance ± SEM for the 100mg/ml dose of methacholine. (E) Airway compliance of 
PBS and HDM-treated mice 24h post final challenge following 3 weeks of exposure. (F) 
Airway compliance is expressed as mean ± SEM for the 100mg/ml dose of methacholine. (G) 
Airway compliance of PBS and HDM-treated mice 24h post final challenge following 5 
weeks of exposure. (H) Airway compliance is expressed as mean ± SEM for the 100mg/ml 
dose of methacholine. (n=4 PBS and n=6 HDM). *, P<0.05 (Mann-Whitney U test) HDM 
compared with PBS from corresponding strain. Data are mean ± SEM. One experiment. 
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Figure 4.16. Inflammatory cell recruitment to the lungs of MyD88 KO mice. 
(A) Total cells, (B) eosinophils, (C) neutrophils and (D) CD4
+
T1ST2
+
 cells recovered from the 
lung 24h after the final i.n. challenge, following either 1, 3 or 5 weeks of exposure. (n=4 PBS and 
n=3-6 HDM). Total cell counts were determined using a haemocytometer with white blood cell 
counting fluid, eosinophils and neutrophils were quantified from Wright-Giemsa stained cytospins 
and CD4
+
T1ST2
+
 cells were quantified by flow cytometry, as described in the Materials and 
Methods. *, P<0.05; (Mann-Whitney U test) HDM compared with PBS from corresponding strain 
and time point. Bars depict median of the groups. One experiment. 
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Figure 4.17. Inflammatory cell recruitment to the BAL of MyD88 KO mice. 
(A) Total cells, (B) eosinophils, (C) neutrophils and (D) CD4
+
T1ST2
+
 cells recovered from the 
BAL 24h after the final i.n. challenge, following either 1, 3 or 5 weeks of exposure. (n=4 PBS and 
n=3-6 HDM). Total cell counts were determined using a haemocytometer with white blood cell 
counting fluid, eosinophils and neutrophils were quantified from Wright-Giemsa stained cytospins 
and CD4
+
T1ST2
+
 cells were quantified by flow cytometry, as described in the Materials and 
Methods. *, P<0.05; (Mann-Whitney U test) HDM compared with PBS from corresponding strain 
and time point. Bars depict median of the groups. One experiment. 
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4.4.3.3. Pro-inflammatory mediator production in MyD88 KO mice 
 
HDM-induced production of eotaxin-1/CCL11 and KC/mCXCL1 was not altered by 
the absence of MyD88 (Figure 4.18A and B). TARC/CCL17, RANTES/CCL5 and 
MCP-1/CCL2 production were not reduced in MyD88 KO mice (Figure 4.18C - E). 
Indeed, TARC/CCL17 (at week 1) and MCP-1/CCL2 (week 3) levels were higher in 
HDM-treated MyD88 KO mice than wt controls (Figure 4.18C and E).  
 
Less IL-1β production was seen in HDM-treated MyD88 KO mice than the wt 
controls at week 3. However, the levels observed in HDM-treated mice were 
equivalent at week 5 (Figure 4.19A). IL-33 production was observed in both wt and 
MyD88 KO mice exposed to HDM from as early as week 1, which then persisted to 
week 5 (Figure 4.19B). HDM did not induce the production of IL-25 (IL-17E) in 
either the C57BL/6 wt controls or the MyD88 KO mice (Figure 4.19C). CCL20/MIP-
3α was elevated in HDM-treated wt and MyD88 KO mice from week 1 compared to 
PBS controls and this continued through the 5 week time course (Figure 4.19D). 
 
4.4.3.4. Allergic immunoglobulin production in MyD88 KO exposed mice 
 
The absence of MyD88 did not abrogate allergic immunoglobulin production in 
response to HDM, with total and HDM-specific IgE, as well as the Th2-associated 
IgG1 levels elevated from PBS controls in MyD88 KO mice (Figure 4.20A – C). 
Indeed, at week 5 total IgE levels were higher in HDM-treated MyD88 KO mice than 
the respective wt (Figure 4.20A). 
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Figure 4.18. Pro-inflammatory chemokine production in MyD88 KO mice. 
(A) Eotaxin-1/CCL11, (B) KC/mCXCL1, (C) TARC/CCL17, (D) RANTES/CCL5 and (E) MCP-
1/CCL2 measured in the lung 24h after the final i.n. challenge. All mediator levels were 
determined by ELISA. (n=4 PBS and n=6 HDM). *, P<0.05; (Mann-Whitney U test) HDM 
compared with PBS from corresponding strain and time point. #, P<0.05 (Mann-Whitney U test) 
HDM MyD88 KO compared with HDM wt from corresponding time point. Bars depict the 
median of the groups. N.S., not significant. N.S., not significant. One experiment.  
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Figure 4.19. Pro-inflammatory mediator release in MyD88 KO mice. 
(A) IL-1β, (B) IL-33, (C) IL-25 (IL-17E) and (D) CCL20/MIP-3α measured in the 
lung 24h after the final i.n. challenge. All mediator levels were determined by ELISA. 
(n=4 PBS and n=6 HDM). *, P<0.05; (Mann-Whitney U test) HDM compared with 
PBS from corresponding strain and time point. #, P<0.05; (Mann-Whitney U test) 
HDM MyD88 KO compared with HDM wt from corresponding time point. Bars 
depict the median of the groups. One experiment. 
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Figure 4.20. Allergic immunoglobulin production in MyD88 KO mice. 
(A) Total IgE, (B) HDM-specific IgE and (C) total IgG1 measured in the serum 24h 
after the final i.n. challenge. All mediator levels were determined by ELISA. (n=4 
PBS and n=6 HDM). *, P<0.05; (Mann-Whitney U test) HDM compared with PBS 
from corresponding strain and time point. #, P<0.05 (Mann-Whitney U test) HDM 
MyD88 KO compared with HDM wt from corresponding time point. Bars depict the 
median of the groups. N.D., not detected. One experiment.  
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4.4.3.5. Goblet cell hyperplasia and peri-bronchial collagen deposition in HDM-
treated MyD88 KO mice 
 
Goblet cell hyperplasia was observed in both wt and MyD88 KO mice following 5 
weeks of HDM exposure. HDM-induced mucus secretion was not altered by the 
absence of MyD88 (Figure 4.21A). Peri-bronchial collagen deposition is a feature of 
airway remodelling and following 5 weeks of HDM exposure, peri-bronchial collagen 
deposition was observed in both wt and MyD88 KO mice (Figure 4.21B). 
Representative photos from PAS and sirius red stained lung sections are shown 
(Figure 4.21C – F). 
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Figure 4.21. Goblet cell hyperplasia and peri-bronchial collagen deposition in 
MyD88 KO mice.  
(A) Semi-quantitative scoring of PAS stained lung sections. (B) Quantification of 
peri-bronchial collagen deposition, expressed as mean intensity. (n=4 PBS and n=6 
HDM). *, P<0.05; (Mann-Whitney U test) HDM compared with PBS from 
corresponding strain. Bars depict the median of the groups. Representative pictures of 
PAS and sirius red stained lung sections from (C) wt PBS, (D) wt HDM, (E) MyD88 
KO PBS and (F) MyD88 KO HDM-treated mice, following 5 weeks of either PBS or 
HDM exposure (original 20X magnification). Scale bar = 50 µm. One experiment. 
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4.4.4. Protocol D: Effect of a SAPS inhibitor on HDM-induced allergic airway 
inflammation 
 
4.4.4.1. AHR in HDM-treated mice 
 
In order to further dissect the role of TLR signalling to HDM-induced allergic 
airways disease, the effects of prophylactic administration of a SAPS inhibitor on 
HDM-induced allergic airways disease was investigated. In vitro SAPS has been 
shown to inhibit TLR1-4, 7 and 8 signalling via disruption of membrane 
microdomains (Parker et al., 2008). Administration of a SAPS inhibitor prevented 
HDM-induced increase in airway resistance however there was no effect on airway 
compliance (Figure 4.22A – D).  
 
4.4.4.2. Reduced inflammatory cell recruitment following TLR antagonism 
 
Following inhibition of TLR signalling with the SAPS inhibitor, there was a 
reduction in the number of total cells and eosinophils and Th2 cells in the lung and 
BAL and neutrophils in the BAL (Figure 4.23A - H).  
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Figure 4.22. SAPS inhibitor prevents HDM-induced increase in airway 
resistance. 
(A) Airway resistance of PBS and HDM-treated mice at 24h post final challenge 
treated with either vehicle or SAPS inhibitor. (B) Airway resistance is expressed as 
mean resistance ± SEM for the 30mg/ml dose of methacholine. (C) Airway 
compliance of PBS and HDM-treated mice at 24h post final challenge treated with 
either vehicle or SAPS inhibitor. (D) Airway compliance is expressed as mean ± 
SEM for the 30mg/ml dose of methacholine. (n=4 PBS and n=6 HDM). *, P<0.05 
(Mann-Whitney U test) HDM compared with PBS from corresponding treatment 
group. Data are mean ± SEM. One experiment. 
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Figure 4.23. Inflammatory cell profile of HDM-treated mice.  
Total cells, eosinophils, neutrophils and CD4
+
T1ST2
+ 
cells recovered from the lung 
(A - D) and BAL (E - H) 24h after the final challenge (n=4 PBS and n=6 HDM). 
Total cell counts were determined using a haemocytometer with white blood cell 
counting fluid, eosinophils and neutrophils were quantified from Wright-Giemsa 
stained cytospins and CD4
+
T1ST2
+
 cells were quantified by flow cytometry, as 
described in the Materials and Methods. *, P<0.05; (Mann-Whitney U test) HDM 
compared with PBS from corresponding treatment. #, P<0.05 (Mann-Whitney U test) 
SAPS inhibitor HDM compared with vehicle HDM. Bars depict median of the 
groups. One experiment. 
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4.4.4.3. Reduction in chemokine production with SAPS inhibitor 
 
The pro-inflammatory chemokines eotaxin-1/CCL11, KC/mCXCL1, TARC/CCL17, 
RANTES/CCL5, MDC/CCL22 and MCP-1/CCL2 were quantified in the lung tissue. 
The administration of the SAPS inhibitor reduced the levels of eotaxin-1/CCL11 and 
TARC/CCL17 and completely abrogated RANTES/CCL5, MDC/CCL22 and MCP-
1/CCL2 production. However, the neutrophil chemoattractant KC/mCXCL1 
production was unaltered (Figure 4.24A – F). 
 
4.4.4.4. Abrogated IL-25 (IL-17E) production following TLR antagonism 
 
Neither IL-4 nor IL-5 production was influenced by the SAPS inhibitor (Figure 4.25A 
and B). However, SAPS-treated HDM exposed mice showed reduced levels of IL-13 
in the lung (Figure 4.25C). HDM-induced IL-1β production was not altered by the 
SAPS inhibitor (Figure 4.25D). HDM-treated mice showed elevated levels of IL-25 
(IL-17E) in the lung tissue as compared to PBS controls, which was completely 
abrogated following the administration of the SAPS inhibitor (Figure 4.25E). Greater 
levels of IL-33 and CCL20/MIP-3α were observed in the lung tissue of HDM-treated 
mice as compared to PBS controls, which were not altered by the SAPS inhibitor 
(Figure 4.25F and G).  
 
4.4.4.5. IgE production in HDM-treated mice 
 
The SAPS inhibitor did not alter the levels of HDM-induced production of serum IgE 
(Figure 4.26A and B). 
 
4.4.4.6. Goblet cell hyperplasia in HDM-treated mice 
 
Goblet cell hyperplasia was observed in HDM-treated mice compared to PBS 
controls. Administration of the SAPS inhibitor had no effect on the mucus production 
in HDM-treated mice (Figure 4.27A). Representative PAS stained lung sections are 
shown (Figure 4.27B – E). 
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Figure 4.24. SAPS inhibitor reduces inflammatory chemokine production.  
(A) Eotaxin-1/CCL11, (B) KC/mCXCL1, (C) TARC/CCL17, (D) RANTES/CCL5, 
(E) MDC/CCL22 and (F) MCP-1/CCL2 levels measured in the lung 24h after the 
final challenge. All mediator levels were determined by ELISA. (n=4 PBS and n=6 
HDM). *, P<0.05; (Mann-Whitney U test) HDM compared with PBS from 
corresponding treatment. #, P<0.05 (Mann-Whitney U test) SAPS inhibitor HDM 
compared with vehicle HDM. Bars depict the median of the groups. N.S., not 
significant. One experiment. 
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Figure 4.25. SAPS inhibitor abrogates HDM-induced production of IL-25 (IL-
17E). 
(A) IL-4, (B) IL-5, (C) IL-13, (D) IL-1β, (E) IL-25 (IL-17E), (F) IL-33 and (G) 
CCL20/MIP-3α measured in the lung 24h after the final challenge. All mediator 
levels were determined by ELISA. (n=4 PBS and n=6 HDM). *, P<0.05; (Mann-
Whitney U test) HDM compared with PBS from corresponding treatment. #, P<0.05 
(Mann-Whitney U test) SAPS inhibitor HDM compared with vehicle HDM. Bars 
depict the median of the groups. One experiment. 
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Figure 4.26. SAPS inhibitor does not prevent allergic immunoglobulin 
production.  
(A) Total IgE and (B) HDM-specific IgE levels measured in the serum 24h after the 
final challenge. All levels were determined by ELISA (n=4 PBS and n=6 HDM). *, 
P<0.05; (Mann-Whitney U test) HDM compared with PBS from corresponding 
treatment. Bars depict the medians of the groups. One experiment. 
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Figure 4.27. SAPS inhibitor does not prevent goblet cell hyperplasia.  
(A) Semi-quantitative scoring of PAS stained lung sections. (n=4 PBS and n=6 
HDM). *, P<0.05; (Mann-Whitney U test) HDM compared with PBS from 
corresponding treatment group. Bars depict the median of the groups. Lung 
histological sections prepared with Periodic-acid Schiff stain from (B) vehicle PBS, 
(C) vehicle HDM, (D) SAPS inhibitor PBS and (E) SAPS inhibitor HDM-treated 
mice (original 20X magnification). Scale bar = 50 µm. One experiment. 
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4.4.5. Results Summary 
 
A summary of the airway inflammatory and remodelling parameters and how these 
were influenced in each of the in vivo experiments is shown below. The table shows 
which parameters were unaltered between the HDM control and HDM-treatment 
groups (↔), which parameters were elevated in the HDM-treatment group compared 
to HDM controls (↑) and which parameters were reduced in the HDM-treatment 
group compared to HDM controls (↓) (Table 4.1). 
 
 TLR4 -ve TLR4 Antagonist MyD88 KO 
SAPS 
Inhibitor 
AHR ↔ ↔ ↔ ↔ 
Lung: Total Cells ↔ ↓ ↔ ↔ 
Lung: Eosinophils ↔ ↓ ↔ ↓ 
Lung: Neutrophils ↓ ↓ ↔ ↔ 
Lung: Th2 Cells ↔ ↔ ↔ ↓ 
Eotaxin-1/CCL11 ↔ ↔ ↔ ↓ 
KC/mCXCL1 ↓ ↔ ↔ ↔ 
TARC/CCL17 ↔ ↔ ↔ ↓ 
RANTES/CCL5 ↔ ↔ ↔ ↓ 
MCP-1/CCL2 ↔ ↔ ↔ ↓ 
IL-4 ↔ ↔ ↔ ↔ 
IL-1β ↔ ↔ ↔ ↔ 
IL-33 ↑ ↔ ↔ ↔ 
IL-25 (IL-17E) ↔ ↓ ↔ ↓ 
CCL20/MIP-3α ↔ ↔ ↔ ↔ 
Serum IgE ↑ ↔ ↔ ↔ 
Goblet Cell Hyperplasia ↔ ↔ ↔ ↔ 
Collagen Deposition Not Done Not Done ↔ Not Done 
 
Table 4.1. A summary of the inflammatory and remodelling parameters and 
how these were influenced by either systemic TLR4 signalling deficiency, a 
TLR4 antagonist, the absence of MyD88 or the SAPS inhibitor.  
 
Key: 
↔ = No change between HDM and HDM-treatment groups. 
 ↑ = Increase in HDM-treatment group compared to HDM. 
 ↓ = Decrease in HDM-treatment group compared to HDM. 
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4.4.6. TLR gene expression in the lung 
 
4.4.6.1. Impact of HDM and MyD88 deficiency on TLR gene expression in the 
lung 
 
To investigate how HDM altered the levels of gene expression of TLRs and 
associated TLR signalling transduction molecules in the lung, the RNA was extracted 
from the lung tissue of C57BL/6 mice exposed to the allergen for three weeks. The 
extracted RNA was then converted to cDNA and the gene expression was assessed by 
PCR array. In HDM-treated mice, high fold increases in gene expression of MCP-
1/CCL2, IP-10/CXCL10 and IFN-β expression and a small fold increase in IL-1β 
were observed (Figure 4.28A). MyD88 KO mice showed higher expression levels of 
TLR1, TLR6, TLR9 and the MyD88-independent signalling molecules TRAM, 
MCP-1/CCL2, IP-10/CXCL10 and IFN-β compared to the C57BL/6 wt controls 
(Figure 4.28B). The impact of MyD88 deficiency on HDM-induced changes in gene 
expression was then investigated. The absence of MyD88 had minimal effect on the 
gene expression alterations caused by HDM, apart from causing a large decrease in 
TLR6 expression (Figure 4.28C). 
 
4.4.6.2. Effects of HDM and the SAPS inhibitor on TLR gene expression in the 
lung 
 
BALB/c mice have been shown to be more susceptible to allergen-induced AHR than 
C57BL/6 mice (Whitehead et al., 2003;Kelada et al., 2011). It was therefore 
investigated whether HDM-induced changes in TLR gene expression differed 
between C57BL/6 and BALB/c mice and also whether the SAPS inhibitor altered 
HDM-induced changes in gene expression in BALB/c mice. In BALB/c mice, HDM 
treatment increased the level of gene expression for MyD88, MCP-1/CCL2 and IP-
10/CXCL10 compared to PBS controls (Figure 4.29A). The SAPS inhibitor alone 
decreased the expression of IL-1β, IL-12 and IFN-β in naive mice (Figure 4.29B) and 
the SAPS inhibitor markedly reduced HDM-induced expression of MyD88 in 
BALB/c mice (Figure 4.29C). 
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Figure 4.28. Impact of HDM and MyD88 deficiency on TLR gene expression in the lung. 
RNA was extracted from the lung tissue and assessment of gene expression was carried out 
by PCR array. (A) Fold regulation of gene expression from HDM-treated C57BL/6 mice, 
compared to PBS-treated C57BL/6 mice. (B) Fold regulation of gene expression from 
MyD88 KO mice compared to C57BL/6 mice. (C) Fold regulation of gene expression from 
HDM-treated MyD88 KO mice compared to HDM-treated C57BL/6 mice. Data is expressed 
as change in fold regulation, with a fold regulation of +1 indicative of no change. (n=2 mice 
for each gene). 
HDM C57/BL6 vs PBS C57BL/6
T
L
R
1
T
L
R
2
T
L
R
3
T
L
R
4
C
D
1
4
M
D
-2
T
L
R
5
T
L
R
6
T
L
R
7
T
L
R
8
T
L
R
9
M
y
D
8
8
T
IR
A
P
T
R
A
F
6 
IL
-1
IL
-1
2
T
N
F
a
T
R
IF
T
R
A
M
IR
F
1
IR
F
3
M
C
P
-1
/C
C
L
2
IP
-1
0
/C
X
C
L
1
0
IF
N
b
-4
-2
0
2
4
6
8
10
45
55
65
TLRs MyD88-dependent MyD88-independent
A
F
o
ld
 R
e
g
u
la
ti
o
n
PBS MyD88 KO vs PBS C57BL/6
T
L
R
1
T
L
R
2
T
L
R
3
T
L
R
4
C
D
1
4
M
D
-2
T
L
R
5
T
L
R
6
T
L
R
7
T
L
R
8
T
L
R
9
M
y
D
8
8
T
IR
A
P
T
R
A
F
6 
IL
-1
IL
-1
2
T
N
F
a
T
R
IF
T
R
A
M
IR
F
1
IR
F
3
M
C
P
-1
/C
C
L
2
IP
-1
0
/C
X
C
L
1
0
IF
N
b
-4
-2
0
2
4
6
TLRs MyD88-dependent MyD88-independent
16
26
B
F
o
ld
 R
e
g
u
la
ti
o
n
HDM MyD88 KO vs HDM C57BL/6
T
L
R
1
T
L
R
2
T
L
R
3
T
L
R
4
C
D
1
4
M
D
-2
T
L
R
5
T
L
R
6
T
L
R
7
T
L
R
8
T
L
R
9
M
y
D
8
8
T
IR
A
P
T
R
A
F
6 
IL
-1
IL
-1
2
T
N
F
a
T
R
IF
T
R
A
M
IR
F
1
IR
F
3
M
C
P
-1
/C
C
L
2
IP
-1
0
/C
X
C
L
1
0
IF
N
b
-12
-10
-8
-6
-4
-2
0
2
4
TLRs MyD88-dependent MyD88-independent
C
F
o
ld
 R
e
g
u
la
ti
o
n
135 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.29. Impact of HDM and SAPS inhibitor on the TLR gene expression in the 
lung. 
RNA was extracted from the lung tissue of mice and assessment of gene expression was 
carried out by PCR array. (A) Fold regulation of gene expression from HDM-treated BALB/c 
mice compared to PBS-treated BALB/c mice. (B) Fold regulation of gene expression from 
SAPS-treated BALB/c mice compared to vehicle-treated BALB/c mice. (C) Fold regulation 
of gene expression from SAPS-treated HDM exposed mice compared to vehicle-treated 
HDM exposed mice. Data is expressed as change in fold regulation, with a fold regulation of 
+1 indicative of no change. (n=3 mice for each gene). *, P<0.05 (Student’s t-test). 
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4.5. Discussion 
 
The focus of this Chapter was to dissect the role of TLR signalling in the 
development of HDM-induced allergic airways disease. Pharmacological approaches 
were carried out to block TLR4 and then multiple TLR activation, with a TLR4 
antagonist and SAPS inhibitor respectively, to investigate the impact of TLR ligation 
on the development of Th2 responses following HDM exposure. Mice lacking 
systemic TLR4 and MyD88 signalling were also exposed to HDM to investigate the 
contribution of downstream TLR signalling pathways to the immune response. From 
these experiments it can be concluded that the MyD88-independent TRIF signalling 
pathway is the key contributor to the development of the immune response to HDM 
in vivo.  
 
C3H-HeJ mice were utilised to dissect the role of systemic TLR4 signalling in HDM-
induced allergic airways disease. C3H-HeJ mice have been shown to develop a less 
severe asthma phenotype in response to OVA than BALB/c mice (Whitehead et al., 
2003) and C3H-HeJ mice do not develop AHR following intermittent exposure to 
HDM (Lewkowich et al., 2008). However, pulmonary eosinophilia and Th2 cytokine 
production are not completely absent in C3H-HeJ mice upon either OVA (Whitehead 
et al., 2003) or HDM exposure (Lewkowich et al., 2008). In the current study in this 
Chapter, C3H-HeJ mice upon continuous exposure to HDM for 3 weeks developed 
AHR and showed robust Th2 cytokine, eosinophil and IgE responses. The only aspect 
of the inflammatory response to HDM that was impaired by systemic TLR4 
signalling deficiency was neutrophil recruitment to the lung. Lajoie and colleagues 
have recently shown that C3H-HeJ mice exposed to HDM produce the Th2-
associated cytokines IL-4, IL-5 and IL-13 but fail to mount a Th17 response (Lajoie 
et al., 2010), which may explain the lack of neutrophils recovered from the lung 
observed here in the current study (Figure 4.2E).  
 
The exact mechanism by which KC/mCXCL1 production in response to HDM is 
reduced in C3H-HeJ mice is unclear as macrophages derived from C3H-HeJ mice are 
not activated upon LPS stimulation (Hoshino et al., 1999). The reduced production of 
this chemokine could occur as a result of either the absence of TLR4 signalling on 
airway epithelial cells or as a result of impaired macrophage function, since both 
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these cells produce KC/mCXCL1 or the human equivalent IL-8 (Koch AE et al., 
1992;Adam et al., 2006). In the current study it was observed that C3H-HeJ mice had 
higher baseline levels of TARC/CCL17, RANTES/CCL5, IL-25 (IL-17E), TSLP and 
CCL20/MIP-3α compared to the C3H-HeN wt mice. Therefore, the administration of 
the TLR4 antagonist via the i.t. route allowed for a more specific tissue targeting 
experiment by blocking TLR4 activation on airway macrophages, DCs and epithelial 
cells. Administration of the TLR4 antagonist reduced eosinophil numbers recovered 
from the lung and BAL and completely abrogated IL-25 (IL-17E) production, 
suggesting that TLR4 signalling in the airways is responsible for IL-25 (IL-17E) 
production. The observations regarding HDM-driven inflammation in mice lacking 
systemic TLR4 signalling are not mirrored in mice treated with the TLR4 antagonist. 
This is likely due to strain differences between C3H and BALB/c mice and the 
impact of deficiency of systemic TLR4 signalling on basal levels of Th2 mediators 
and cell functions (Hoshino et al., 1999). In contrast, the TLR4 antagonist had no 
impact on the baseline levels of TARC/CCL17, RANTES/CCL5, IL-25 (IL-17E), 
TSLP and CCL20/MIP-3α in BALB/c mice.  
 
Results from the TLR4 targeting experiments discussed in this Chapter conflict with a 
recent study that proposes a vital role for TLR4 in promoting HDM sensitisation and 
Th2 responses (Hammad et al., 2009). Hammad and colleagues showed that TLR4 
present on lung structural cells was required for mucosal DC activation and for the 
production of GM-CSF, IL-25 (IL-17E) and IL-33 (Hammad et al., 2009). The 
authors also showed that the inhalation of a TLR4 antagonist reduced eosinophil 
numbers in the BAL and HDM-induced AHR (Hammad et al., 2009), thus showing a 
vital role for TLR4 activation in the immune response to HDM. The observations 
from Hammad and colleagues differ from those in the current study whereby mice 
lacking systemic TLR4 signalling or mice treated with a TLR4 antagonist developed 
HDM-induced AHR. The observations from the Hammad study and the current study 
are likely to differ because of a number of factors, including differing dosage 
regimens, time points of analyses and techniques utilised to analyse the role of TLR4. 
The dosing protocols utilised in this Chapter involve exposing mice to a more 
frequent dose of HDM than the Hammad study. Thus a dependence on TLR4 may be 
overridden in the more continuous dosing protocols because of more frequent 
exposure to allergenic epitopes within HDM that do not signal via TLR4, such as β-
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glucans (Nathan et al., 2009) or proteases that can degrade epithelial tight junctions 
(Wan et al., 1999;Wan et al., 2001). The mice used in the TLR4 antagonist 
experiment in the current study were of the BALB/c strain, whereas in the Hammad 
study the HDM TLR4 antagonist-treated mice were of the C57BL/6 strain (Hammad 
et al., 2009). BALB/c mice are more susceptible to allergen-induced AHR 
(Whitehead et al., 2003;Kelada et al., 2011) and differences in gene expression of 
molecules involved in TLR signalling in response to HDM were observed between 
BALB/c and C57BL/6 mice. Specifically, BALB/c mice displayed an upregulation of 
MyD88 gene expression in the lung in response to HDM, whereas C57BL/6 mice did 
not. Therefore, strain differences may also contribute to the differing observations 
between the current work and that of Hammad and colleagues. 
 
A mechanism by which the observations in the current study may differ from those of 
Hammad and colleagues is that other TLR family members are more important in 
driving the in vivo immune response following continuous, as opposed to intermittent, 
HDM exposure. One such TLR family member that may be important in driving the 
immune response to HDM is TLR2 because in addition to TLR4, LPS and Der p 2 
have also been shown to signal via TLR2 (Kirschning et al., 1998;Chiou and Lin, 
2009). Thus, interfering with TLR2 signalling may reduce the inflammatory response 
to HDM as this receptor is located on DCs (Asai et al., 2007), macrophages (Zhang et 
al., 2006) and airway epithelial cells (Bailey et al., 2008) and TLR2-MyD88 
signalling results in IL-13, GM-CSF and IL-1β production (Ritz et al., 2002;Wynn, 
2003;Takeda and Akira, 2005). TLR2 has also been associated with asthma and 
polymorphisms in TLR2 are linked to the development of asthma and allergies in 
children (Eder et al., 2004). TLR2 activation also promotes Th2 responses from DCs 
in vitro (Agrawal et al., 2003) and in vivo (Dillon et al., 2004) and TLR2 activation 
also heightens OVA-induced allergic airways disease (Redecke et al., 2004). 
Therefore, the first approach to investigate the contribution of multiple TLRs, 
including TLR2, to the immune response to HDM in vivo, was to expose MyD88 KO 
mice to the allergen.  
 
Following exposure to HDM for either 1, 3 or 5 weeks, MyD88 KO mice developed 
Th2-driven, eosinophilic inflammation, IgE responses, AHR and features of airway 
remodelling. These results strongly suggest that MyD88 is not required for the 
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development of Th2 inflammatory responses to HDM and that the MyD88-
independent TRIF pathways of TLR3 and TLR4 are the key contributors to driving 
HDM-induced Th2 inflammation. Indeed, the TLR4 antagonist, which blocked both 
MyD88-dependent and MyD88-independent TLR4 signalling, had a greater impact 
on dampening the features of allergic airways disease than MyD88 deficiency. This 
non-requirement of MyD88 also conflicts with a recent study, where Phipps and 
colleagues reported that the induction of the features of allergic airways disease in 
response to inhaled HDM was dependent on MyD88 (Phipps et al., 2009). The 
authors showed that the absence of either TLR4 or MyD88 attenuated Th2-driven 
eosinophilia and AHR and the diminished Th2 responses were associated with fewer 
OX40L positive mDCs in the draining LNs (Phipps et al., 2009). As with the 
Hammad study, the HDM exposure protocols carried out by Phipps and colleagues 
are more intermittent than the continuous, uninterrupted inhalation protocols carried 
out in Chapter 4. Therefore, it is plausible that a certain dependency on TLR4 and 
MyD88 may be overridden in more continuous dosage regimens. Importantly, 
increased epithelial permeability and impaired airway barrier function are not 
observed following a single dose of HDM in vivo (Turi et al., 2011) and are most 
likely a consequence of continuous exposure. It is possible that the intermittent 
dosing protocols used in the Phipps and Hammad studies allow for the epithelium to 
repair, whereas there is no such lag in exposure to HDM for the epithelium in the 
continuous dosing protocols used in Chapter 4.  
 
A key mechanism by which the results in Chapter 4 differ from the Phipps 
publication is that the MyD88 KO mice used in the current study were bred on a 
C57BL/6 background, whereas in the Phipps study the adaptor protein deficient mice 
were bred on a BALB/c background (Phipps et al., 2009). This is important with 
regards to AHR, as C57BL/6 mice are less susceptible to OVA and HDM-induced 
AHR than BALB/c mice (Whitehead et al., 2003;Kelada et al., 2011). The array data 
in this Chapter showed that C57BL/6 mice had no increase in MyD88 gene 
expression in the lung following HDM exposure, whereas there is a very clear 
upregulation in BALB/c mice. Therefore, in BALB/c mice MyD88 may be more 
important in the immune response to HDM and thus explain why MyD88 KO mice 
on a BALB/c background show resistance to HDM-induced airway inflammation, 
whereas MyD88 KO mice bred on a C57BL/6 background do not. Data from the gene 
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array also suggests that MyD88 KO mice are predisposed to TRIF signalling as there 
are basal increases in TRAM, MCP-1/CCL2, IP-10/CXCL10 and IFN-β gene 
expression compared to C57BL/6 mice. Indeed, non-allergic MyD88 KO mice 
showed increased IRF3, MCP-1/CCL2 and IP-10/CXCL10 expression, which was 
also seen in C57BL/6 mice in response to HDM.  
 
The production of IgE in MyD88 KO mice is also a key observation, since there is 
conflicting data regarding the role of MyD88 in the generation of IgE in vivo, with 
Piggott and colleagues proposing a vital role for MyD88 in the generation of IgE in 
OVA-LPS driven inflammation (Piggott et al., 2005), whereas Schnare and 
colleagues have shown that MyD88 is dispensable in OVA-alum sensitisation models 
(Schnare et al., 2001). With regards to HDM there are antigenic epitopes within the 
extract that can promote IgE responses independently of MyD88 signalling, including 
Der p 1 that can cleave the low affinity IgE receptor CD23 (Hewitt et al., 
1995;Schulz et al., 1995). Schnare and colleagues and Phipps and colleagues have 
also reported that baseline levels of IgE in the serum of MyD88 KO mice are higher 
than the respective wt controls (Schnare et al., 2001;Phipps et al., 2009), however this 
was not observed in the experiments discussed in this Chapter.  
 
In view of the fact that MyD88 KO mice developed AHR and Th2-driven airway 
inflammation, another approach was undertaken to target multiple TLR pathways. 
The next experiment was designed to assess the impact of the TRIF signalling 
pathways, in addition to certain MyD88 signalling cascades, on disease pathology. 
The administration of a SAPS inhibitor blocked TLR1-4, 7 and 8 signalling by 
disruption of membrane microdomains and preventing the association of TLR2 and 
TLR4 with their respective membrane partners (Parker et al., 2008). Therefore, the 
absence of HDM-induced increase in MyD88 gene expression in SAPS-treated mice 
is likely a consequence of SAPS-mediated TLR blockade preventing MyD88 
signalling. The SAPS inhibitor reduced the numbers of eosinophils and Th2 cells 
recovered from the lung, concomitant with reduced levels of eotaxin-1/CCL11 and 
TARC/CCL17 respectively, and ablated IL-25 (IL-17E) production. Indeed, 
RANTES/CCL5 and MCP-1/CCL2 production which can be induced via TRIF 
signalling (Akira et al., 2006) was abrogated with the SAPS inhibitor. Therefore, 
these results show that blockade of the TLR-TRIF signalling pathways, as well as the 
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MyD88 pathways of TLR1, 2, 4, 7 and 8, has the most significant impact on the 
development of inflammation as opposed to targeting either TLR4 or MyD88. In 
order to test the precise role of the TRIF pathway, TRIF KO mice should be exposed 
to HDM to specifically determine the contribution of this signalling pathway to the 
immune response. Further to this to determine the combined contribution of both 
MyD88 and TRIF signalling pathways to the immune response to HDM, MyD88 KO 
mice should be treated with the SAPS inhibitor prior to exposure to HDM, as this 
would inhibit all TLR MyD88 and TRIF signalling. Alternatively, available MyD88 
and TRIF double KO mice could also be used, as these mice have no functional 
signalling TLRs and have been used to show that alum-induced Th2 responses are not 
attenuated in mice deficient in both MyD88 and TRIF (Gavin et al., 2006;Eisenbarth 
et al., 2008).  
 
The results discussed in this Chapter suggest that the TRIF signalling pathway is the 
key contributor from TLR signalling cascades to HDM-induced allergic airways 
disease and this is highlighted with three key observations. Firstly, the SAPS inhibitor 
blocking TLR1-4, 7 and 8 had the greatest impact on reducing the number of 
eosinophils and Th2 cells in the lung following HDM exposure. Secondly, the TLR4 
antagonist blocking the TRIF and MyD88 pathways of this receptor had a greater 
anti-inflammatory effect compared to when MyD88 alone was deficient. Thirdly, 
MyD88 KO mice developed features of allergic airways disease and were found to 
have elevated gene expression levels of TRIF signalling molecules in the lung. 
Indeed, the elevations in gene expression of TRIF signalling molecules in MyD88 
KO mice mirrored the gene expression changes seen in HDM-treated C57BL/6 mice.  
 
TLR-TRIF signalling has been shown to promote Th2 inflammatory responses, 
whereby LPS in vitro can induce MyD88-deficient DC maturation and upregulation 
of costimulatory molecules to support Th2 cell differentiation (Kaisho et al., 2002). 
TLR3, which signals exclusively via TRIF, has also been associated with the 
promotion of Th2 responses. Signalling via TLR3, which is expressed on innate 
immune cells, including epithelial cells (Ritter M et al., 2005;Akira et al., 2006), 
leads to the production of IL-1β, GM-CSF, IL-6, TNF-α, IP-10/CXCL10, 
RANTES/CCL5, CCL3/MIP-1α and IL-8 (Ritter et al., 2005;Matsukura et al., 
2006;Wang et al., 2007). TLR3 mRNA is upregulated in OVA-sensitised rats and 
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blockade of TLR3 reduces IgE production and IL-4 mRNA expression levels (Meng 
et al., 2011). dsRNA signalling via TLR3 promotes eotaxin-1/CCL11, TARC/CCL17 
and TSLP release from airway epithelial cells (Kato et al., 2007;Bogiatzi et al., 
2007;Torres et al., 2010). TLR3 can also recognise endogenous danger signals, such 
as heterologous mRNA, which are released from necrotic cells (Kariko et al., 
2004a;Kariko et al., 2004b). TLR3 activation has also been shown to activate mast 
cells (Orinska et al., 2005) and, as a result, TLR3 signalling could enhance Th2-
mediated inflammation (Kinoshita et al., 2009).  
 
This Chapter has focused specifically on the contribution of the TLR family to the 
immune response to inhaled HDM. Although the SAPS inhibitor had the greatest 
impact on reducing HDM-induced disease pathology, HDM-specific IgE and IL-4 
production were unaltered, suggesting that other PRRs could contribute to Th2-driven 
inflammation and direct HDM-induced airway inflammation. One such PRR family 
that has been shown to promote Th2 responses are the C-type lectin receptor (CLR) 
family and carbohydrate moieties, signalling via CLRs, are strong Th2 promoting 
PAMPs that include β-glucans that are present in HDM extracts (Douwes et al., 
2000). In vitro, β-glucans have been shown to recruit immature DCs via the release of 
CCL20/MIP-3α from airway epithelial cells (Nathan et al., 2009). In the current 
study, HDM-induced production CCL20/MIP-3α was not reduced by either the TLR4 
antagonist, the SAPS inhibitor or MyD88 deficiency, suggesting that the production 
of this chemokine and recruitment of immature DCs occurs independently of TLR 
activation and MyD88 signalling in vivo. DCs have also been shown to express the 
mannose receptor (MR), which has a crucial role in DC maturation (Li et al., 
2010;Royer et al., 2010), and Dectin-2, which mediates HDM-driven Th2 
inflammation via the generation of cysteinyl leukotrienes from DCs (Barrett et al., 
2009;Barrett et al., 2011). Thus, in addition to TLRs there are other PRRs which may 
contribute to the development of Th2 immunity following continuous exposure to 
HDM. Although mainly associated with anti-viral immunity, IRF3 KO mice have 
also been shown to be resistant to HDM-induced goblet cell hyperplasia, AHR and 
BAL inflammation, with DCs derived from these mice having impaired maturation 
and migration (Marichal et al., 2010). Marichal and colleagues also rule out a role for 
TLR4 in the IRF3-dependent effects of HDM on the pro-allergic functions of DCs 
and postulate that other PRRs, such as RIG-I–like receptors (RLRs), can also activate 
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IRF3 (Marichal et al., 2010). It is therefore possible that in the continuous HDM 
exposure protocols utilised in the current study that CLRs and RLRs play a prominent 
role in promoting the immune response to HDM. 
 
From the experiments undertaken in this Chapter it can be concluded that the 
MyD88-independent TRIF signalling pathway is the key contributing TLR signalling 
pathway in promoting the immune response to HDM in vivo. However, HDM 
contains multiple antigenic epitopes which can promote the development of Th2 
inflammation, independently of TLR signalling. One such feature of HDM that has 
been shown to promote Th2 responses is the intrinsic protease activity and the impact 
of proteases on the immune response was then investigated in Chapter 5. 
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Chapter 5 - Contribution of protease activity to 
HDM-induced allergic airways disease 
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5.1. Introduction 
 
The intrinsic protease activity of HDM allergens is believed to be central to allergic 
sensitisation and atopic asthma (Chapman et al., 2007). The major HDM allergen Der 
p 1 is an active cysteine protease (Chua et al., 1988;Gough et al., 1999), while Der p 
3, 6 and 9 have been shown to possess serine protease activity (Nishiyama et al., 
1995;Bennett and Thomas., 1996;King et al., 1996;Flores et al., 2003). There is a 
significant amount of in vitro data linking these enzymatic epitopes of HDM with the 
development of Th2-mediated inflammation and IgE responses, summarised in Table 
5.1. 
 
Together these data show that the activities of HDM-associated proteases promote the 
development of Th2 immunity and IgE production, acting via multiple sites on the 
airway epithelium and various cells. For example, Der p 1 has been shown to increase 
IgE synthesis directly from B cells via cleavage of the low affinity IgE receptor CD23 
(Schulz et al., 1995;Hewitt et al., 1995). In addition to this, Der p 1 has also been 
shown to cleave components of epithelial tight junctions (TJs) (Wan et al., 1999), 
thereby resulting in greater epithelial permeability and accessibility to antigen 
presenting cells (APCs) residing in the airway mucosa. Airway epithelial cells 
exposed to Der p 1 release a vast assortment of pro-inflammatory mediators, which 
promote DC, eosinophil and Th2 cell recruitment. These mediators include IL-6, IL-
8, MCP-1/CCL2, GM-CSF, RANTES/CCL5, eotaxin-1/CCL11 (King et al., 
1998;Asokananthan et al., 2002a;Adam et al., 2006;Kauffman et al., 2006), TSLP 
(Pichavant et al., 2005;Ying et al., 2005) and IL-25 (IL-17E) (Yu et al., 2010). Mast 
cells pulsed with Der f 1 produce IL-4, IL-6, and TNF-α (Yu and Chen, 2003) and 
basophils exposed to Der p 1 release IL-4 and IL-13 (Phillips et al., 2003). In 
addition, Der p 1 promotes further Th2 inflammatory bias by activating T cells via 
the cleavage of CD25 (Shakib et al., 1998;Schulz et al., 1998;Ghaemmaghami et al., 
2001;Harris et al., 2004), directly activating DCs which increases Th2 cell 
recruitment (Hammad et al., 2001;Hammad H et al., 2003) and reducing IL-12 
(Ghaemmaghami et al., 2002) and IL-10 responses (Furmonaviciene et al., 2007). 
Der p 3, 6 and 9 also further polarise the Th2 response by promoting the release of 
GM-CSF, eotaxin-1/CCL11 and IL-8 from airway epithelial cells (Tomee et al., 
1998;King et al., 1998;Sun et al., 2001;Adam et al., 2006) and by cleaving 
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components of both epithelial TJs (Wan et al., 2001) and the complement system 
(Maruo et al., 1997).  
 
Thus, there is substantial evidence linking the intrinsic protease activity of HDM to 
the development of allergy and Th2 responses, with many of the pro-inflammatory 
effects occurring at the airway epithelium (as summarised in Figure 5.1.). However, 
precisely how the protease activity of HDM contributes to the immune response in 
vivo remains to be determined. In order to investigate this, HDM was boiled to 
interfere with the protease activity of the extract and the impact on disease 
pathogenesis assessed. In addition, the effects of boiling on the antigenicity of HDM 
and the recognition of HDM by APCs in the airways were also investigated. 
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Protease Epitope Function Consequence Reference 
Der p 1 Cleavage of tight junction components Increased epithelial permeability (Herbert et al., 1995;Wan et al., 1999;Roche et al., 2000) 
 
PAR2-dependent and PAR2-independent 
activation 
Epithelial activation and release of pro-
inflammatory mediators 
(King et al., 1998;Asokananthan et al., 2002a;Gough et al., 2003;Ying 
et al., 2005Adam et al., 2006;Kauffman et al., 2006;Pichavant et al., 
2005;Heijink et al., 2010a) 
 Cleave CD25 T cell activation 
(Shakib et al., 1998;Schulz et al., 1998;Ghaemmaghami et al., 
2001;Harris et al., 2004)  
 Activate DCs Th2 polarisation (Hammad et al., 2001) 
 
Induce production of TARC/CCL17 and 
MDC/CCL22 
Activate and recruit Th2 cells (Hammad et al., 2003) 
 Cleave CD40 Failure to induce IL-12 (Ghaemmaghami et al., 2002) 
 Cleave DC-SIGN and DC-SIGN-R Failure to induce regulatory IL-10 (Furmonaviciene et al., 2007) 
 Cleave CD23 Stimulate IgE production by B cells (Hewitt et al., 1995;Schulz et al., 1995) 
 Cleave SP-A and SP-D Reduce innate immune defence (Deb et al., 2007) 
 Degrade α1-anti-trypsin Enhanced tissue damage (Kalsheker et al., 1996;Takai et al., 2005) 
Der p 3 Cleavage of tight junction components Increased epithelial permeability (Wan et al., 2001) 
 Activation of PAR2 
Epithelial activation and release of pro-
inflammatory mediators 
(Sun et al., 2001;Adam et al., 2006) 
 Cleave complement components C3 and C5 Recruitment of innate immune cells (Maruo et al., 1997) 
Der p 6 Cleavage of tight junction components Increased epithelial permeability (Wan et al., 2001) 
 Activation of PAR2 
Epithelial activation and release of pro-
inflammatory mediators 
(Tomee et al., 1998) 
Der p 9 Cleavage of tight junction components Increased epithelial permeability (Wan et al., 2001) 
 Activation of PAR2 
Epithelial activation and release of pro-
inflammatory mediators 
(King et al., 1998;Tomee et al., 1998;Sun et al., 2001)  
Table 5.1. Summary of the interactions of protease active epitopes within HDM extracts with the host defence.
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Figure 5.1. Summary of the interactions of proteases within HDM with the airway epithelium (highlighted in red). 
Protease active epitopes within HDM have been shown to promote pro-inflammatory mediator release from the airway epithelium, via PAR-2-
dependent and –independent mechanisms. Protease active HDM allergens can also degrade components of epithelial tight junctions and 
surfactant proteins that make up crucial components of the innate host defence.  
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5.2. Hypothesis and Aims 
 
5.2.1. Hypothesis 
 
Intrinsic protease activity of HDM promotes the immune response to HDM in vivo 
and boiling of HDM will inactivate serine and cysteine proteases, thereby reducing 
the magnitude of the Th2 inflammatory response. In addition to disrupting the 
protease activity of the extract, boiling HDM will also result in reduced recognition 
by APCs in the airways. 
 
5.2.2. Aims 
 
The aims of Chapter 5 are to determine:  
 
 The impact of HDM on the integrity and function of the airway epithelium 
 
 How boiling of HDM effects the development of airway inflammation, AHR 
and airway remodelling in vivo 
 
 How boiling impacts the antigenicity of HDM and the process by which the 
immune system is activated.  
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5.3. Experimental Plan 
5.3.1. Protocol A: Induction of HDM-induced allergic airways disease and 
investigation into effect of boiling on disease development 
 
In order to investigate how boiling impacted the immune response to inhaled HDM in 
vivo, HDM was boiled for 10 minutes at 100
o
C, prior to challenge, to disrupt 
enzymatic activity (Lombardero et al., 1990). This heat treatment has been shown to 
reduce the binding of Der p 1 to both IgE antibodies and to non-overlapping epitopes 
by approximately l00-fold, whereas Der p 2 allergens are heat stable (Lombardero et 
al., 1990). The migration of immunoreactive Der p 1 across Madin-Darby canine 
kidney (MDCK) epithelial cell monolayers has been shown to depend upon 
enzymatic activity and is abolished upon boiling (Wan et al., 1999).  
 
Female BALB/c mice were administered either 25 µl PBS, 25 µg (in 25 µl) HDM or 
25 µg (in 25 µl) boiled HDM (bHDM) i.n. 5 times a week for 5 weeks and culled 24h 
post final challenge.  
 
5.3.2. Protocol B: Effects of HDM administration on epithelial permeability 
 
To investigate and quantify epithelial permeability in response to acute HDM 
exposure, mice were exposed to either 25 µl PBS, 25 µg (in 25 µl) HDM or 25 µg (in 
25 µl) bHDM i.n. 5 times a week for one week. 24h after the final PBS, HDM or 
bHDM challenge, each mouse was administered 20 µl of 50 mg/ml FITC-Dextran i.n. 
and culled 1h later. The FITC-Dextran is 4 kDa in size and normally resides in the 
airway lumen in a naive mouse. The presence of FITC-Dextran in the lung tissue is 
indicative of increased airway epithelial permeability.  
 
5.3.3. Protocol C: Effects of boiling on the identification of HDM by APCs 
 
To determine how boiling influenced HDM recognition by APCs, mice were given 
either 25 µl PBS, 25 µg (in 25 µl) HDM or 25 µg (in 25 µl) bHDM i.n. 3 times a 
week for 1 week. All mice were then administered 25 µg (in 25 µl) of Alexa-488-
labelled HDM. A group of PBS-treated mice did not receive the Alexa-488-labelled 
HDM. Mice were culled 24h post Alexa-488-labelled HDM administration.  
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5.4. Results 
 
5.4.1. Protocol A: Influence of boiling on HDM-induced allergic airways disease 
 
5.4.1.1. Protease activity of HDM reduced by boiling 
 
In order to determine the protease activity of HDM and to investigate the effects of 
boiling on the degree of protease activity, an in vitro colorimetric protease assay was 
developed. N-Benzoyl-Phe-Val-Arg-p-nitroanilide hydrochloride (NBP-VANA) is a 
substrate that is broken down by both serine and cysteine proteases leading to an 
increase in absorbance (Lottenberg et al., 1981). For normalisation, the rate of 
breakdown is represented as a percentage increase from baseline. PBS did not 
breakdown NBP-VANA, whereas both trypsin (a control serine protease) and papain 
activated with DTT (a control cysteine protease) were observed to breakdown the 
substrate. When trypsin was incubated with the serine protease inhibitor AEBSF and 
papain and DDT were incubated with the cysteine protease inhibitor E-64, breakdown 
of NBP-VANA was abrogated (Figure 5.2A).  
 
HDM degraded NBP-VANA throughout the 120 minute time course. When bHDM 
was assessed, there was a significant 5-fold reduction in the breakdown of NBP-
VANA compared to HDM. However, the breakdown of NBP-VANA was not ablated 
with boiling, suggesting that boiling does not completely destroy all the protease 
activity, and that there are thermostable proteases within the HDM extract. To 
determine the specific contribution of serine and cysteine proteases, HDM was 
incubated with both AEBSF and E-64. A 40% reduction in the protease activity was 
observed compared to HDM alone (Figure 5.2B). Thus, this assay showed that with 
boiling the protease activity of the HDM extract was reduced.  
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Figure 5.2. Assessment of protease activity of HDM.  
Percentage increase from baseline of NBP-VANA breakdown following incubation 
with (A) PBS, trypsin, trypsin and AEBSF, papain activated with DTT and papain 
activated with DTT and E-64 and (B) PBS, HDM, bHDM and HDM with E-64 and 
AEBSF. 
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5.4.1.2. Onset of AHR is delayed in bHDM-treated mice - Whole Body 
Plethysmography 
 
To investigate the effects of boiling on the immune response to inhaled HDM in vivo, 
mice were challenged i.n. with either PBS, HDM or bHDM for 5 weeks. AHR was 
measured weekly in each mouse, non-invasively by whole body plethysmography, as 
this technique can be used to monitor the development of AHR. At each time point, 
HDM was observed to induce AHR. However, there was a delay in onset of AHR 
development following bHDM exposure, as these mice had significantly reduced 
AHR from HDM at week 1 and only showed increased Penh compared to PBS at 
weeks 3 and 4 (Figure 5.3).  
 
5.4.1.3. bHDM-treated mice do not develop increased airway resistance – 
Flexivent 
 
Airway resistance and compliance were measured invasively in anesthetised mice at 
week 5, 24h post final challenge. HDM significantly increased airway resistance in 
response to methacholine as expected. In contrast, no increase in airway resistance 
was observed after bHDM treatment compared to PBS controls (Figure 5.4A and B). 
Decreased compliance of the airways was observed in HDM and bHDM-treated mice. 
However, boiling attenuated allergen-induced decrease in airway compliance (Figure 
5.4C and D). 
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Whole Body Plethysmography 
 
 
 
 
Figure 5.3. Development of AHR after HDM exposure. 
AHR was measured at weekly time points using an EMMS Penh system. Results are 
expressed as Penh for the 100mg/ml dose. (n=5 PBS and n=7 HDM or bHDM at each 
time point). *, P<0.05 (Mann-Whitney U test) HDM or bHDM compared with PBS. 
#, P<0.05 (Mann-Whitney U test) bHDM compared with HDM. Data are mean ± 
SEM. Representative of two experiments. 
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Airway Resistance    Airway Compliance 
 
 
 
 
Figure 5.4. Absence of increased airway resistance in bHDM-treated mice.  
(A) Airway resistance of PBS, HDM and bHDM-treated mice at 5 weeks 24h post 
final challenge. (B) Airway resistance is expressed as mean ± SEM for the 30mg/ml 
dose of methacholine. (C) Airway compliance of PBS, HDM and bHDM-treated mice 
at 5 weeks 24h post final challenge. (D) Airway compliance is expressed as mean ± 
SEM for the 30mg/ml dose of methacholine. (n=5 PBS and n=7 HDM or bHDM). *, 
P<0.05 (Mann-Whitney U test) HDM or bHDM compared with PBS. #, P<0.05 
(Mann-Whitney U test) bHDM compared with HDM. Data are mean ± SEM. 
Representative of two experiments. 
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5.4.1.4. Reduction in the recruitment of inflammatory cells following bHDM 
treatment 
 
Both HDM and bHDM lead to the recruitment of inflammatory cells in the airways as 
shown in H and E stained lung sections. However, the degree of inflammation was far 
more severe in HDM-treated mice compared to bHDM-treated mice (Figure 5.5A - 
C). The total number of cells present in the lung and BAL were attenuated following 
boiling of HDM (Figure 5.6A and B). In addition, the number of eosinophils was 
reduced, with approximately a 4-fold reduction in the lung and 10-fold reduction in 
the BAL (Figure 5.6C and D), as was the number of neutrophils and Th2 cells present 
in the lung and BAL (Figure 5.6E – H). Whilst the cellular recruitment was reduced 
in bHDM-treated mice, the number of eosinophils, neutrophils and Th2 cells 
recovered from the lung and BAL remained significantly higher compared to PBS 
controls. This suggests that despite boiling of HDM and dramatically reducing 
enzymatic activity, bHDM is still able to induce an inflammatory response. 
 
5.4.1.5. Altered chemokine profile of boiled HDM-treated mice 
 
HDM increased the levels of eotaxin-1/CCL11, KC/mCXCL1 and TARC/CCL17 in 
the lung and BAL (Figure 5.7A - F). The production of these chemokines was 
reduced in response to bHDM with the levels of eotaxin-1/CCL11 and TARC/CCL17 
in the BAL reduced back to baseline (Figure 5.7D and F). 
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A. PBS     
 
 
 
 
 
 
 
 
B. HDM                  
 
 
 
 
 
 
 
 
C. bHDM 
 
 
 
 
 
 
 
 
Figure 5.5. Reduction in cellular inflammation in bHDM-treated mice. 
Representative pictures from paraffin embedded lung sections from (A) PBS, (B) 
HDM and (C) bHDM-treated mice stained with Haematoxylin and Eosin (original 
20X magnification). Scale bar = 50 µm..  
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Figure 5.6. Attenuated cellular inflammation in response to bHDM.  
Total cells, eosinophils, neutrophils and CD4
+
T1ST2
+
 recovered from the lung (A, C, 
E and G) and BAL (B, D, F and H) at 5 weeks 24h after the final i.n. challenge. (n=5 
PBS and n=6-7 mice treated with HDM or bHDM). Total cell counts were 
determined using a haemocytometer with white blood cell counting fluid, eosinophils 
and neutrophils were quantified from Wright-Giemsa stained cytospins and 
CD4
+
T1ST2
+
 cells were quantified by flow cytometry, as described in the Materials 
and Methods. *, P<0.05 (Mann-Whitney U test) HDM or bHDM compared with PBS. 
#, P<0.05 (Mann-Whitney U test) bHDM compared with HDM. Bars depict median 
of the groups. Representative of two experiments. 
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Figure 5.7. Reduced inflammatory chemokine production in response to bHDM. 
Eotaxin-1/CCL11, KC/mCXCL1 and TARC/CCL17 were measured in the lung (A - 
C) and BAL (D - F) at 5 weeks, 24h after the final i.n. challenge. Eotaxin-1/CCL11 
and TARC/CCL17 levels were determined by ELISA and KC/mCXCL1 levels were 
determined by MSD. (n=5 PBS and n=6-7 HDM or bHDM). *, P<0.05 (Mann-
Whitney U test) HDM or bHDM compared with PBS. #, P<0.05 (Mann-Whitney U 
test) bHDM compared with HDM. Bars depict the median of the group. 
Representative of two experiments. 
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5.4.1.6. Reduction in Th2 cytokine production following boiling of HDM 
 
Th2 cytokines IL-4, IL-5 and IL-13 were quantified in the lung and BAL at the end of 
week 5. As expected, HDM induced an increase in IL-4 production in the lung 
compared to PBS controls. Treatment with bHDM led to a 4-fold decrease in IL-4 
production when compared to HDM alone (Figure 5.8A). HDM-induced production 
of IL-4 in the BAL was abrogated in response to bHDM exposure (Figure 5.8B). 
There was also a 50% reduction in HDM-induced IL-5 production in the lung and 
BAL following bHDM administration (Figure 5.8C and D), whilst IL-13 levels in the 
lung and BAL were reduced back to baseline (Figure 5.8E and F). A decrease in Th2 
cytokine production in response to bHDM, correlates with a reduction in the number 
of Th2 cells recruited to the lung and BAL (Figure 5.6G and H).  
 
5.4.1.7. Altered innate cytokine profile of boiled HDM-treated mice 
 
IL-25 (IL-17E), TSLP, IL-33 and CCL20/MIP-3α were quantified in the lung tissue 
of PBS, HDM and bHDM-treated mice in order to investigate the effect of boiling on 
the release of these pro-allergic mediators. HDM exposure resulted in the production 
of all 4 cytokines in the lung and this was significantly greater than PBS controls 
(Figure 5.9A – D). Following boiling, the increases in IL-25 (IL-17E) and TSLP were 
completely abolished (Figure 5.9A and B) and IL-33 production was reduced in 
response to bHDM (Figure 5.9C). In contrast, levels of CCL20/MIP-3α remained 
unaltered by boiling (Figure 5.9D). 
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Figure 5.8. Attenuated in Th2 cytokine production in response to bHDM. 
IL-4, IL-5 and IL-13 were measured in the lung (A, C and E) and BAL (B, D and F) 
at 5 weeks 24h after the final i.n. challenge. IL-4 and IL-5 levels were determined by 
MSD and IL-13 by ELISA. (n=5 PBS and n=6-7 HDM or bHDM). *, P<0.05 (Mann-
Whitney U test) HDM or bHDM compared with PBS. #, P<0.05 (Mann-Whitney U 
test) bHDM compared with HDM. Bars depict the median of the group. 
Representative of two experiments. 
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Figure 5.9. Altered pro-allergic cytokine production in response to bHDM. 
(A) IL-25 (IL-17E), (B) TSLP, (C) IL-33 and (D) CCL20/MIP-3α were measured in 
the lung at 5 weeks 24h after the final i.n. challenge. Mediator levels were determined 
by ELISA. (n=5 PBS and n=7 HDM or bHDM). *, P<0.05 (Mann-Whitney U test) 
HDM or bHDM compared with PBS. #, P<0.05 (Mann-Whitney U test) bHDM 
compared with HDM. Bars depict the median of the group. Representative of two 
experiments. 
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5.4.1.8. Absence of allergic immunoglobulin class switching in bHDM-treated 
mice 
 
Tail bleeds were performed at the end of each week throughout the 5 week time 
course in order to monitor the onset of immunoglobulin class switching in response to 
allergen. To determine how boiling impacted the antigenic properties of HDM and 
the immunoglobulin response to HDM, the levels of total IgM, IgA, IgE, IgG1 and 
IgG2a in the serum were quantified. In HDM-treated mice there was a steady increase 
in the production of total IgM throughout the time course. From week 2 onwards the 
levels of IgM were significantly greater than those detected in PBS-treated mice. The 
levels of IgM were reduced following boiling of HDM, but still remained elevated 
compared to PBS-treated mice (Figure 5.10A). Both HDM and bHDM were observed 
to induce the production of serum IgA and levels increased throughout the time 
course. From week 3 onwards, the levels of IgA were significantly greater in HDM 
and bHDM-treated mice compared to PBS controls. However, there were no 
differences in IgA production at any time point between HDM and bHDM-treated 
mice (Figure 5.10B). As expected a steady increase in production of IgE was seen in 
response to HDM throughout the time course. In contrast, IgE was not detected in the 
serum of bHDM-treated mice (Figure 5.10C). Levels of IgG1, the Th2-associated 
immunoglobulin, in bHDM-treated mice were similar to PBS levels and reduced 
compared to HDM treatment (Figure 5.10D). Both HDM and bHDM-induced the 
production of total IgG2a, which is associated with Th1 inflammation, throughout the 
time course and, from week 3 onwards, these levels were greater than those detected 
in PBS-treated mice. There were no differences in the IgG2a levels quantified at any 
time point between HDM and bHDM-treated mice (Figure 5.10E). 
 
In addition to total immunoglobulin levels, HDM-specific IgA, IgE, IgG1 and IgG2a 
from the treated mice were also measured throughout the time course. HDM-specific 
IgA was significantly elevated in both HDM and bHDM-treated mice at weeks 4 and 
5 compared to PBS controls. However, HDM-specific IgA production was greater in 
HDM-treated mice compared to bHDM-treated animals (Figure 5.11A). HDM-
specific IgE and IgG1 were detected at greater levels than PBS controls at weeks 4 
and 5. HDM-specific IgE and IgG1 production was completely ablated following 
boiling (Figure 5.11B and C). The levels of HDM-specific IgG2a were elevated in 
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response to both HDM and bHDM and these levels were greater than those of PBS 
controls at weeks 4 and 5. However, there was no difference in HDM-specific IgG2a 
production between HDM and bHDM-treated mice (Figure 5.11D). 
 
5.4.1.9. Reduction in mast cell numbers and activation with removal of protease 
activity 
 
Since IgE production was attenuated in response to bHDM, the numbers of mast cells 
in the lung tissue and the degree of mast cell degranulation and activation, as 
quantified by mMCP-1 in the serum, were assessed. Paraffin embedded lung sections 
were stained using an antibody which recognises mast cell tryptase 7 (MCPT7) by 
immunohistochemistry. Representative pictures are shown from PBS, HDM and 
bHDM-treated mice (Figure 5.12A - C). There was a dramatic 15-fold reduction in 
mast cells recruited in mice which received bHDM. No intraepithelial mast cells were 
present in PBS controls (Figure 5.12D). mMCP-1 is released following mast cell 
degranulation and is therefore, an indicator of mast cell activation. mMCP-1 was 
quantified in the serum and HDM-induced increase in mMCP-1 was abrogated by 
boiling (Figure 5.12E).  
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Figure 5.10. Altered immunoglobulin profile in response to bHDM.  
Total (A) IgM, (B) IgA, (C) IgE, (D) IgG1 and (E) IgG2a levels were measured in the 
serum at weekly time points. All levels were determined by ELISA. (n=5 PBS and 
n=7 HDM or bHDM at each time point). *, P<0.05 (Mann-Whitney U test) HDM or 
bHDM compared with PBS. #, P<0.05 (Mann-Whitney U test) bHDM compared with 
HDM. Data are mean ± SEM. Representative of two experiments. 
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Figure 5.11. Altered HDM-specific immunoglobulin profiles.  
HDM-specific (A) IgA, (B) IgE, (C) IgG1 and (D) IgG2a levels were measured in the 
serum at weekly time points. All levels were determined by ELISA. (n=5 PBS and 
n=7 HDM or bHDM at each time point). *, P<0.05 (Mann-Whitney U test) HDM or 
bHDM compared with PBS. #, P<0.05 (Mann-Whitney U test) bHDM compared with 
HDM. Data are mean ± SEM. Representative of two experiments. 
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A. PBS   B. HDM   C. bHDM 
 
 
D. MCPT7
+
 Cells Lung                           E. mMCP-1 Serum 
 
 
Figure 5.12. Reduction in mast cell numbers and activation in response to 
bHDM.  
Paraffin embedded lung sections from (A) PBS, (B) HDM and (C) bHDM-treated 
mice were stained with mast cell tryptase 7 (MCPT7) by immunohistochemistry. 
MCPT7
+
 cells are indicated by the black arrows (original 20X magnification). Scale 
bar = 50 µm. (D) The number of MCPT7
+
 cells located in the airway epithelium of 
PBS, HDM and bHDM-treated mice were quantified per lung section. (E) mMCP-1 
was quantified in the serum 24h post final challenge by ELISA. Bars depict the 
median of the groups. (n=5 PBS and n=7 HDM or bHDM). *, P<0.05 (Mann-
Whitney U test) HDM or bHDM compared with PBS. #, P<0.05 (Mann-Whitney U 
test) bHDM compared with HDM. Representative of two experiments. 
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5.4.1.10. Airway remodelling is attenuated in bHDM-treated mice 
 
To assess the impact of boiling of HDM on the development of airway remodelling, 
the degree of goblet cell hyperplasia and peri-bronchial collagen deposition were 
assessed.  
 
Goblet cell hyperplasia was semi-quantitatively scored on PAS stained lung sections. 
Both lung sections stained from HDM and bHDM-treated mice stained positive for 
PAS, however, there was a greater degree of mucus production in the non-boiled 
HDM-treated group. No positive cells were observed in PBS controls (Figure 5.13A). 
Representative pictures from PAS stained lung sections are shown (Figure 5.13D – F; 
left panel). 
 
Total lung collagen was quantified in the lungs from PBS, HDM and bHDM-treated 
mice using a biochemical Sircol assay. The amount of collagen was significantly 
greater in HDM-treated mice compared to bHDM-treated mice and PBS controls 
(Figure 5.13B). Paraffin embedded lung sections from the three groups of mice were 
stained with sirius red. HDM-treated mice showed a greater mean intensity of peri-
bronchial collagen deposition compared to bHDM-treated mice (Figure 5.13C). There 
was no difference in collagen deposition between PBS and bHDM-treated mice 
(Figure 5.13B and C). Representative pictures from sirius red stained lung sections 
are shown (Figure 5.13D – F; right panel). Intense positive red stain is observed 
around the lung section from HDM-treated mice indicating sub-epithelial collagen 
deposition, whereas this is not seen in PBS and bHDM-treated mice (Figure 5.13D – 
F; right panel).  
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A. Mucus Score                                    D. PBS 
 
 
B. Total Lung Collagen                       E. HDM 
 
 
C. Mean Intensity of Peri-                   F. bHDM 
bronchial Collagen Deposition            
 
           PAS    Sirius Red 
 
                             
Figure 5.13. Reduction in airway remodelling in bHDM-treated mice. 
(A) Semi-quantitative scoring of PAS stained lung sections. (B) Total lung collagen 
was quantified in the lung tissue 24h post final challenge by a Sircol assay. (C) 
Quantification of peri-bronchial collagen deposition, expressed as mean intensity. 
Representative pictures of PAS and sirius red stained lung sections from (D) PBS, (E) 
HDM and (F) bHDM-treated mice (original 20X magnification). Scale bar = 50 µm.. 
(n=5 PBS and n=7 HDM or bHDM). *, P<0.05 (Mann-Whitney U test) HDM or 
bHDM compared with PBS. #, P<0.05 (Mann-Whitney U test) bHDM compared with 
HDM. Bars depict the median of the groups. Representative of two experiments. 
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5.4.1.11. HDM causes the disruption of epithelial tight junctions 
 
The effect of HDM on the integrity of the tight junctions (TJs) of the airway 
epithelium was investigated by immunofluorescence. Paraffin embedded lung 
sections were stained with ZO-1, a key component of TJs (green), and all nuclei 
stained with DAPI (blue). Sections were sliced through the epithelial cells and viewed 
as a lateral cross section by confocal microscopy (Figure 5.14A – C). Sections stained 
from PBS-treated mice showed ZO-1 in the inter-epithelial areas and formed a 
continuous network around the epithelial cells (Figure 5.14A). In sections from 
HDM-treated mice, there was interrupted ZO-1 staining suggesting disorganisation of 
epithelial TJs (Figure 5.14B). In response to bHDM, the ZO-1 was continuous in 
some areas, but disrupted and disorganised in others (Figure 5.14C), indicating that 
boiling reduced HDM-mediated TJ disorganisation.  
 
5.4.2. Protocol B: Epithelial permeability in response to inhaled HDM 
5.4.2.1. HDM exposure increases epithelial permeability 
 
Since HDM was shown to degrade epithelial TJs (Figure 5.14B), it was hypothesised 
that this could increase epithelial permeability. Thus, to investigate the functional 
consequences of HDM on airway epithelial permeability in vivo, mice were 
administered either 25 µl PBS, 25 µg HDM or 25 µg bHDM, 5 times a week, for 1 
week. Following this HDM exposure, all mice were given FITC-Dextran i.n. FITC-
Dextran resides in the airway lumen, as it is of sufficient size not to cross the 
epithelial barrier (4 kDa). Therefore, the presence of FITC-Dextran in the lung 
homogenate of HDM-treated mice indicates an increase in epithelial permeability. 
Increased airway epithelial permeability was observed in HDM-treated mice, whereas 
this was not observed in mice that had received the boiled allergen (Figure 5.15). 
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A. PBS      
 
 
 
 
 
 
 
 
 
B. HDM                  
 
 
 
 
 
 
 
 
 
C. bHDM 
 
 
 
 
 
 
 
 
 
 
Figure 5.14. Lack of epithelial tight junction organisation in HDM-treated mice. 
Paraffin embedded lung sections from (A) PBS, (B) HDM and (C) bHDM-treated 
mice were stained with ZO-1 (green) and the epithelial cell marker DAPI (blue) by 
immunofluorescence (original 40X magnification). Representative of two 
experiments. 
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Figure 5.15. Increased epithelial permeability in HDM-treated mice. 
FITC-Dextran was quantified in the lung homogenate of PBS, HDM and bHDM-
treated mice after 1 week of exposure. FITC-Dextran was quantified by fluorescence 
read out, as described in the Materials and Methods. (n=8 PBS, n=6 HDM and n=5 
bHDM). *, P<0.05 (Mann-Whitney U test) HDM or bHDM compared with PBS. #, 
P<0.05 (Mann-Whitney U test) bHDM compared with HDM. Bars depict median of 
the groups. 
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5.4.3. Protocol C: Impact of boiling on the recognition of HDM by APCs 
5.4.3.1. Both HDM and bHDM increase total cell numbers in the lung and BAL 
 
In order to determine whether boiling influenced how HDM was recognised by 
APCs, mice were administered either 25 µl PBS, 25 µg HDM or 25 µg bHDM for 1 
week, followed by an i.n. dose of 25 µg Alexa-488-labelled HDM. A group of PBS-
treated mice did not receive Alexa-488-labelled HDM, to test whether there was any 
intrinsic effect of administrating an Alexa-conjugated allergen.  
 
The administration of a single dose of Alexa-488-labelled HDM did not cause an 
increase in the total number of cells in either the lung or BAL, revealing that there 
was no inherent effect of administering the Alexa-conjugated allergen alone (Figure 
5.16A and B). Following HDM and bHDM pre-treatment, mice showed higher 
numbers of total cells in the lung (Figure 5.16A). However, the number of total cells 
recovered from the BAL was greater in HDM exposed mice than bHDM-treated mice 
(Figure 5.16B). 
 
Microscopic examination of paraffin embedded lung tissue sections revealed 
distribution of Alexa-488-labelled HDM (green) in the lung parenchyma, with 
epithelial cell nuclei stained with DAPI (blue) (Figure 5.16C).  
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C. Distribution of Alexa-488-labelled HDM in the lung parenchyma 
 
 
Figure 5.16. Elevated total cells in HDM-treated mice and distribution of Alexa-
488-labelled HDM in the lung parenchyma. 
Total cells were quantified in the (A) lung and (B) BAL 24h post final challenge. 
(n=4-5 for each treatment group. Total cell counts were determined using a 
haemocytometer with white blood cell counting fluid, as described in the Materials 
and Methods. *, P<0.05 (Mann-Whitney U test) HDM or bHDM compared with 
PBS-Alexa-488. #, P<0.05 (Mann-Whitney U test) bHDM compared with HDM. 
Bars depict median of the groups. (C) Paraffin embedded lung section stained with 
the epithelial cell marker DAPI (blue). The Alexa-488-labelled HDM is green and 
indicated with the white arrows (original 20X magnification). Scale bar = 50 µm. 
Representative of two experiments. 
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5.4.3.2. Inhaled HDM is recognised by APCs in the lung and allergen loaded 
mDCs migrate to the lymph nodes 
 
mDCs, pDCs and basophils were quantified by flow cytometry in the lung tissue and 
lymph nodes (LNs) in order to assess which cells localised with the labelled HDM in 
the lung and which cells then subsequently migrated to the lung draining LNs. 
Representative flow cytometry plots are shown, with mDCs classed as Gr-1
-
CD11c
+
CD11b
+
MHCII
+
 (Figure 5.17A – B) and pDCs classified as Gr-
1
int
CD11c
int
CD11b
-
120G8
+
 (Figure 5.18A – B).  Basophils could not be detected in 
either the lung or the LNs in response to HDM administration (plots and data not 
shown). 
 
Both HDM and bHDM-treated mice showed greater numbers of mDCs in the lung 
when compared to PBS controls (Figure 5.19A). Boiling did not alter either the 
number or percentage of mDCs that localised with the Alexa-488 conjugated allergen 
(Figure 5.19B and C). Neither HDM nor bHDM pre-treatment altered the number of 
pDCs residing in the lung compared to PBS controls (Figure 5.19D). Far fewer pDCs 
localised with the labelled antigen as compared to the mDCs and the number of pDCs 
that localised with Alexa-488-labelled HDM was not altered by boiling (Figure 5.19E 
and F). 
 
Following allergen challenge, only mDCs were observed in the LNs and the number 
and percentage of these cells that localised with the Alexa-488-HDM was not altered 
by boiling of HDM (Figure 5.19G – I). 
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Figure 5.17. Representative plots for mDCs.  
After digestion of the lungs, cells were stained for Gr-1, CD11c, CD11b and MHCII 
expression and gated on live cells. Tissue was stained with either (A) isotype control 
antibodies or (B) antibodies of interest. From R1 (Gr-1
-
CD11c
+
), mDCs were 
identified by expression of both CD11b and MHCII and were classed as Gr-1
-
CD11c
+
CD11b
+
MHCII
+
. mDCs that localised with Alexa-488-labelled HDM were 
quantified by flow cytometry.  
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Figure 5.18. Representative plots for pDCs. 
After digestion of the lungs, cells were stained for Gr-1, CD11c, CD11b and 120G8 
expression and gated on live cells. Tissue was stained with either (A) isotype control 
antibodies or (B) antibodies of interest. From R1 (Gr-1
int
CD11c
int
) pDCs were 
identified by the absence of expression of CD11b and the presence of 120G8 
expression. pDCs were classed as Gr-1
int
CD11c
int
CD11b
-
120G8
+
.  pDCs that were 
localised with the Alexa-488-labelled HDM were quantified by flow cytometry.
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Figure 5.19. APC populations in the lung tissue and LNs. 
Left panel: (A) Total number of mDCs in the lung. (B) Number of mDCs that localised with the Alexa-488-labelled HDM in the lung. (C) Percentage of mDCs that localised 
with the Alexa-488-labelled HDM, from the total number of mDCs, in the lung.  
Middle panel: (D) Total number of pDCs in the lung. (E) Number of pDCs that localised with the Alexa-488-labelled HDM in the lung. (F) Percentage of pDCs that localised 
with the Alexa-488-labelled HDM, from the total number of pDCs, in the lung. 
Right panel: (G) Total number of mDCs in the LNs. (H) Number of mDCs that localised with the Alexa-488-labelled HDM in the LNs. (I) Percentage of mDCs that localised 
with the Alexa-488-labelled HDM, from the total number of mDCs, in the LNs. 
All cells were quantified by flow cytometry. (n=5 for each treatment group). *, P<0.05 (Mann-Whitney U test) HDM or bHDM compared with PBS. Bars depict median of 
the groups. Representative of two experiments. 
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5.5. Discussion 
 
The experiments in Chapter 5 investigated how boiling influenced the immune 
response to inhaled HDM in vivo. Through these experiments it was observed that 
boiling reduced 80% of the enzymatic activity within the extract. Continuous 
administration of the boiled allergen led to a significant reduction in the parameters of 
pulmonary inflammation, such as the number of total cells and eosinophils recovered 
from the lung and BAL and pulmonary Th2 cytokine production, compared to mice 
that received unaltered allergen. Moreover, bHDM-treated mice did not develop AHR 
and had attenuated features of airway remodelling despite 5 weeks of exposure. 
Boiling of HDM reduced the impact of HDM on the organisation of the airway 
epithelium and the production of innate cytokines, since less ZO-1 degradation and 
abrogated IL-25 (IL-17E) and TSLP production were observed in response to bHDM. 
Heat treatment of HDM also eliminated the IgE-mast cell and IgG1 responses in vivo, 
whilst the IgA and IgG2a responses remained intact. However, boiling of HDM did 
not alter how the inhaled allergen was recognised by APCs residing in the airway, 
suggesting that boiling does not disrupt how the allergen is initially identified by DCs 
in the lung. 
 
The results from this Chapter show a striking impact of boiling on the immune 
response to HDM in vivo. The immunogenicity of HDM, although markedly reduced, 
was not eliminated following boiling since eosinophils and Th2 cells were quantified 
in the lung and BAL albeit at reduced levels compared to the unaltered allergen. 
However, a reduction in IgM production in response to bHDM showed that the 
primary humoral response from B cells, and thus how HDM was recognised as an 
allergen by B cells, was altered following heat treatment. Further analysis of 
immunoglobulin class switching from IgM revealed an insight into the mechanisms 
by which HDM generates Th2 responses, since boiling of HDM did not alter the 
production of IgA and IgG2a, whereas circulating IgE and IgG1 levels were ablated 
following heat treatment. This can be explained by dissection of the precise 
mechanisms behind IgM class switching to IgE, IgG1, IgG2a and IgA and how these 
relate to the various features of the HDM allergen.  
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T cell-dependent signalling is required for IgE and IgG1 class switching, whereas 
non-T cell-dependent and non-HDM-specific signals can mediate IgG2a and IgA class 
switching. IFN-γ is the only cytokine that promotes IgM class switching to IgG2a 
(Bossie and Vitetta, 1991) and NK cells have been suggested to play an important 
role in IgG2a regulation, since activated NK cells secrete large quantities of IFN-γ 
(Satoskar et al., 1999). NK cells are activated by DCs (Ferlazzo and Munz, 2004), 
which can recognise antigenic epitopes within the HDM extract that are resistant to 
boiling, as bHDM was still localised with mDCs in the lung. Thus, systemic 
activation of innate DCs and NK cells by signals that are resistant to boiling likely 
explain the IgG2a production. Class switching from IgM to IgA can be induced by 
either T cell-dependent or T cell-independent mechanisms (Fagarasan and Honjo, 
2000). T-cell-independent antigens that activate B cells include LPS, signalling via 
TLRs (Peng, 2005), and polysaccharides, which activate B cells through the BCR 
(Mond et al., 1995). Both LPS and the polysaccharide β-glucan are detected in HDM 
extracts (Douwes et al., 2000) and LPS-induced TNF-α production from macrophages 
has also been shown to be heat-resistant (Asea et al., 2000;Dybdahl et al., 2002;Gao 
and Tsan, 2003), suggesting that LPS within the HDM extract is not denatured by 
boiling. T-cell-independent antigens can also provide additional B-cell-stimulating 
signals through DCs (Batista et al., 2001;Balazs et al., 2002;Litinskiy et al., 
2002;Schneider, 2005;Qi et al., 2006) and epithelial cells (Kett et al., 1986;Hebel et 
al., 2006;Kato et al., 2006;Xu et al., 2007;He et al., 2007) via ligation of PRRs.  
 
However, in contrast, IgE and IgG1 class switching from IgM is induced by either IL-
4 or IL-13 (Xu and Stavnezer, 1992;Delphin and Stavnezer, 1995). Indeed, there was 
an absence of IL-4 and IL-13 production in the lung and BAL in response to bHDM. 
Once class switching occurs, ligation of CD86 on the B cell surface results in 
increased production of both IgE and IgG1 (Kasprowicz et al., 2000). In comparison, 
IFN-γ-driven IgG2a class switching is not subject to up-regulation following 
signalling through CD86 (Bossie and Vitetta, 1991;Kasprowicz et al., 2000). 
Together with the serum data this suggests that increased total IgE and IgG1 levels are 
associated with heat sensitive epitopes within the HDM extract, whereas IgG2a and 
IgA levels reflect broader patterns of B cell activation that can be triggered by non-
HDM-specific ligands, such as LPS (Lewkowich et al., 2004). Indeed, the absence of 
IgE production in response to bHDM may be due in part to an absence of CD23 
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cleavage by Der p 1 (Hewitt et al., 1995;Schulz et al., 1995), as Der p 1 is inactivated 
by boiling (Lombardero et al., 1990). Concomitant with an absence of IgE and IL-4, 
mast cell activation was ablated in response to bHDM. The lack of mast cell 
activation and absence of IL-13 in response to bHDM likely contribute to the absence 
of development of AHR in these mice (Wills-Karp, 2004;Yu et al., 2006). 
 
Boiling of HDM reduced allergen-induced inflammatory chemokine production in the 
lung tissue. Thus, concomitant with decreased eotaxin-1/CCL11, KC/mCXCL1 and 
TARC/CCL17 production, fewer numbers of eosinophils, neutrophils and Th2 cells 
were present in the airways. This may occur as a result of boiling preventing Der p 1, 
3, 5 and 9-induced release of these chemokines from the airway epithelium. The 
attenuated pulmonary Th2 responses can also be explained by the ablated production 
of TSLP and IL-25 (IL-17E), as well as decreased IL-33 production in response to 
bHDM, since all three cytokines promote Th2 responses (Al-Shami et al., 
2005;Angkasekwinai et al., 2007;Kondo et al., 2008). However, it is important to 
recognise that the remaining IL-33 and unaltered CCL20/MIP-3α production in 
response to bHDM would still be able to exert a degree of Th2 polarisation and 
recruitment of immature DCs. Since CCL20/MIP-3α secretion is unaltered by boiling, 
this also suggests that the β-glucan structures within the HDM, responsible for 
CCL20/MIP-3α production (Nathan et al., 2009), are not denatured by boiling.  
 
Staining of ZO-1, a key component of epithelial TJs, revealed that disruption of 
epithelial TJ organisation could still occur in response to bHDM and that the protease 
activity of Der p 1, 3, 6 and 9 are not the sole contributors to this TJ disruption. In 
view of the fact that eosinophils and neutrophils were present in the lung in response 
to bHDM, it is likely that these cells are responsible for the damage to the epithelial 
TJs, as both eosinophils and neutrophils can cause tissue damage via the release of 
stored mediators (Kato et al., 1991;Hogan et al., 2008). The production of eotaxin-
1/CCL11, IL-5, IL-33 and KC/mCXCL1, although reduced, was not ablated in 
bHDM-treated mice, therefore, allowing for the recruitment of a small number of 
eosinophils and neutrophils to the lung. However, only HDM-induced epithelial TJ 
disruption resulted in the functional consequence of increased epithelial permeability 
in vivo. This likely contributes to the increased Th2 inflammation in response to 
HDM, as the allergen would have greater access to cells residing in the airway 
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mucosa, including DCs and basophils. Not only may this result in more APCs 
recognising the allergen, but Der p 1 can induce IL-4 release from both DCs 
(Hammad et al., 2003) and basophils (Phillips et al., 2003), which may further 
amplify Th2 and IgE responses. 
 
In view of the fact that boiling HDM dramatically reduced in the in vivo response to 
the allergen, the effects of boiling on the allergenic epitopes within the extract 
identified by APCs were investigated. Heat treatment of 100
o
C for 10 minutes, in 
addition to denaturing enzymes, may also alter the tertiary and quaternary structures 
of other allergenic proteins. Thus, the reduction in the immune response to HDM with 
boiling cannot be solely attributed to a lack of protease activity. In agreement with 
others, mDCs were identified as the primary APC subset which recognised inhaled 
HDM in the airway (Hammad et al., 2010). Interestingly boiling did not alter either 
the number of mDCs recruited to the lung, the number of mDCs that localised with 
the Alexa-conjugated allergen or the number of mDCs present in the LNs. Despite 
not altering how HDM was identified by mDCs, other aspects of the antigen 
presentation process may be altered. This could include how HDM allergens are 
processed and presented to naive T cells in the LNs, and whether boiling influences 
DC maturation or co-stimulatory molecule expression. Heat treatment of HDM will 
also prevent Der p 1-mediated Th2 cytokine release from DCs, which has been 
shown in vitro (Hammad et al., 2003). Therefore, in order to proceed from the 
experiments in this Chapter, inflammatory DCs should be stimulated with either 
HDM or bHDM ex vivo and the cytokine production and the degree of DC maturation 
assessed.  
 
The observations from this Chapter raise further important questions regarding the 
precise interactions between HDM and the airway epithelium and how immune 
responses are generated. This includes determining the contribution of PAR2 to the in 
vivo response to HDM, since a vital role has been proposed in vitro (Asokananthan et 
al., 2002a;Winter et al., 2006) and it is unclear whether HDM-induced epithelial TJ 
disorganisation and increased epithelial permeability occur as a result of PAR2 
cleavage. Since ZO-1 is located in the intracellular regions of airway epithelial cells, 
it is unlikely to be directly cleaved by extracellular HDM proteases. Alterations to 
ZO-1 are therefore likely caused by either PAR2-mediated signalling cascades or as a 
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consequence of direct TJ disruption by cleavage of extracellular claudins and 
occludin by HDM proteases. If indeed PAR2 is required for TJ degradation, this 
suggests that therapeutic targeting of this receptor would be beneficial to asthmatics 
in preventing epithelial damage and injury, especially since PAR2 expression has 
been shown to be elevated on respiratory epithelial cells from asthmatics (Knight et 
al., 2001).  
 
Another important question that arises from the results in this Chapter, together with 
the current literature, is whether protease active epitopes within HDM enhance the 
allergenicity of other allergens. Therefore, in addition to epithelial TJ disruption and 
inducing pro-inflammatory cytokine and chemokine production, protease active 
allergens may promote IgE responses to other allergens. Der p 1 has been shown to 
enhance the IgE response to OVA (Gough et al., 2001) and collaboration between 
Der p 1 and other HDM allergens has also been illustrated. Der p 1 has been 
implicated in promoting the activation of Der p 3 (Dumez et al., 2008) and protease-
active Der p 1 increases Der p 1-specific IgE compared to protease-inactive Der p 1 
(Gough et al., 1999). Therefore, it would be important in understanding HDM 
functionality to investigate the effects of Der p 1, 3, 6 and 9 on the sensitisation to 
Der p 2 to further elucidate these intricate and complex interactions. For example, 
Der p 1, 3, 6 and 9 cleavage of epithelial TJs could enhance Der p 2 activation on 
TLR4 on DCs and Der p 1 cleavage of DCs by facilitating greater epithelial 
permeability and access to these cells residing in the airway mucosa. It has also been 
shown that in response to Der p 1, total IgE and Der p 1-specific IgE production were 
reduced in mice treated with inactive Der p 1 (Gough et al., 2003;Kikuchi et al., 
2006). Thus, these findings along with the results obtained here, suggest that protease 
active Der p 1 is vital for the induction of IgE responses to Der p 1 and HDM.   
 
Protease activity is not unique to HDM and the mechanisms regarding HDM 
sensitisation and requirement of proteases likely translate to other allergens, since 
other allergens associated with allergy and atopic asthma possess protease activity. 
Removal of proteases from Aspergillus fumigatus (Kheradmand et al., 2002), German 
cockroach frass (Page et al., 2008), American cockroach Per a 10 antigen (Sudha et 
al., 2009), Epi p 1 antigen from the fungus Epicoccum purpurascens (Kukreja et al., 
2008) or Cur 11 antigen from the mold Curvularia lunata (Tripathi et al., 2009) has 
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been shown to decrease airway inflammation and AHR in mice. Co-administration of 
either Der p 1 or active proteases from Aspergillus fumigatus with OVA resulted in 
enhanced IgE production (Ghaemmaghami et al., 2001;Kheradmand et al., 2002). 
However, it is important to recognise that each allergen has a distinct nature and 
subtle differences may still occur. For example, different allergen-specific memory T 
cell responses have been observed following exposure to either perennial allergens, 
such as HDM (Der p 1), or seasonal allergens, such as birch pollen (Bet v 1), 
therefore suggesting that memory CD4
+
 responses can vary between protease-active 
allergens (Wambre et al., 2011). Conversely, it would also be necessary to determine 
exactly how non-enzymatic allergens, such as the major timothy grass pollen allergen 
Phl p 1 (Röschmann et al., 2009), promote immune responses and whether this can be 
applied to HDM. 
 
From Chapter 5, it can be concluded that boiling substantially reduces the intrinsic 
protease activity, as well as allergenicity of HDM, and this has a profound effect on 
reducing the development of disease pathogenesis in vivo. Thus, the results obtained 
support a vital role for proteases in the induction of Th2 responses to HDM and 
enhance our understanding regarding the mechanisms by which HDM elicits an 
immune response in vivo. It was revealing that even with boiling, the breakdown of 
NBP-VANA was not completely ablated. The likely causes of this are that heat stable 
proteases are present within the HDM extract and that these are derived from 
bacterial contaminants within the HDM preparation. HDM extracts have been found 
to contain various bacterial species including Bartonella (henselae, quintana, vinsonii, 
and grahamii), Escherichia coli, α-proteobacteria, Pseudomonas species, and 
Acinetobacter species (Valerio et al., 2005). Both Pseudomonas (Jackman et al., 
1983;Stepaniak and Fox., 1985) and α-proteobacteria (Durham et al., 1987) can 
produce heat stable proteases which likely explain why boiling does not eliminate 
NBP-VANA breakdown. In addition to this, there may be as yet other unidentified 
proteases within the HDM extract that are heat stable and account for the residual 
protease activity, such as heat stable aspartic proteases (Rao et al., 1998) and MMPs 
(Bracho and Haard, 1995). It is thus plausible that any heat-resistant proteases within 
the HDM could contribute to ZO-1 degradation in bHDM-treated mice. Prior to 
carrying out the experiments in this Chapter, dissecting the specific roles of cysteine 
and serine proteases in the immune response to HDM had been avenue of interest. 
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However, using the available serine and cysteine protease inhibitors, AEBSF and E-
64 respectively, only a 40% reduction in the protease activity of HDM was observed. 
Therefore, this was not pursued in vivo as boiling of the allergen had a greater impact 
on reducing the protease activity of HDM. 
 
Better molecular understanding of the activities of protease allergens on the airway 
epithelium could lead to the development of new therapeutic strategies against 
allergic asthma. Indeed, the results from this Chapter suggest that targeting proteases 
within HDM would be of clinical benefit, since the severity of disease pathogenesis 
was dramatically reduced with boiling concomitant with an 80% reduction in 
enzymatic activity. Subcutaneous injection of the serine protease inhibitor nafamostat 
mesilate during sensitisation to HDM has been shown to attenuate the development of 
allergic inflammation and AHR (Chen et al., 2006). However, it would be impossible 
to treat HDM with protease inhibitors prior to human exposure and unsafe to treat 
humans with protease inhibitors, as endogenous proteases are vital to microbial 
defence (Reece et al., 2010). Serine proteases make up an important component of the 
host defence against Mycobacterium tuberculosis infection (Reece et al., 2010) and a 
delicate protease-anti-protease balance is required for lung mucosal homeostasis 
(Greene and McElvaney, 2009). This therefore leads to the idea that protecting or 
treating an already injured airway epithelium may be a potential therapeutic avenue, 
as epithelial injury and damage are routinely seen in asthmatics (Bertorelli et al., 
1998;Bucchieri et al., 2002;Shebani et al., 2005;Shahana et al., 2006). Not only has 
epithelial damage associated with asthma been replicated here in vivo following 
exposure to HDM, potential new treatment strategies can also be tested in this model. 
Thus through the experiments undertaken in this Chapter it can be concluded that 
protease activity of the HDM allergen plays a critical role in causing epithelial 
damage and specifically promoting Th2 responses. 
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Chapter 6 - The role of TGF-β in HDM-induced 
allergic airways disease 
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6.1. Introduction 
 
The transforming growth factor-β (TGF-β) superfamily consists of approximately 30 
mammalian cytokines, including three TGF-β isoforms (TGF-β1, -β2 and -β3), 
activins and bone morphogenetic proteins (BMPs) (Attisano and Wrana, 2002). TGF-
-β1 is the most prominent and widely studied family member and is produced by both 
structural cells, including epithelial cells and fibroblasts, and immune cells, such as 
eosinophils and mast cells (Sporn and Roberts, 1990). 
 
TGF-β is encoded as a biologically large precursor peptide (pre-pro-TGF-β) (Rifkin 
et al., 1993). Endopeptidases catalyse the cleavage of these precursor molecules, 
which then yield mature TGF-β molecules (Dubois et al., 1995). Mature TGF-β is 
secreted as a heterodimeric complex with latency-associated protein (LAP) 
(Saharinen et al., 1999) and latent TGF-β is activated in vivo via multiple mechanisms 
that are not fully understood (Khalil, 1999). TGF-β signalling is facilitated through 
the binding of two specific subfamilies of cell transmembrane receptors, type I (TβR-
I) and type II receptors (TβR-II) (Piek et al., 1999). Both receptor types have intrinsic 
serine/threonine kinase activity and both are essential for transducing TGF-β signals 
(Piek et al., 1999). 
 
TGF-β induces its cellular responses through the formation of receptor complexes 
involving interaction between TβR-I and TβR-II dimers (Yamashita et al., 1994). The 
activated TβR-I directly phosphorylates specific intracellular target proteins called 
Smads, that transduce extracellular signals from TGF-β to the nucleus where they 
activate downstream TGF-β gene transcription (Heldin et al., 1997). There are three 
families of Smads: receptor-activated (or R-) Smads (Smads 1, 2, 3, 5 and 8), 
common-partner (or Co-) Smads (Smads 4a and 4b) and inhibitory (or I-) Smads 
(Smads 6 and 7) (Abdollah et al., 1997). Smads 2 and 3 are activated by TGF-β (Piek 
et al., 1999). Co-Smads interacts with R-Smads to participate in signalling (Shi et al., 
1997) and I-Smads block the activation of R-Smads and Co-Smads (Itoh et al., 2001). 
A summary of the TGF-β signalling pathway is shown in Figure 6.1 (Pinzani and 
Marra, 2001). 
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Figure 6.1. The TGF-β signalling pathway.  
TGF-β binds to the receptor TβR-II and this binding can be enhanced by the presence 
of TβR-III. After binding to TGF-β, TβR-II recruits and phosphorylates TβR-I, 
leading to activation of Smad2 and Smad3 by phosphorylation (P). This process is 
inhibited by Smad7. Activated Smad2 and Smad3 form heterodimers with Smad4 and 
translocate to the nucleus. Together with co-activators, co-repressors and other 
transcription factors, the Smad complex regulates gene expression (Pinzani and 
Marra, 2001). 
 
 
TGF-β has been strongly implicated in the development of airway remodelling in 
asthma. Clinical studies have shown increased TGF-β expression in lung biopsies 
(Ohno et al., 1996;Minshall et al., 1997;Magnan et al., 1997;Vignola et al., 1997) and 
the BAL of asthmatics (Redington et al., 1997). TGF-β is essential for the 
transformation of fibroblasts into myofibroblasts, which are major producers of 
collagen, and gene transfer of TGF-β1 in mouse lungs promotes lung fibrosis with 
ECM protein deposition (Sime et al., 1997;Kolb et al., 2002). In addition to asthmatic 
studies, TGF-β expression has also been shown to be increased in murine models of 
allergic airway disease, induced by fungal extracts (Blease et al., 2002) and OVA 
respectively (Kumar et al., 2004;McMillan and Lloyd, 2004;Kelly et al., 2005). 
Indeed, TGF-β levels were higher in the lung tissue of HDM-treated mice than PBS 
controls in Chapter 3 (Figure 3.7E). TGF-β has been directly implicated in the 
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development of lung structural changes as the blockade of TGF-β reduced OVA-
induced airway remodelling (McMillan et al., 2005;Alcorn et al., 2007). TGF-β 
signalling through Smad 2/3 also mediates fibroblast α-smooth muscle actin 
expression, which is a marker of myofibroblast differentiation, and Smad 3 KO mice 
demonstrate reduced OVA-induced airway remodelling (Kobayashi et al., 2006;Le et 
al., 2007). However, concurrent with the work in this Chapter, in a HDM model of 
allergic airways disease, TGF-β was observed to regulate airway inflammation but 
not remodelling. Blockade of TGF-β worsened HDM-induced AHR and BAL 
eosinophilia and Smad 3 KO mice developed airway remodelling to the same 
extent
 
as HDM-exposed wt mice (Fattouh et al., 2008).  
 
TGF-β plays a critical role in maintaining lung immune homeostasis and actively 
suppressing immune responses. One of the major mechanisms by which TGF-β exerts 
immunosuppressive actions is through the tight control of T cell development, 
tolerance and differentiation. Several studies have shown that transgenic mice with T 
cells that are unresponsive specifically to TGF-β develop autoimmune diseases, 
indicating that TGF-β signalling is essential for T cell homeostasis (Gorelik and 
Flavell, 2000;Marie et al., 2006;Li et al., 2006a). In the absence of TGF-β signalling 
specifically in T cells, T cells undergo hyperproliferation, activation, and effector 
T cell differentiation that results in the infiltration of leukocytes into multiple vital 
organs (Marie et al., 2006;Li et al., 2006a). A vital role for TGF-β-mediated immune 
suppression is through the induction of regulatory T cells (Tregs) (O'Garra et al., 
2004). TGF-β has been shown to induce FoxP3 transcription (Chen et al., 2003), 
which is the key transcription factor for naturally occurring Tregs (Marie et al., 
2005;Josefowicz and Rudensky, 2009). Deficiency of FoxP3 in mice results in T cell-
dependent inflammatory phenotype similar in severity to that of T cell-specific TGF-
β receptor II-deficient mice (Brunkow et al., 2001;Fontenot et al., 2003;Marie et al., 
2005). Tregs are also a major source of TGF-β in the immune system. The latent form 
of TGF-β exists as a dimeric pro-protein, known as latency-associated peptide (LAP) 
and Tregs express LAP on their membrane surface at high levels (Chen et al., 2008). 
CD4
+
CD25
+
LAP
+
 Tregs are more potent in their regulatory activity than 
CD4
+
CD25
+
LAP
−
 T cells (Nakamura et al., 2004;Chen et al., 2008). 
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The precise mechanism by which TGF-β blockade worsens HDM-induced airway 
inflammation and AHR remains to be elucidated. In view of the fact that TGF-β has a 
central role in controlling T cell homeostasis and maintaining lung immune 
homeostasis, a potential mechanism by which the blockade of TGF-β may worsen 
HDM-induced AHR and BAL eosinophilia is through reduced Treg-mediated 
immunosuppression.  
 
 
6.2. Hypothesis and Aims 
 
6.2.1. Hypothesis 
 
Therapeutic blockade of TGF-β will worsen HDM-induced airway inflammation and 
AHR by reducing the numbers of Tregs in the lung.  
 
6.2.2. Aims 
 
The aims of Chapter 6 are to determine how therapeutic neutralisation of TGF-β 
impacts on the development of HDM-induced airway remodelling and determine how 
the blockade of TGF-β leads to exaggerated AHR and airway inflammation.  
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6.3. Experimental Plan 
 
6.3.1. Protocol A: Induction of HDM-induced allergic airways disease and 
therapeutic blockade of TGF-β 
 
Female BALB/c mice were administered either 15 µl PBS or 15 µg (in 15 µl) HDM 
i.n. 3 times a week for 5 weeks. A therapeutic regimen of anti-TGF-β Ab was 
instigated at the beginning of week 3 and mice were given 100 µl of either 0.5 mg/Kg 
or 5 mg/Kg i.p. before each airway challenge. Control mice received an isotype 
(IgG1) Ab. Mice were culled either at 4h post-final challenge (for analysis of 
pulmonary inflammatory cells, IgE levels, mucus production and cytokine 
production) or at 24h (for lung function analysis).  
 
6.3.2. Protocol B: Induction of HDM-induced allergic airways disease and 
prophylactic blockade of TGF-β 
 
Female BALB/c mice were administered either 15 µl PBS or 15 µg (in 15 µl) HDM 
i.n. 3 times a week for 3 weeks. A prophylactic regimen of anti-TGF-β Ab was 
instigated prior to the first i.n. dose and mice were given 100 µl of either 0.5 mg/Kg 
or 5 mg/Kg i.p. before each airway challenge. Control mice received an isotype 
(IgG1) Ab. Mice were culled 24h post-final challenge.  
 
The doses of anti-TGF-β were chosen as these have been used previously in vivo. 
McMillan and colleagues used a 0.5 mg/Kg dose to show that blockade of TGF-β 
reduced airway remodelling in OVA exposed mice (McMillan et al., 2005), and 
Fattouh and colleagues used doses equivalent to 0.5 mg/Kg and 5 mg/Kg in the HDM 
studies (Fattouh et al., 2008). The blocking Ab neutralises all mouse isoforms of 
TGF-β (McMillan et al., 2005). 
 
 
 
 
 
 
192 
 
6.4. Results  
 
6.4.1.1. Therapeutic Blockade of TGF-β: Impact of anti-TGF-β on pulmonary 
TGF-β expression 
 
The levels of TGF-β were analysed in the lung tissue following HDM exposure and 
respective Ab treatment. There was a reduction, but a non-significant decrease, in the 
levels of TGF-β in the lung following the administration of the 0.5 mg/Kg dose. 
However, HDM-induced increase in TGF-β was completely abolished by the 
administration of the 5 mg/Kg dose (Figure 6.2). 
 
6.4.1.2. Blockade of TGF-β exacerbates HDM-induced AHR 
 
Increased airway resistance in response to inhaled HDM was not decreased by either 
dose of anti-TGF-β. Interestingly, at the highest dose of neutralising antibody, airway 
resistance was exacerbated (Figure 6.3A - D). Similarly, this was also observed with 
the airway compliance. All HDM-treated mice showed decreased airway compliance 
as compared to the respective control groups. HDM exposed mice, treated with 5 
mg/Kg anti-TGF-β, showed decreased airway compliance as compared to Ig-treated 
HDM exposed mice (Figure 6.3E - H).  
 
6.4.1.3. Neutralisation of TGF-β aggravates BAL inflammation 
 
The administration of anti-TGF-β did not alter the total number of cells or eosinophils 
present in the lung in response to HDM (Figure 6.4A and B). Both Ig and anti-TGF-
β-treated HDM exposed mice also showed greater numbers of total cells and 
eosinophils in the BAL as compared to the respective PBS control groups. At both 
doses of TGF-β neutralising Ab, the numbers of eosinophils in the BAL were 
increased (Figure 6.4C and D). 
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Figure 6.2. Impact of anti-TGF-β on active pulmonary TGF-β expression.  
TGF-β was measured in the lung 4h after the final challenge. TGF-β was quantified 
by ELISA. (n=4 PBS Ig, n=6 HDM Ig, n=4 PBS and either 0.5 mg/Kg or 5 mg/Kg 
anti–TGF-β and n=6 HDM and either 0.5 mg/Kg or 5 mg/Kg anti–TGF-β). *, P<0.05; 
(Mann-Whitney U test) HDM compared with corresponding PBS-treated control 
group. #, P<0.05 (Mann-Whitney U test) HDM-α-TGF-β compared with HDM-Ig. 
Bars depict the median of the groups. Representative of two experiments. 
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Airway Resistance    Airway Compliance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3. Therapeutic blockade of TGF-β worsens HDM-induced AHR. 
(A) Airway resistance of PBS and HDM-treated mice at 24h post final challenge treated with either Ig 
or 0.5 mg/Kg anti-TGF-β. (B) Airway resistance is expressed as mean ± SEM for the 30mg/ml dose of 
methacholine. (C) Airway resistance of PBS and HDM-treated mice at 24h post final challenge treated 
with either Ig or 5 mg/Kg anti-TGF- β. (D) Airway resistance is expressed as mean ± SEM for the 
30mg/ml dose of methacholine. (E) Airway compliance of PBS and HDM-treated mice at 24h post 
final challenge treated with either Ig or 0.5 mg/Kg anti-TGF- β. (F) Airway compliance is expressed as 
mean ± SEM for the 30mg/ml dose of methacholine. (G) Airway compliance of PBS and HDM-treated 
mice at 24h post final challenge treated with either Ig or 5 mg/Kg anti-TGF- β. (H) Airway compliance 
is expressed as mean ± SEM for the 30mg/ml dose of methacholine. (n=4 PBS Ig, n=6 HDM Ig, n=4 
PBS and either 0.5 mg/Kg or 5 mg/Kg anti–TGF-β and n=6 HDM and either 0.5 mg/Kg or 5 mg/Kg 
anti–TGF-β). *, P<0.05; (Mann-Whitney U test) HDM compared with corresponding PBS-treated 
control group. #, P<0.05 (Mann-Whitney U test) HDM-anti-TGF-β compared with HDM-Ig. Data are 
expressed as mean ± SEM. Representative of two experiments. 
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Figure 6.4. Therapeutic neutralisation of TGF-β elevates HDM-induced BAL 
eosinophilia.  
(A) Total cells and (B) eosinophils in the lung and (C) total cells and (D) eosinophils 
in the BAL 4h after the final challenge. (n=4 PBS Ig, n=6 HDM Ig, n=4 PBS and 
either 0.5 mg/Kg or 5 mg/Kg anti–TGF-β and n=6 HDM and either 0.5 mg/Kg or 5 
mg/Kg anti–TGF-β). Total cell counts were determined using a haemocytometer with 
white blood cell counting fluid and eosinophils were quantified from Wright-Giemsa 
stained cytospins as described in the Materials and Methods.*, P<0.05; (Mann-
Whitney U test) HDM compared with corresponding PBS-treated control group. #, 
P<0.05 (Mann-Whitney U test) HDM-anti-TGF-β compared with HDM-Ig. Bars 
depict the median of the groups. Representative of two experiments. 
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6.4.1.4. Blockade of TGF-β increases Th2 cell populations  
 
All HDM-treated mice showed higher numbers of Th2 (CD4
+
 T1ST2
+
) cells in the 
lung tissue and BAL compared to PBS controls. However, greater numbers of these 
cells were observed in the lung and BAL of 0.5 mg/Kg anti–TGF-β-treated HDM 
exposed mice than Ig-treated HDM exposed mice (Figure 6.5A and B). 
 
6.4.1.5. Neutralisation of TGF-β reduces regulatory T cell populations 
 
Representative flow cytometry plots are shown from of lung tissue that was either 
unstained or had received either FoxP3 or IL-10 isotype control Abs. Representative 
dot plots are also shown of stained lung tissue samples from PBS and HDM-treated 
mice (Figure 6.6A - D and 6.7A - D). All HDM-treated mice had higher numbers of 
CD4
+
CD25
+
FoxP3
+
 and CD4
+
IL-10
+
 cells in the lung tissue than the respective PBS 
control groups. However, 5 mg/Kg anti–TGF-β-treated HDM exposed mice showed 
lower numbers of CD4
+
CD25
+
FoxP3
+
 and CD4
+
IL-10
+ 
cells than Ig-treated HDM 
exposed controls (Figure 6.8A and B). 
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Figure 6.5. Blockade of TGF-β increases Th2 cell numbers.  
CD4
+
T1ST2
+
 T Cells recovered from the lung (A) and BAL (B) 4h after the final 
challenge (n=3-4 PBS Ig, n=6 HDM Ig, n=3-4 PBS and either 0.5 mg/Kg or 5 mg/Kg 
anti–TGF-β and n=6 HDM and either 0.5 mg/Kg or 5 mg/Kg anti–TGF-β). Cells 
were quantified by flow cytometry. *, P<0.05; (Mann-Whitney U test) HDM 
compared with corresponding PBS-treated control group. #, P<0.05 (Mann-Whitney 
U test) HDM-anti-TGF-β compared with HDM-Ig. Bars depict the median of the 
groups. Representative of two experiments. 
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Figure 6.6. Flow cytometry plots for staining of CD4
+
CD25
+
FoxP3
+
 regulatory T 
cells. 
Representative dot plots from (A) unstained cells, (B) CD4
+
CD25
+
FoxP3 isotype 
stained cells, (C) CD4
+
CD25
+
FoxP3
+
 cells from PBS-treated mice and (D) 
CD4
+
CD25
+
FoxP3
+
 cells from HDM-treated mice.  
Top panel of B - D: Percentage of CD4
+
 cells expressing CD25
+
. 
Bottom panel of B - D: Percentage of CD4
+
CD25
+
 cells expressing FoxP3
+
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Figure 6.7. Flow cytometry plots for staining of CD4
+
IL-10
+
 cells. 
Representative dot plots from (A) unstained cells, (B) CD4
+
IL-10 isotype stained 
cells, (C) CD4
+
IL-10
+
 cells from PBS-treated mice and (D) CD4
+
IL-10
+
 cells from 
HDM-treated mice.  
Left panel A - D: Percentage of CD4
+
 lymphocytes from total lymphocytes. 
Middle panel A - D: CD4
+
 lymphocytes in blue and CD4
-
 lymphocytes in red. 
Right panel B - D: Percentage of CD4
+
 cells expressing IL-10. 
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Figure 6.8. Blockade of TGF-β reduces regulatory T cell numbers in the lung.  
(A) CD4
+
CD25
+
FoxP3
+
 and (B) CD4
+
IL-10
+
 T Cells recovered from the lung 4h after 
the final challenge (n=4 PBS Ig, n=5-6 HDM Ig, n=3-4 PBS and either 0.5 mg/Kg or 
5 mg/Kg anti–TGF-β and n=5-6 HDM and either 0.5 mg/Kg or 5 mg/Kg anti–TGF-
β). Cells were quantified by flow cytometry. *, P<0.05; (Mann-Whitney U test) HDM 
compared with corresponding PBS-treated control group. #, P<0.05 (Mann-Whitney 
U test) HDM-anti-TGF-β compared with HDM-Ig. Bars depict the median of the 
groups. Representative of two experiments. 
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6.4.1.6. Neutralisation of TGF-β results in elevated IL-13 and IL-33 levels 
 
The signature Th2 cytokines IL-4, IL-5 and IL-13, as well as IL-17, were quantified 
in the BAL and lung to investigate whether the effects of blocking TGF-β on T cell 
populations influenced the pulmonary production of these cytokines. IL-4 and IL-5 
production was not altered by either dose of anti–TGF-β (Figure 6.9A – D). IL-13 
levels were elevated in the BAL and lung of all HDM-treated mice as compared to 
PBS controls. Greater IL-13 production was observed in 5 mg/Kg anti–TGF-β-treated 
HDM exposed mice compared to Ig-HDM-treated mice (Figure 6.9E - F). IL-17 was 
also elevated in the BAL of all HDM-treated groups compared to the respective PBS 
control groups. The levels of IL-17 in the BAL were lower in 5 mg/Kg anti–TGF-β-
treated HDM exposed mice than Ig-treated HDM exposed mice (Figure 6.9G). Both 
doses of anti-TGF-β further enhanced HDM-induced production of IL-33 (Figure 
6.9H).  
 
6.4.1.7. Neutralisation of TGF-β does not alter mast cell activation 
 
Mast cell activity was determined by quantification of mMCP-1 in the serum. The 
administration of either 0.5 mg/Kg or 5 mg/Kg anti–TGF-β did not alter HDM-
induced production of mMCP-1 in the serum, suggesting that mast cell activity is not 
influenced by blocking TGF-β (Figure 6.10A). 
 
6.4.1.8. Blockade of TGF-β does not elevate IgE production 
 
To investigate whether the humoral response to HDM, was influenced by 
neutralisation of TGF-β, total and HDM-IgE were quantified in the serum. All HDM-
treated mice showed higher IgE levels in the serum than the respective control groups 
and there was no effect of anti–TGF-β on the IgE response to HDM (Figure 6.10B 
and C). 
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Figure 6.9. Blockade of TGF-β increases IL-13 production in the BAL and lung.  
IL-4, IL-5 and IL-13 measured in the BAL (A, C and E) and lung (B, D and F), IL-17 measured in 
the BAL (G) and IL-33 measured in the lung (H) 4h after the final challenge. IL-4, IL-5 and IL-17 
were quantified by MSD and IL-13 and IL-33 by ELISA. (n=4 PBS Ig, n=6 HDM Ig, n=4 PBS 
and either 0.5 mg/Kg or 5 mg/Kg anti–TGF-β and n=6 HDM and either 0.5 mg/Kg or 5 mg/Kg 
anti–TGF-β). *, P<0.05; (Mann-Whitney U test) HDM compared with corresponding PBS-treated 
control group. #, P<0.05 (Mann-Whitney U test) HDM-anti-TGF-β compared with HDM-Ig. Bars 
depict the median of the groups. Representative of two experiments. 
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Figure 6.10. Blockade of TGF-β does not alter mast cell activity or IgE 
production.  
(A) mMCP-1, (B) total IgE and (C) HDM-specific IgE measured in the serum 4h 
after the final challenge. All mediators were quantified by ELISA. (n=4 PBS Ig, n=6 
HDM Ig, n=4 PBS and either 0.5 mg/Kg or 5 mg/Kg anti–TGF-β and n=6 HDM and 
either 0.5 mg/Kg or 5 mg/Kg anti–TGF-β). *, P<0.05; (Mann-Whitney U test) HDM 
compared with corresponding PBS-treated control group. Bars depict the median of 
the groups. Representative of two experiments. 
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6.4.1.9. Blockade of TGF-β does not influence HDM-induced mucus production 
or collagen deposition 
 
To investigate whether in vivo blockade of TGF-β influenced HDM-induced airway 
remodelling, the degree of goblet cell hyperplasia and peri-bronchial collagen 
deposition were then assessed. HDM exposed mice treated with either Ig, 0.5 mg/Kg 
anti-TGF-β or 5 mg/Kg anti-TGF-β developed goblet cell hyperplasia and showed 
peri-bronchial collagen deposition. There was no effect of the blockade of TGF-β on 
the degree of goblet cell hyperplasia or collagen deposition (Figure 6.11A and B). 
Representative PAS and sirius red stained lung sections from the respective groups of 
mice are shown (Figure 6.11C – H). 
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A. Mucus Score             B. Mean Intensity of Peri-bronchial 
                                                                     Collagen Deposition  
 
C. PBS + Ig                   F. HDM + Ig 
 
D. PBS + 0.5 mg/Kg α-TGF- β         G. HDM + 0.5 mg/Kg α–TGF-β              
 
E. PBS + 5 mg/Kg α–TGF-β                H. HDM + 5mg/Kg α–TGF-β 
    
PAS       Sirius Red          PAS             Sirius Red 
 
Figure 6.11. Development of goblet cell hyperplasia and peri-bronchial collagen 
deposition following TGF-β neutralisation. 
(A) Semi-quantitative scoring of PAS stained lung sections. (B) Quantification of 
peri-bronchial collagen deposition, expressed as mean intensity. Bars depict the 
median of the groups. *, P<0.05; (Mann-Whitney U test) HDM compared with PBS. 
(n=4 PBS Ig, n=6 HDM Ig, n=4 PBS and either 0.5 mg/Kg or 5 mg/Kg anti–TGF-β 
and n=6 HDM and either 0.5 mg/Kg or 5 mg/Kg anti–TGF-β). Representative 
pictures of PAS and sirius red stained lung sections from (C) Ig PBS, (D) 0.5 mg/Kg 
anti-TGF-β-PBS, (E) 5 mg/Kg anti-TGF-β-PBS, (F) Ig HDM, (G) 0.5 mg/Kg anti-
TGF-β-HDM and (H) 5 mg/Kg anti-TGF-β-HDM-treated mice (original 20X 
magnification). Scale bar = 50 µm. Representative of two experiments. 
PBS HDM PBS HDM PBS HDM PBS HDM
0
1
2
3 * * **
Ig -TGF- -TGF-Ig
0.5 mg/Kg 5 mg/Kg0.5 mg/Kg 5 mg/Kg
A
rb
it
ra
y
 U
n
it
s
PBS HDM PBS HDM PBS HDM PBS HDM
0
10000
20000
30000
40000
50000
60000
70000
* * *
Ig -TGF- -TGF-Ig
*
0.5 mg/Kg 5 mg/Kg0.5 mg/Kg 5 mg/Kg
A
rb
it
ra
y
 U
n
it
s
206 
 
6.4.2. Protocol B: Prophylactic blockade of TGF-β  
 
6.4.2.1. Prophylactic treatment with anti-TGF-β does not alter HDM-induced 
AHR or airway inflammation 
 
When the anti-TGF-β Ab was administered concurrently with HDM exposure for 
three weeks, no alterations were observed in the parameters of either AHR or airway 
inflammation. The 0.5 mg/Kg dose of anti-TGF-β Ab did not alter HDM-induced 
AHR (Figure 6.12A - D), eosinophilia or pulmonary IL-4, IL-5 and IL-13 production 
(Figure 6.13A – H) and the 5 mg/Kg dose of Ab did not alter pulmonary eosinophilia 
or Th2 cytokine levels (6.14A – F). 
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Figure 6.12. Prophylactic TGF-β neutralisation does not alter HDM-induced 
AHR. 
(A) Airway resistance of PBS and HDM-treated mice at 24h post final challenge, 
treated with either Ig or 0.5 mg/Kg anti-TGF-β. (B) Airway resistance is expressed as 
mean RI ± SEM for the 30mg/ml dose of methacholine. (C) Airway compliance of 
PBS and HDM-treated mice measured 24h post final challenge, treated with either Ig 
or 0.5 mg/Kg anti-TGF-β. (D) Airway compliance is expressed as mean Cdyn ± SEM 
for the 30mg/ml dose of methacholine. (n=4 PBS Ig, n=6 HDM Ig, n=4 PBS and 0.5 
mg/Kg anti–TGF-β and n=6 HDM and 0.5 mg/Kg anti–TGF-β). *, P<0.05; (Mann-
Whitney U test) HDM compared with corresponding PBS-treated control group. Data 
are expressed as mean ± SEM. One experiment. 
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Figure 6.13. Preventative TGF-β blockade does not alter HDM-induced airway 
inflammation. 
Total cells, eosinophils and IL-13 in the lung (A, C and E) and BAL (B, D and F) and 
(G) IL-4 and (H) IL-5 in the lung 24h post final challenge. Total cell counts were 
determined using a haemocytometer with white blood cell counting fluid and 
eosinophils were quantified from Wright-Giemsa stained cytospins, as described in 
the Materials and Methods. IL-4, IL-5 and IL-13 were quantified by ELISA. (n=4 
PBS Ig, n=6 HDM Ig, n=4 PBS and 0.5 mg/Kg anti–TGF-β and n=6 HDM and 0.5 
mg/Kg anti–TGF-β). *, P<0.05; (Mann-Whitney U test) HDM compared with 
corresponding PBS-treated control group. Bars depict the median of the groups. One 
experiment. 
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Figure 6.14. Prophylactic TGF-β neutralisation does not alter HDM-induced 
airway inflammation. 
Total cells and eosinophils in the lung (A and C) and BAL (B and D) and (E) IL-4 
and (F) IL-5 quantified in the lung 24h post final challenge. (n=4 PBS Ig, n=6 HDM 
Ig, n=4 PBS and 5 mg/Kg anti–TGF-β and n=6 HDM and 5 mg/Kg anti–TGF-β). 
Total cell counts were determined using a haemocytometer with white blood cell 
counting fluid and eosinophils were quantified from Wright-Giemsa stained 
cytospins, as described in the Materials and Methods. IL-4 and IL-5 were quantified 
by ELISA. *, P<0.05; (Mann-Whitney U test) HDM compared with corresponding 
PBS-treated control group. Bars depict the median of the groups. One experiment. 
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6.5. Discussion 
 
Following therapeutic blockade of TGF-β in a HDM model of allergic airways 
disease there was no impact on peri-bronchial collagen deposition or mucus 
production, which are key features of airway remodelling. However, neutralisation of 
TGF-β led to worsened AHR and BAL eosinophilia, together with elevated levels of 
IL-13 and IL-33 in the lung. Conversely, the numbers of CD4
+
IL-10
+
 and 
CD4
+
CD25
+
FoxP3
+
 Tregs were decreased in the lung following the blockade of TGF-
β in vivo. Thus, these results show a vital role for TGF-β in regulating HDM-induced 
airway inflammation and AHR, while airway remodelling progressed independently 
of TGF-β. 
 
The elevated HDM-induced AHR following blockade of TGF-β can be attributed to 
the decreased numbers of Tregs and elevated IL-13 and IL-33 levels in the lung. 
Naturally occurring CD4
+
CD25
+
 Tregs have been shown to suppress OVA-induced 
AHR in mice,
 
via a TGF-β–dependent mechanism (Joetham et al., 2007). The anti-
TGF-β Ab administered would therefore prevent the inhibitory effects of these cells 
on AHR here in the current study. CD4
+
CD25
+
FoxP3
+
 cells have also been shown to
 
induce Th2 cell apoptosis and increase tolerance to OVA, which contribute to the 
resolution of AHR (Strickland et al., 2006;Finotto et al., 2007). Adoptive transfer of 
antigen-specific CD4
+
CD25
+
 Tregs suppressed OVA-induced AHR (Kearley et al., 
2005) via IL-10 production from bystander CD4
+
 cells (Kearley et al., 2008). 
Depletion of CD4
+
CD25
+
 cells has also been shown to elevate HDM-induced AHR 
(Lewkowich et al., 2005). Consequently, following anti-TGF-β Ab administration, 
there would be a loss of suppression of AHR with a reduction in the number of the 
CD4
+
CD25
+
FoxP3
+
 and CD4
+
IL-10
+
 cells in the lung. The reduction in the number of 
CD4
+
CD25
+
FoxP3
+
 cells in anti-TGF-β-treated HDM exposed mice would occur as a 
result of blocking CD4
+
CD25
+
FoxP3
+
 differentiation from naive CD4
+
 cells, as TGF-
β is required for this process (Chen et al., 2003;Fontenot et al., 2003;Ramsdell, 2003). 
However, CD4
+
CD25
+
FoxP3
+
 cells are not completely absent from the lungs of anti-
TGF-β-treated HDM exposed mice because the therapeutic protocol was only 
instigated after 2 weeks of HDM exposure, thereby allowing for the differentiation of 
these cells to occur prior to Ab administration.  
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IL-13 is central to the development of AHR (Wills-Karp et al., 1998;Wills-Karp, 
1999;Wills-Karp, 2004) and IL-33 also promotes AHR (Kondo et al., 2008). 
Therefore, elevations in the levels of these mediators in the lung are also likely to 
contribute to the exaggerated AHR when TGF-β was neutralised. However, exactly 
how the blockade of TGF-β results in heightened levels of these mediators in the lung 
remains to be determined. Decreased numbers of CD4
+
CD25
+
FoxP3
+
 cells in the lung 
are the likely cause since these cells can suppress both OVA (Joetham et al., 2007) 
and Der p 1-induced IL-13 production (Leech et al., 2007). Indeed, depletion of 
CD4
+
CD25
+
 cells also elevated HDM-induced Th2 cytokine production by increasing 
the ability of DCs to present HDM (Lewkowich et al., 2005). In addition to blocking 
TGF-β-mediated FoxP3 differentiation, TGF-β neutralisation would also inhibit 
CD4
+
CD25
+
FoxP3
+
-TGF-β-mediated suppression of Th2 responses. A possible 
mechanism by which IL-33 is elevated following TGF-β blockade in HDM exposed 
mice is that there is a loss of regulation of IL-33 production. Mice lacking TGF-β 
responsiveness in epithelial cells or T cells develop severe intestinal inflammation 
(Beck et al., 2003;Fahlen et al., 2005) and TGF-β limits IL-33 production from 
alveolar macrophages (Rani et al., 2011). Therefore, a loss of TGF-β-mediated 
regulation of IL-33 from alveolar macrophages may explain the increased mediator 
production in the lung.  
 
The heightened BAL eosinophilia, following blockade of TGF-β, can be attributed to 
the decreased regulatory T cell populations and elevated IL-33 levels. Transfer of IL-
10 to the lungs and adoptive transfer of IL-10-transfected T cells block eosinophilic 
inflammation in the airways of mice (Stampfli et al., 1999;Oh et al., 2002) and 
CD4
+
CD25
+
 Tregs also suppress OVA-induced eosinophilia (Kearley et al., 
2005;Joetham et al., 2007;Kearley et al., 2008). This is not specific to OVA as 
CD4
+
CD25
+
FoxP3
+
 regulatory cells attenuate Der p 1-induced eosinophilia in the 
lung (Leech et al., 2007). However, mast cell activity was not altered by the blockade 
of TGF-β, despite CD4+CD25+FoxP3+ Tregs having been shown to suppress mast cell 
degranulation, via interference with OX40-OX40L interactions (Gri et al., 2008). The 
increased IL-33 levels may also contribute to the heightened eosinophilia, since IL-33 
has been shown to exacerbate eosinophil-mediated inflammation (Cherry et al., 
2008;Pecaric-Petkovic et al., 2009;Chow et al., 2010;Stolarski et al., 2010). Indeed, 
with both doses of blocking Ab, elevated eosinophilia was observed in the BAL 
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together with heightened IL-33 production. However, the increased eosinophilia here 
was not observed as a consequence of increased IL-5 levels, as the blockade of TGF-
β did not enhance pulmonary IL-5 production. This conflicts with Fattouh and 
colleagues, who observed elevated IL-5 levels in cultured splenocytes (Fattouh et al., 
2008) and may reflect the limitations of using the ex vivo restimulations.  
 
The findings reported in this Chapter are important in furthering our understanding of 
the mechanisms regulating both airway inflammation and the development of airway 
remodelling following HDM exposure. However, it is important to consider that the 
experimental system in which a mediator with a wide range of functions, such as 
TGF-β, is investigated likely influences certain observations. Previously, TGF-β 
neutralisation was shown to
 
prevent the progression of airway remodelling in
 
OVA 
challenged mice (McMillan et al., 2005), whereas this does not occur when HDM is 
used as the sensitising allergen. This is not completely unforeseen due to differences 
between the OVA and HDM models, whereby Th2 immune responses to OVA 
require peripheral sensitisation with alum, whereas with HDM sensitisation occurs in 
the airway mucosa. Thus, OVA and HDM are likely to possess distinct 
immunological profiles even though the same outcomes of airway inflammation, 
AHR and airway remodelling occur.  
 
The complexity of understanding the role of TGF-β has also been illustrated when 
subtle differences in observations have occurred within both OVA and HDM models 
of allergic airways disease. Using different approaches to investigate the role of TGF-
β, several studies have illustrated a role for TGF-β in regulating OVA-induced 
allergic airways disease. Nakao and colleagues showed in mice expressing Smad7 (an 
intracellular antagonist of TGF-β signalling) selectively in mature T cells developed 
enhanced AHR and pulmonary eosinophilia and IL-5 production in response to OVA 
compared to wt controls (Nakao et al., 2000). Schramm and colleagues observed in 
mice possessing impaired TGF-β signalling in T cells, via the expression of a 
dominant-negative TGF-β type II receptor, that these mutant mice showed increased 
AHR, pulmonary eosinophilia and IL-13 production in response to OVA (Schramm 
et al., 2003). Scherf and colleagues using mice heterozygous for the deletion of the 
TGF-β1 gene showed elevated eosinophilia, goblet cell hyperplasia and pulmonary 
IL-4, IL-5 and IL-13 levels in response to OVA (Scherf et al., 2005). In contrast to 
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the Nakao and Schramm studies, Scherf and colleagues did not observe heightened 
AHR in response to OVA, indicating that 30% of the normal TGF-β levels can 
regulate OVA-induced AHR (Scherf et al., 2005). TGF-β neutralisation with a 
blocking Ab has also been shown
 
to increase AHR in an acute OVA
 
model with 
increased production
 
of IL-4 and IL-13, however, these authors reported no increased 
airway eosinophilia (Alcorn et al., 2007). Indeed, the complexity of elucidating a 
systemic role for TGF-β was also underscored in this Chapter, whereby anti-TGF-β 
Ab administered concurrently with HDM sensitisation had no impact on the 
development of airway inflammation and AHR, whereas there was a clear loss of 
regulation of AHR when the Ab was administered therapeutically. Certainly, the role 
of TGF-β is likely to be influenced by the cytokine environment in the lung at the 
time of Ab administration, as following two weeks of HDM exposure Th2 cytokines 
and eosinophils are present in the lung (Gregory et al., 2009), whereas this is not the 
case in the preventative blocking experiment. 
 
The results from the therapeutic intervention study accompany the fundamental roles 
for TGF-β and Tregs in maintaining lung immune homeostasis. However, despite the 
reduction in regulatory T cell numbers and elevation of both IL-13 and IL-33 
production, the systemic neutralisation of TGF-β may also influence other key 
immunosuppressive mechanisms in the lung which may contribute to loss of 
regulation of AHR and eosinophilia. For example, mouse and human airway 
epithelial cells secrete TGF-β that inhibits DC maturation and subsequent T cell 
activation (Bilyk and Holt., 1993;Bleck et al., 2006;Mayer et al., 2008;Wang et al., 
2009). Epithelial production of IL-10 and TGF-β also maintain the expression of the 
CD200 receptor (CD200R) on macrophages, which is important in lung homeostasis 
and for the resolution of myeloid cell activity (Snelgrove et al., 2008). Further to this, 
alveolar macrophages are poor APCs (Steinmuller et al., 2000;Janssen et al., 2008), 
and actively inhibit T cell responses in part via the secretion of TGF-β (Roth and 
Golub, 1993;Chelen et al., 1995;Balbo et al., 2001). Therefore, the therapeutic 
systemic blockade of TGF-β may increase T cell activation and DC activity, while 
reducing regulatory CD200R expression, which could also contribute to the worsened 
HDM-induced airway inflammation. For those reasons, to proceed forward from the 
experiments in Chapter 6, investigating the specific role of TGF-β signalling in a 
single cell type would further enhance our understanding of the role of TGF-β at a 
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specific cellular level in HDM-induced allergic airways disease. To date, cell-specific 
blockade of TGF-β signalling has been carried out in OVA-based models and should 
be pursued with HDM, as the observations may not directly translate between 
systems. Indeed, TGF-β secreted by T cells was shown to suppress immune responses 
to high doses of OVA (Haneda et al., 1999) and Th cells engineered to express latent 
TGF-β abolished OVA-induced AHR and airway inflammation (Hansen et al., 2000). 
Transgenic mice with selective expression of Smad 7 in mature T cells to block TGF-
β signalling in T cells showed enhanced OVA-induced airway inflammation and 
AHR (Nakao et al., 2000). The Nakao study therefore accompanies a crucial role of 
TGF-β plays in maintaining T cell tolerance and homeostasis (Li et al., 2007). 
However, TGF-β is also secreted from epithelial cells and the impact on OVA-
induced airway inflammation has also been assessed. In contrast to when TGF-β 
signalling in T cells was inhibited, blockade of TGF-β signalling in airway epithelial 
cells attenuated OVA-induced Th2 cytokine production and slowed the development 
of airway remodelling (Luo et al., 2010). These opposing roles of TGF-β, comparing 
T cell to epithelial signalling, further underscore the importance of TGF-β in 
modulating local inflammatory responses. However, epithelial blockade of TGF-β 
signalling when HDM is the sensitising allergen should be carried out as a pro-
inflammatory and pro-remodelling role for epithelial TGF-β signalling with OVA, 
may not translate to HDM. 
 
The data obtained in this Chapter also reveal an important insight into HDM-induced 
airway remodelling and the relationship with AHR. Despite the neutralisation of 
TGF-β there was no impact on features of airway remodelling, while AHR was 
elevated, suggesting that the degree of structural changes in the lung do not directly 
correlate with the severity of AHR. Indeed, eosinophils, which have been shown by 
some research groups to be the major source of TGF-β in asthmatics (Minshall et al., 
1997;Vignola et al., 1997;Flood-Page et al., 2003), have also been shown to be 
dispensable for the development of HDM-induced airway remodelling in vivo 
(Fattouh et al., 2011). However, an important consideration with the interpretation of 
results from the experiments in this Chapter is that the other TGF-β family members 
contribute to airway remodelling and the continued presence of these mediators may 
explain why TGF-β neutralisation had no impact on airway structural changes. One 
such family member that has been implicated as a key factor in the development of 
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airway remodelling is activin-A. Adenoviral-induced over-expression of Smad 2 in 
airway epithelial cells resulted in enhanced HDM-induced airway remodelling and 
AHR, together with elevated production activin-A and IL-25 (IL-17E). Neutralisation 
of activin-A in vivo attenuated airway remodelling and AHR together with a decrease 
in IL-25 (IL-17E) production (Gregory et al., 2010).  
 
The findings from Chapter 6 address the role of TGF-β in the context of Th2 driven 
inflammation in the lung in vivo following exposure to the environmental allergen 
HDM. Here, TGF-β has been shown to contribute to the regulation of HDM-induced 
Th2-driven airway inflammation and it is thus likely that TGF-β plays a dual role in 
asthma by regulating
 
both the inflammatory and injury repair responses. TGF-β may 
dampen and oppose the inflammatory response elicited
 
upon HDM exposure 
while
 
also initiating tissue repair cascades in order to protect the lung from 
inflammation
 
and tissue damage. Overall the data from this Chapter suggests that 
targeting TGF-β with a blocking Ab in HDM-induced allergic airways disease is not a 
viable therapeutic avenue for the treatment of asthma, as there was no improvement 
in airway remodelling and there was a loss of regulation of the inflammatory 
response. The loss of regulation of HDM-induced airway inflammation following 
systemic neutralisation of TGF-β is supportive of the vital role TGF-β and Tregs play 
in suppressing allergen-driven Th2 inflammation in the lung. 
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Chapter 7 - General Discussion 
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The main findings from this thesis were that the TLR-TRIF signalling pathway and 
the protease activity of HDM played prominent roles in the immune response to the 
inhaled allergen and were vital for disease pathogenesis. In addition to this, TGF-β 
was shown to regulate HDM-driven airway inflammation and AHR, whereby 
systemic in vivo blockade resulted in elevated IL-13 and IL-33 levels, concomitant 
with a decrease in regulatory T cell numbers.  
 
7.1. Murine models and relation to man 
 
In the last several years murine models of allergic airways disease have moved from 
OVA sensitisation and challenge models, to those which use environmental allergens, 
such as HDM, that negate the requirement for adjuvant and provide a highly 
physiological system to study asthma pathology. HDM was selected for this thesis 
since this allergen is ubiquitous in the environment and exposure is almost 
unavoidable. Asthmatics are also not subjected to seasonal variations associated with 
other allergens, such as grass and pollens, and worldwide sensitisation to HDM is the 
strongest risk factor for the development of asthma (Sears et al., 2003). The 
establishment and manipulation of a HDM murine model of allergic airways disease, 
has allowed insights into underlying disease mechanisms, as well as allowing 
dissection of the roles of particular features of the allergen in disease pathogenesis. 
Furthermore, refinement and characterisation of this model, as well as improved 
understanding of the complex immune response to HDM, will allow for the 
development of novel therapeutic strategies to treat asthma.  
 
The use of HDM in vivo will build on knowledge from OVA-based systems which 
may be misleading with regard to essential contributions from innate immune 
pathways and therefore has implications for understanding asthma pathogenesis. In 
addition to HDM, a diverse repertoire of other common allergens including ragweed, 
pollen, animal dander and cockroach are also associated with allergic asthma. The 
observations in this thesis regarding the roles of TLR signalling, proteases and TGF-β 
in the immune response to HDM likely translate to these other allergens since all the 
afore mentioned allergens possess intrinsic protease activity and upon inhalation first 
come into contact with the lung at the airway epithelium. However, it must be 
stressed that although these allergens in mice may produce similar characteristics of 
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asthma, such as AHR, airway inflammation and airway remodelling, the distinct 
nature of these allergens needs to be recognised.  
 
Other research groups have also investigated HDM-induced allergic airways disease 
using different dosing protocols and time points of analysis which may influence the 
relative importance of different signalling pathways (Phipps et al., 2009;Hammad et 
al., 2009). However, these differences could reflect variations that might occur in 
humans and, rather than being contradictory, may provide key insights into 
subpopulations of people with asthma (Moore et al., 2010). For the purpose of this 
thesis, a continuous HDM exposure protocol was followed as this most closely 
replicates natural human exposure to environmental HDM and, rather than isolated 
Der p proteins, a complete HDM extract was utilised in these studies. However, 
future research should also continue to use purified natural or recombinant mite 
allergens in addition to whole mite extracts. Different allergens within HDM extracts 
may stimulate distinct aspects of the innate immune system and possess unique 
mechanisms of sensitisation, which may be difficult to delineate from whole HDM 
extracts. Recombinant Der p 2, and not a whole HDM extract, was utilised in vitro 
and in vivo by Trompette and colleagues to show that this allergen acted as an MD-2 
homologue (Trompette et al., 2009) and thus to define mechanisms of sensitisation 
for Der p 5 and 7 that are currently unknown, single recombinant allergens should be 
used for these investigations. 
 
7.2. HDM immune response: remaining questions  
 
HDM allergy is strongly associated with asthma (Sears et al., 2003) and this is likely 
because HDM possesses multiple antigenic epitopes that can promote the immune 
response. Unpublished data from our laboratory suggests that the allergenicity of 
HDM is determined by a delicate balance between several components of the 
allergen. A separate batch of HDM obtained from a different source from the Greer 
HDM (used in this thesis), was observed to induce a comparatively low immune 
response in vivo compared to the Greer HDM, despite the non-Greer HDM 
possessing vastly greater protease activity. Upon further analysis of this allergen, the 
non-Greer HDM contained approximately a 100-fold less Der p 2 content than the 
Greer HDM. This can be expected to contribute to the functional in vivo immune 
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response as Der p 2 has the highest rate of skin test positivity in HDM allergic 
patients (Kidon et al., 2011). It is therefore plausible that proteolytic activity 
contributes to the potency of Der p 2, since an increased protease activity alone does 
not correlate with an elevated immune response.  
 
The observations from the non-Greer HDM studies suggest that the allergenic 
potency of HDM is determined by a delicate balance of several different allergenic 
epitopes and that no single feature of the HDM allergen dominates in the 
development of the immune response. This is further illustrated when LPS alone is 
administered to mice, whereby LPS administration does not recapitulate the full 
asthma phenotype and the inflammatory response differs markedly to that of HDM 
(Szarka et al., 1997). One possible scenario is that the protease activity of Der p 1, 3, 
5 and 9 enhances the allergenicity of non-protease allergens, such as Der p 2, by 
facilitating easier access to TLR-expressing DCs residing in the airway mucosa. 
When Der p 2 was administered in vivo by Trompette and colleagues and Ye and 
colleagues, Der p 2 was shown to elicit the features of allergic airways disease when 
accompanied by an exogenous adjuvant (Trompette et al., 2009;Ye et al., 2011). Thus 
it may be that Der p 2, within a whole extract, is able promote an immune response in 
vivo because of the adjuvant properties of the proteases Der p 1, 3, 6 and 9 (Chapman 
et al., 2007). In view of the finding that Der p 1 can promote the activation of Der p 3 
(Dumez et al., 2008), the potency of other HDM allergens, such as Der p 5 which is a 
lipid binding protein (Mueller et al., 2010b), may also be augmented by protease 
activity. Therefore, the synergistic effects of biologically active enzyme allergens on 
Th2 responses and inflammation may explain why HDM is the predominant allergen 
associated with atopic asthma. However, other important asthma-associated allergens 
are not proteolytic enzymes and it is therefore difficult to identify a unifying theory of 
allergenicity based on biological function. Clearly, both enzymatic and non-
enzymatic allergens can mediate Th2 responses, inflammation, and asthma and there 
is also the further complication as to whether augmentation of these responses to mite 
allergens is influenced by asthma susceptibility genes or gene-environment 
interactions.  
 
Several important questions remain concerning the precise contributions of PRRs and 
pathways, or combinations of receptor pathways that mediate Th2-driven immune 
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responses to HDM. Concurrent with the work described in this thesis several 
important PRRs and associated signalling molecules have been shown to be important 
in driving the immune response to inhaled HDM in vivo, most notably TLR4 
(Hammad et al., 2009;Trompette et al., 2009), MyD88 (Phipps et al., 2009) and 
Dectin-2 (Barrett et al., 2011). Important roles for the MR (Deslee et al., 2002;Royer 
et al., 2010) and DC-SIGN (Hsu et al., 2010) present on DCs have also been shown in 
vitro in promoting the immune response to HDM allergens. In the future, studies 
should focus on the contribution of other PRRs to HDM immune responses including 
nucleotide-binding oligomerisation domain protein (NOD)-like receptors (NLRs). 
This is necessary because NLR polymorphisms have been associated with asthma 
(Hysi et al., 2005) and Der p 1 has recently been shown to trigger the assembly of 
NLRP3 inflammasome in keratinocytes (Dai et al., 2011). Although not investigated 
in this thesis, there are many structures within HDM, such as Der p 5 and 7 that are 
lipid-binding proteins (Mueller et al., 2010a;Mueller et al., 2010b). The receptor 
signalling pathways lipid binding proteins engage require identification because in 
addition to TLR activation, lipids can stimulate the activation of innate lymphocyte 
populations (Brutkiewicz, 2006). Carbohydrate structures, such as β-glucans are 
present in HDM (Douwes et al., 2000;Fahlbusch et al., 2003) and are also strong Th2 
stimulators (Nathan et al., 2009). The precise carbohydrate moieties associated with 
allergens and the array of PRRs and signalling pathways they activate warrant further 
investigation. Moreover, studies are also required to determine the molecular and 
cellular mechanisms by which allergen engagement of PRRs, such as TLR4, 
preferentially drive Th2 inflammatory responses as opposed to either Th1, Th17 or 
tolerogenic responses, and whether these can be manipulated. It would also be 
necessary to determine if allergic diseases are associated with functional variants in 
allergen-activated PRRs or signalling pathways and which of these pathways is the 
most attractive therapeutic target. 
 
A concept that has recently emerged is receptor cooperativity, which has been shown 
between TLRs and PAR2 in vitro and in vivo, in the context of orthomyxovirus and 
paramyxovirus infections (Nhu et al., 2009). Activation of PAR2 leads to intracellular 
signals that intersect with TLR/IL-1R signalling pathways (Fyfe et al., 
2005;Ostrowska et al., 2007;Trinchieri and Sher, 2007;Uehara et al., 2008) and PAR2 
activation has been shown to synergistically enhance LPS-induced IL-8 production in 
221 
 
HEK293 cells (Rallabhandi et al., 2008). PAR2 activation has also been shown to 
increase TLR3-driven expression of IL-8, whereas RANTES/CCL5 was suppressed 
in mucosal epithelial cell lines (Nhu et al., 2009). Both TLRs and PARs have been 
implicated in the development of HDM-induced allergic airways disease and in view 
of the fact that HDM possess both TLR and PAR ligands, it is plausible that this 
receptor interplay occurs in response to HDM in vivo. To test this hypothesis further, 
the effect of HDM on this receptor interplay should be investigated firstly in vitro in 
airway epithelial cell lines and then investigated in TLR4-PAR2 double KO mice. 
This in vivo experiment may also shed further light on how a dependence on a single 
receptor or pathway, such as TLR4, may be overridden in continuous uninterrupted 
HDM dosing protocols, as proteinase-rich microenvironments may influence the 
composition of infiltrating leukocytes. Moreover, receptor cooperativity may not be 
restricted to PARs and TLRs, as HDM can trigger CLRs, PAR2 and TLRs and these 
receptors share similar signalling pathways and molecules, specifically MAPK and 
NF-κB (Jacquet, 2011). 
  
HDM and associated proteases have not only been linked with the development of 
atopic asthma, but also to atopic dermatitis (Lee et al., 2010). Atopic dermatitis is an 
inflammatory skin disease which is commonly associated with atopic asthma and is 
characterised by genetic barrier defects and allergic inflammation (Lee et al., 2010). 
The mechanisms by which HDM exerts its effects on the airway epithelium likely 
translate to the skin in atopic dermatitis as HDM is also linked with the development 
of this disorder (Sanda and Yasue, 1991;Tupker et al., 1996;Tan et al., 1996;Ricci et 
al., 1999) and atopic dermatitis is characterised by epithelial barrier dysfunction 
(Cork et al., 2009). In view of this, Der p 1 has also been shown to be a danger signal 
via activation of the inflammasome on keratinocytes (Dai et al., 2011) and this may 
occur with airway epithelial cells in the lung. 
 
To date, modelling asthma in mice has largely focused on immune-mediated
 
mechanisms and phenotypic changes to mesenchymal cells and the
 
products that they 
secrete. However, there is an opportunity to use these models to study the impact of 
structural
 
and functional changes to the airway epithelium and translate
 
these results 
back to human disease, as epithelial injury is frequently seen in asthmatics (Hackett 
and Knight., 2007;Bhure et al., 2009). In view of the finding that uric acid has been 
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shown to play a key role in HDM-induced airway inflammation (Kool et al., 2011), 
this DAMP may be released because of protease-induced epithelial damage and 
injury. It is also important to recognise that epithelial injury may occur as a 
consequence of chronic HDM exposure as opposed to acute exposure, since epithelial 
barrier function remained intact following a single dose of HDM in vivo (Turi et al., 
2011) but not after multiple doses (Chapter 5). Since airway epithelial injury is 
associated with asthma, the development of therapies targeting epithelial injury and 
repair are an attractive proposition. The HDM model described in this thesis could be 
used for such a purpose, since impaired epithelial barrier function and epithelial TJ 
disorganisation was observed following chronic HDM exposure. Restoration of full 
barrier function has been seen when EGF and keratinocyte growth factor were applied 
to a damaged asthmatic epithelium in vitro and in vivo (Berlanga et al., 2002;Basuroy 
et al., 2006;Tillie-Leblond et al., 2007). Clinical trials are also currently progressing 
to investigate the effect of surfactant as a potential epithelial barrier treatment for 
chronic asthma, by preventing environmental allergens from damaging the airway 
wall (Babu et al., 2003).  
 
7.3. Asthma Therapies: Where next? 
 
One of the key aims of this thesis was to relate properties of the HDM allergen to the 
pathological features of the disease and a vital role of the intrinsic protease activity of 
the HDM extract to the development of the immune response was determined. Also 
from this thesis, as well as from the current literature, inhibitors of the innate pro-
allergic cytokines IL-25 (IL-17E), IL-33 and TSLP, or the respective receptors for 
these cytokines, may offer new therapeutic options for the treatment of atopic asthma. 
These cytokines were routinely elevated in HDM exposed mice, and boiling of HDM, 
to inactivate proteases dramatically reduced the production of these cytokines, 
together with reduced airway inflammation and remodelling. In addition to this, a 
newly identified innate cell population that promotes the development of Th2 cell-
dependent inflammation at mucosal sites in the gut may also provide a new 
therapeutic target. These new cell populations were termed either natural helper cells 
(NHCs) (Price et al., 2010), multi-potent progenitor type 2 (MPP
type2
) cells (Saenz et 
al., 2010), nuocytes (Neill et al., 2010) or innate type 2 helper (Ih2) cells (Moro et al., 
2010) and are required for the type-2 response to the helminthic parasite 
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Nippostrongylus brasiliensis (Neill et al., 2010). Both IL-25 (IL-17E) and IL-33 can 
induce the production of IL-4, IL-5 and IL-13 (Neill et al., 2010) from these cells and 
this has raised important questions about the mechanisms by which cells of the innate 
immune system promote adaptive Th2 responses. In addition to being sources of Th2 
cytokines, NHCs, MPP
type2
, nuocytes and Ih2 cells may act as APCs. Therefore, it is 
important to determine whether these cells have a role in HDM-induced disease and 
whether this can be directly translated to humans to establish novel therapeutic 
targets. 
 
Genomic studies have revealed the association between many genes and the 
development of asthma, such as orosomucoid 1-like 3 (ORMDL3) (Moffatt et al., 
2007;Galanter et al., 2008) and IL-33 (Moffatt et al., 2010). Mice provide an 
invaluable tool in further dissecting a role of these genes in allergic airways disease 
because there are tools available for genetic manipulation in mice and key asthmatic 
parameters in mice, such as AHR, are well established. Mice also have the advantage 
over other rodents in that mice share a similar chromosomal arrangement with 
humans, therefore allowing for a more accurate translation back to the human 
scenario (Seldin, 2001). In addition to this, gene expression can also be carried out in 
a tissue or cell specific manner and this is especially important with asthma 
susceptibility genes that are located in the airway epithelium. The HDM model of 
allergic airways disease described in this thesis could be used to investigate the 
effects of manipulating the expression levels of asthma susceptibility genes on the 
development of disease. Besides genetic factors that may predispose individuals to 
atopic diseases, considerations should also be made to the environment, age, sex and 
exposure to viruses and bacteria, as these factors may influence epithelial-allergen 
interactions.  
 
Indeed, studies have been carried out to investigate the complex interactions behind 
the development of asthma. Utilising a murine model of HDM-induced allergic 
airways disease, acute infection with influenza A was observed to promote allergen 
responsiveness in mice at an age approximately equivalent to the first 2 years of life 
in humans (Al-Garawi et al., 2011). The study from Al-Garawi and colleagues 
accompanies the findings that co-exposure to air pollution, LPS, or bacterial and viral 
TLR ligands significantly enhance inflammatory responses to either OVA or 
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cockroach extracts (Hamada et al, 2000;Kulhankova et al., 2009;Phipps et al., 2009). 
However, conversely to respiratory viral infections, a lack of early exposure to 
microbial antigens is believed to contribute to the increasing incidences of asthma in 
developed countries because microbial antigens may contribute to the maturation of 
the pulmonary immune system (Blaser and Falkow, 2009). Arnold and colleagues 
have recently reported that early infection of mice with the gastric pathogen 
Helicobacter pylori increased the number of Tregs in the airways that prevented the 
development of both OVA and HDM-induced allergic airways disease (Arnold et al., 
2011). Dietary patterns are also believed to participate in the development of asthma, 
whereby a lack of vitamin D in the diet is likely to contribute to the high prevalence 
of vitamin D deficiency (54%) and insufficiency (86%) associated with asthma in 
inner-city African-American children (Freishtat et al, 2010). Decreased respiratory 
tract infections in children receiving vitamin D supplementations have also been 
reported (Majak et al., 2011). 
 
A high proportion of asthmatics respond therapeutically to inhaled corticosteroids and 
long-acting β2-adrenoceptor agonists. However, a significant number of asthmatics 
respond inadequately to the current mainstay of asthma therapy. Substantial efforts 
have since been made to develop new asthma therapies targeting inflammatory 
cytokines associated with asthma, such as IL-5. However, it is clear that anti-IL-5 
therapy was only efficient in suppressing eosinophilia in the mild asthmatics and not 
severe asthmatics (Leckie et al., 2000;Flood-Page et al., 2007;Haldar et al., 2009;Nair 
et al., 2009). This has led onto the development of more patient-specific therapies, 
especially since the different subtypes of asthma are believed to have distinct 
underlying pathophysiological mechanisms (Moore et al., 2010). One such example 
of new therapeutic effort has been in the development of allergen-specific 
immunotherapy that was designed to treat the underlying cause of the allergic 
disorder and is aimed at promoting immunological tolerance (Larche et al., 
2006;Focke et al., 2010;Frew, 2010). Allergen-specific immunotherapy has been 
shown to provide long term clinical benefits, including long-term disease remission, 
prevention of new atopic sensitisations and a reduction in disease progression from 
rhinitis to asthma (Keles et al., 2011). HDM-directed immunotherapy has been shown 
to improve lung function in HDM-allergic asthmatics (Abramson et al., 2010) and 
decrease HDM-specific IgE levels (Blumberga et al., 2011). Certainly, allergen-
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specific immunotherapy holds great promise for HDM-allergic patients. However, 
careful considerations should be made in the design of immunotherapy as patients 
within the ‘HDM-allergic’ category may be more sensitive to the minor allergens, 
such as Der p 10, as opposed to the major allergens Der p 1 and 2 (Resch et al., 
2011). 
 
7.4. Concluding Remarks 
 
There is an urgent need for more tailored and specific therapies for the treatment of 
asthma. This is so because it has emerged that asthma encompasses a range of 
different disease phenotypes, each with a distinct underlying cause and therefore a 
single treatment may not be sufficient to adequately treat all asthmatics. Certainly, 
one of the major obstacles in improving treatments for asthma is an incomplete 
understanding of the underlying disease mechanisms. The characterisation and 
development of murine models of allergic airways disease utilising environmental 
allergens, such as HDM, represent a significant step forward in a bid to delineate the 
mechanisms of allergic sensitisation and to identify new therapeutic targets for atopic 
asthma. There are also the added advantages that the mechanisms of allergic 
sensitisation to HDM translate to other allergens associated with atopic asthma, since 
all inhaled allergens interact with the airway epithelium in the lung, and that these 
observations also relate to atopic dermatitis and rhinitis because HDM is associated 
with the development of these conditions.  
 
The mechanisms underlying the development of airway remodelling remain to be 
elucidated and this is important for chronic asthma sufferers. The focus for the 
immediate future should be on the role of structural components of the airway, in 
particular the airway epithelium, on the development of airway remodelling. The 
characterisation of a HDM model of allergic airways disease will allow for the 
mechanisms of airway remodelling to be further investigated by building on 
knowledge from previous OVA-based models and allow for the development of novel 
therapeutic targets, thus opening up a new era in drug discovery. 
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Background: Inhaled house dust mite results in Th2 type pathology in unsensitised 
mice, in conjunction with airway hyperreactivity and airway remodelling. However 
the pulmonary cytokine and chemokine profile has not been reported. Methods: We 
have performed a time course analysis of the characteristic molecular mediators and 
cellular influx in the BAL and lung in order to define the pulmonary inflammatory 
response to inhaled HDM extract. Mice were exposed five times a week to soluble 
HDM extract for three weeks. Lung function was measured in groups of mice at 
intervals following the final HDM challenge. Recruitment of inflammatory cells and 
inflammatory mediator production was then assessed in BAL and lungs of individual 
mice. Results: We found that Th2 cytokines were significantly increased in BAL and 
lung after HDM challenge from as early as 2 hours post final challenge. The levels of 
cytokines and chemokines correlated with the influx of eosinophils and Th2 cells to 
the different compartments of the lung. However, the production of key cytokines 
such as IL-4, IL-5 and IL-13 preceded the decrease in airways resistance. 
Conclusion: Inhaled HDM challenge induces a typical Th2 inflammatory mediator 
profile in the BAL and lung. These data are important for studies determining the 
efficacy of novel treatment strategies for allergic airways disease.  
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